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ABSTRACT 
CATIONIC AMINOOXY LIPIDS: 
SYNTHESIS, LlPOSOME STABILIZATION AND APPLICATIONS 
Xuan Huang 
May 3rd 2012 
This dissertation describes research focused on the synthesis, polymerization and 
applications of cationic aminooxy lipids. An efficient and convenient method was 
developed to stabilize liposomes using 'click chemistry'. The 'click stabilized 
liposomes' are fortified via covalent crosslinks generated between aldehyde and 
aminooxy functionalities in the lipid bilayers. Compared to untreated liposomes (i.e., 
no lipid-lipid bonding), the 'click' stabilized liposomes are considerably more stable 
against surfactant-mediated liposome disruption or serum-mediated liposome 
aggregation. Stabilized liposomes also can react with 'clickable' targeted ligands on 
the liposome surface for specific organ (e.g. breast cancer cells or liver) targeting. In 
this thesis, I have explored the feasibility of using the click stabilized liposomes in 
three different applications: i) colonic targeted delivery ii) gene vector iii) enzyme 
nanoreactor. 
iv 
This dissertation is divided into six chapters. Chapter 1 gives a review of liposomes 
and liposome stabilization. Chapter 2 describes the synthesis and characterization of 
cationic aminooxy compounds 2.1 and 2.2 as the headgroup domains of prototype 
lipids. Chapter 3 describes the synthesis, characterization and hydrolysis of cationic 
aminooxy enol ether lipids 3.1 and 3.2. The liposomes formulated from lipid 3.2 were 
stabilized using a pH-triggered lipid polymerization strategy. Chapter 4 describes the 
synthesis and characterization of a variety of aminooxy lipids and dextran 
polyaldehydes (DPAs). The liposomes formulated from lipids 4.1 were stabilized by 
simply mixing with DPAs. The resultant 'click' stabilized liposomes have potential 
applications such as drug carriers for colonic targeted delivery and as nano-reactors. 
Chapter 5 focuses on applying 'click' stabilized liposomes as gene carriers. The initial 
results of in vitro gene transfection revealed that the stabilized lipoplexes formulated 
from lipid 4.1 successfully transfected MFC-7 cells, but with lower transfection potency. 
A liver-targeted ligand 5.2 based on lactose was synthesized for future in vivo gene 
transfection applications. Chapter 6 details all experimental procedures and 
approaches used for compound characterizations. 
v 
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1.1 Liposome Introduction 
Liposomes, first introduced by Bangham et al. in 1965,1 have an aqueous core 
domain surrounded by unilamellar or multilamellar lipid bilayers with diameters from 
20 nm to 100 IJm (Figure 1). Liposomes have attracted considerable attention since 
Bangham's report and over 40,000 papers related to the study of liposomes have 
been published.2 Due to their biocompatibility, biodegradability and ease of 
preparation, liposomes are widely applied as universal carriers in drug/gene delivery 
systems as well as other applications including artificial cell models, biosensors, 
nanoreactors and cosmetic products. 3.4 Many commercial products apply liposomes 
to fulfill various jobs, such as to improve drug solubility (AmBisome™, Visudvne™), 
reduce drug toxicity (Doxil™, Myocet™), increase the response to vaccines (Epaxal™, 





Figure 1. Liposome structures. 
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The unique structure of liposomes allows hydrophilic cargo to be encapsulated in 
aqueous core domain whereas the hydrophobic cargo can be bound in the lipid bilayer. 
For the charged cargo, liposomes can carry small molecules via association on the 
lipid surface, and charged macromolecules can be packaged via complexes into the 
lipid bilayer (Figure 2). For example, cationic liposomes may complex negatively 
charged DNA to form compacted, charge affinity complexes called lipoplexes, which 
tend to form as mutilamellar vesicles.7,B The lipid bilayer offers protection by 
separating the cargo from the surrounding environment which makes liposomes ideal 
carriers. 
A B c D 
Figure 2. Cargo placements within liposomes. 
The black dots and bars in the figure represent cargo molecules: A. Hydrophilic cargo; B. 
Hydrophobic cargo; C. Charged cargo; D. Charged macromolecules (e.g. plasmid DNA). 
According to their different size and morphology, liposomes can be classified as 
various vesicles: the Small Unilamellar Vesicles (SUVs) refer to single-shelled 
vesicles with diameters ranged from 25 to 50 nm; the Large Unilamellar Vesicles 
(LUVs) ranged from 50 to 500 nm; the Multilamellar Vesicles (MLVs) have "onion-like" 
structure and usually range from 100 nm to 10 IJm (Figure 1); and the Giant Vesicles 
(GVs) with very large size range from 10 to 100 IJm which can be either unilamellar or 
multilamellar.9,1o The size of the liposomal vesicles significantly influences their 
biodistribution. Usually, SUVs and MLVs with diameters less than 200 nm are applied 
2 
as systemic drug/gene delivery vehicles because they can pass through the capillary 
veins without clogging after intravenous injection administration. 
1.2 Cationic Liposomes as Gene Carriers 
Broadly speaking, gene therapy seeks to use genetic material as a drug to treat 
genetic or acquired diseases. In the past three decades, the meaning of gene therapy 
expanded from gene replacement through addition of recombinant plasmid DNA 
(pDNA) to regulation of a particular gene via RNA interference (RNAi).11 To date, 
increasing numbers of biological studies and clinical trials have attempted to use gene 
therapy to treat cancers, chronic inflammatory diseases, severe combined 
immunodeficiency, cardiovascular diseases etc. 12 Despite the great potential of pDNA 
and siRNA-based (small interference RNA) gene therapy, there have been few 
successful outcomes in early clinical trials, and no gene therapy products have been 
approved by the FDA so far. One important reason is the difficulty in delivering pDNA 
or siRNA into targeted cells. 
The simplest gene delivery strategy is injection/inhalation of 'naked' (uncomplexed) 
nucleic acids (e.g. pDNA, siRNA). However, the direct injection of 'naked' nucleic 
acids into tissue or blood is ineffective and limited to a few tissues due to the following 
reasons: first, nucleic acids generally undergo rapid enzymatic degradation by 
nucleases in vivo; second, 'naked' nucleic acids cannot reach many organs by 
systemic injection because they are rapidly cleared by the liver (naked siRNA, due to 
its relatively smaller size, is cleared by the kidney and as a result, the half-life of RNA 
in plasma is less than 5 minutes while the half-life of DNA in serum is 10 
3 
minutes.13,14); lastly, the net negative charge of a cellular membrane may repel 
negatively charged oligonucleotides or pDNA, which leads to low efficiency of cellular 
uptake. To overcome these limitations, it is necessary to develop gene delivery 
carriers to safely transport DNA/RNA into targeted cells. 
The most successful gene delivery vector as chosen by nature is the virus. Viruses 
have evolved as a highly efficient way of encapsulating and delivering nucleic acids 
into human cells. Several viruses, such as the retrovirus, adenovirus, pox virus and 
adeno-associated virus have been reengineered as pDNA and siRNA delivery vectors 
to treat cancers, AIDS (acquired immune deficiency syndrome) and many other 
diseases in clinical trials.11, 15 Although viral vectors are the most powerful tool for 
gene transfection due to their high efficiency, they are difficult to produce on large 
scale and hard to modify for desired tissue selectivity. Moreover, viral approaches 
have a variety of other potential problems, such as the potential for oncogenesis due 
to chromosomal integration, gene mutation, out-of-control immune response and 
inflammatory responses which may lead to the death of patients. Therefore, using 
non-viral delivery vectors, in principal, is a preferred approach due to safety issues. 
Cationic liposomes are promising nonviral gene vectors because of various 
advantages besides the safety issues. First, the mutation-free synthesized 
compounds are compatible to mass production and quality control with relatively low 
cost. Second, nonviral vectors can acquire tissue specificity by conjugation to 
targeting groups such as ligands, peptides and antibodies. Third, nonviral vectors can 
deliver large genes (e.g. pDNA containing hundreds of Kbp), whereas viruses have 
limited loading capacity (e.g. adeno-associated virus has 4.8 Kbp genome limit). 
4 










Figure 3. Structures of cationic lipids for gene transfer. 
Since Feigner and colleagues applied DOTMA as gene delivery vector in 1987, 
hundreds of new cationic lipids including DMDHP, DC-Chol, DOSPA have been 
developed (Figure 3).16-18 Generally, cationic lipids are amphiphilic compounds with 
three domains: the hydrophilic head, the hydrophobic tail and the linker. The 
hydrophilic head, usually with positive charge in an aqueous environment, interacts 
with negatively charged nucleic acids. The hydrophobic tail, with one or two linear 
carbon chain tails or ring structures, such as a cholesterol group, help form the interior 
of the protective bilayer. The linker domain can be a variety of functional groups, such 
as ether, amide, ester, acetal, carbamate or oxime functionalities 19-21, which serve to 
connect the hydrophobic tail to the hydrophilic head. 
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The first step of cationic lipid mediated gene delivery is complex formation. Usually, 
nucleic acids are mixed with cationic liposomes in aqueous solution. Due to the 
electrostatic interactions between cationic lipids and negatively charged DNA, bilayer 
vesicular-like structures called lipoplexes are formed?,8 Because of the 
time-dependent aggregation tendency, lipoplexes usually are administered shortly 
after their formation. 
After administration via intravenous injection, lipoplexes must circulate through 
and/or diffuse intercellularly before arriving at the surface of a targeted cell. During this 
process, the lipids can protect the pDNAlsiRNA against nuclease cleavage. For 
successful gene therapy, the final destination of siRNA is the cytoplasm of the target 
cells, while for pDNA it is the nucleus. This means both formulations have to pass 
through the cell membrane. Usually, lipoplexes bind to the cell surface via nonspecific 
interactions of the cationic lipids with anionic membrane components. 
Theoretically, there are two different possible transmembrane mechanisms. The 
lipoplex can fuse with the membrane of the target cells, dumping its contents (pDNA or 
siRNA) into the cytoplasm. Alternatively, the lipoplex can enter cells through an 
endocytosis pathway. The actual process is thought to occur more often by the second 
mechanism, as verified by electron microscopy which shows that the vast majority of 
lipoplex complexes are localized within endosome-like compartments.22 
Once the lipoplex has been trapped within an endosome, the nucleic acids may be 
released through different pathways. The cationic lipid forms ion pairs with the 
endosomal lipid which leads to the fusion of the lipoplex with endosomal membrane 
and release of the nucleic acids. Alternatively, the lipoplex may have a large amount of 
6 
unprotonated amines that can induce the influx of protons, chloride ions and water into 
the endosome. Eventually the endosome bursts due to increased osmotic pressure. 
This so-called "proton sponge effect" enhances endosomal release of lipoplexes. The 
free lipoplex will disassemble to release nucleic acids in the cytoplasm. If the 
lipoplexes are disassembled in the endosome, the nucleic acids can be released in the 
endosome and then go to the cytoplasm. 16.23 The mechanistic process is illustrated in 
Figure 4. 
However, liposome blood instability is one of the biggest problems in gene/drug 
delivery. Cationic lipoplexes are likely to aggregate with blood proteins due to charge 
interactions and consequently this disassembles the lipoplexes. The liposome-protein 
aggregation leads to a high rate of clearance by the reticuloendothelial system, which 
in turn prevents in vivo applications via intravenous administration. 24 Liposomes also 
show chemical and physical instabilities in aqueous dispersions during long-term 
storage. For example, the phospholipids may be hydrolyzed or oxidized under 
aqueous conditions; the encapsulated cargoes may leak out due to liposome fusion; 
and liposomes may from precipitate due to aggregation. Although lyophilization is a 
good way to preserve many drugs, the ice crystals formed during lyophilization can 
damage the integrity of lipid bilayer.25 Therefore, to realize the full potential of 
liposome applications, it is necessary to stabilize the liposomes. This strategy is the 
focus of my thesis research. 
7 
~ pDNA/siRNA 







Figure 4. Cationic liposome mediated gene delivery. 
A. The cationic lipoplex interacts with a cell membrane; B. Starting formation of endosome; C. The 
endosome is destabilized by lipids; D. G. I. Release of gene materials; E. Lipoplex containing 
molecules with buffer capacity in endosomal pH range which can trigger proton sponge effect; F. 
Lipoplex decomposes inside the endosome and releases genetic materials; H. Intact lipoplex 
escapes from the ruptured endosome; I. Lipoplex decomposes inside the cytoplasm and releases 
genetic materials. 
8 
1.3 Methods to Stabilize Liposomes 
Liposome stability is a complex issue. Many researchers have defined liposome 
stability differently based on their research interests.26-29 Because our lab's research 
interest centers on the applications of cationic liposomes as drug/gene carries, we 
focused on the liposome capability to maintain structural integrity (mechanical stability) 
and unimpeded suspension in serum (colloid stability). 
Liposomes can be destabilized through fusion, aggregation or disassembly 
(Figure 5). The fusion of liposomes naturally happens when liposomes encounter 
each other. 3o After they adhere, their lipid bilayers fuse together (e.g. lipid mixing). 
During the "open-and-fuse" process, bigger liposomes are formed. Liposome 
aggregation decreases the colloid stability and consequently leads to particle 
precipitation. Usually, charged liposomes aggregate due to electrostatic interactions in 
the presence of oppositely charged macromolecules or high salt conditions. 31 A good 
example is that cationic liposomes precipitate in the presence of serum, which 
contains many negatively charged proteins. Disassembly of liposomes is the process 
whereby lipid bilayers break down to smaller ones and release contents. Usually 
liposomes can be disassembled by shear force, high temperature or exposure to 
surfactants. Some designed liposomes can be disassembled under certain conditions 
(acid, reduction conditions, light, ultrasound, etc) to achieve a controlled release 
effect. 
Generally, there are two strategies to stabilize liposomes: (1) liposome surface 
modification and (2) lipid bilayer modification. The former strategy stabilizes liposomes 
mainly through changing liposome surface properties to generate electrostatic or 
9 
steric barriers to discourage lipid interactions with other liposomes or molecules (e.g. 
serum proteins). The latter strategy stabilizes liposomes mainly through lipid 
composition modification or crosslinking lipid bilayers to prevent disassembly of 
liposomes. In some cases, the two strategies can be combined to stabilize liposomes. 
~0~··  v Aggregation 
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Figure 5. Liposome destabilization processes. 
It is well appreciated that charged liposomes have better stability than neutral 
liposomes due to the electrostatic force discouraging liposomes approaching each 
other. Therefore, liposomes can be stabilized by adding charge to the surface to work 
as an electrostatic barrier (Figure 6 A). Zhang et al. reported that neutral phospholipid 
DLPC liposomes can be stabilized by absorbing charged nanoparticles at the 
surface.26 The resultant liposomes were stable for more than 50 days, while the similar 
yet untreated liposomes lasted less than 4 days. The presence of the surface 
nanoparticles did not induce content leakage, as determined by fluorescence 
measurement. However, charged liposomes can not be stabilized using this method. 
10 
Figure 6. Methods to stabilize liposomes. 
A. Addition of charged nanoparticles; B. Addition of an outer layer of charged polymers; C. Surface 
absorbed polymers; D. Anchored polymers; E. Anchored polymers in both sides of a lipid bilayer; F. 
Lipid/polymer layer stabilization; G. Lipid layer crosslinking; H. Surface crosslinking. 
To stabilize charged liposomes, a layer-by-Iayer (LBL) strategy (Figure 6 8) can 
be applied. The LBL strategy involves fabricating multilayer films on the surface of 
targeted liposomes via sequential deposition of oppositely charged polyelectrolytes. 32 
11 
The multilayer not only imparts a steric and electrostatic barrier, but also stabilizes 
lipids against disassembly due to electrostatic interactions between polyelectrolytes 
and oppositely charged lipids. Fukui et al. stabilized negatively charged liposomes by 
the LBL strategy using chitosan (a cationic polysaccharide) and anionic polymers 
(dextran sulfate or DNA). The four layer liposomes displayed a dramatic increase in 
stability against a surfactant (Triton X-100) treatment that completely disassembles 
bare liposomes.27,33 They also demonstrated that the encapsulated cargo release rate 
from the stabilized liposomes is slower than that from bare liposomes. However, this 
strategy has an intrinsic problem when applied to stabilize cationic liposomes. It is well 
known that liposomes change their aggregation morphology by collapse and fusion 
when they interact with oppositely charged polyelectrolytes. The collapse and fusion 
during the LBL deposition process will result in cargo leakage and decreased 
encapsulation efficiency. The detailed mechanism of DNA cargo release from cationic 
lipoplexes after adding anionic dextran sulfate has been well elaborated by Xu et al. 22 
Uncharged steric barriers can also be applied to stabilize liposomes. Usually, the 
steric barriers are made from hydrophilic molecules such as poly(vinyl alcohol)34,35, 
poly(ethylene glycol) (PEG) 36,37, polysorbate 8038,39, and polysaccharides4o-42. The 
hydrophilic layers can be introduced via absorption onto the liposome surface (Figure 
6 C). However, the ease of dissociation of the adsorption compounds is a problem and 
leaves the liposomes unstable after dilution. To decrease the dissociation rate, 
anchored amphiphilic polymers have been developed. Those polymers, equipped with 
a hydrophobic domain that can insert into the lipid bilayer, can be immobilized on the 
liposome surface with less dissociation (Figure 6 D, E). 
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There are two formulation procedures that can be applied to generate anchored 
polymers to stabilize liposomes. One is a premodification formulation process where 
stealth molecules mix with the lipids prior to liposome formulation by either 
dehydration-rehydration or reverse-phase evaporation procedures. The resultant 
stabilized liposomes have stealth molecules distributed on both sides of the lipid 
bilayer (Figure 6 E). However, the presence of stealth molecules in the inner leaflet of 
liposomes is not preferred because it remarkably reduces the interior volume (carrying 
capacity) of the liposomes and interferes with the interaction between cationic lipids 
and pDNA.43 .44 Another is a postmodification formulation process where stealth 
molecules may be absorbed and anchored into the outer layer of liposomes (Figure 6 
D). By simply mixing the liposomal suspension with the polymer solution, the polymers 
can be adsorbed and anchored on the liposomes surface. Although this strategy was 
successesful in applications of stealth liposomes for drug delivery, there have not 
been many reports using this approach for gene delivery. 45 Alternatively, the 
postmodification can occur through chemical conjugation of stealth molecules onto the 
liposome surface. So far, variable success using amide, imine, hydrazone linking, 
thiol-maleimide coupling, azide-alkyne coupling as well as Staudinger ligation has 
been achieved.46-5o 
Besides surface modifications, changing the lipid bilayer composition can also 
stabilize liposomes. Initial research showed that changing the composition of lipids, 
such as adding co-lipids (cholesterol), can dramatically improve liposome stability.51 
Considering that bigger molecules have lower mobility than smaller molecules, the 
incorporation of co-polymers into liposomes can lead to stabilization by reducing 
liposome fusion and aggregation. Ruyssaheert et al. reported that ABA triblock 
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copolymers can be inserted into liposomes via simple mixing. The resultant hybrid 
membrane had better stability against dehydration.28.52 However, this method may not 
provide suitable stability to protect liposomes against serum-induced aggregation. 
Highly stable liposomes have been generated through polymerization techniques, 
either in the lipid bilayer or at the liposome surface (Figure 6 G, H). Most examples 
involved polymerization of acrylate (CH2=CHCOO-) domains. O'Brien et al. published 
a good review on this subject. 53 Our group also developed polymerized lipids as gene 
carriers. 54.55 However, the free radicals produced during the polymerization process 
may react with cargo compounds or other resident functional groups (e.g. target 
ligands or pH liable groups). Although it is possible to first polymerize the liposomes 
and then incorporate a cargo and other functional groups to prevent side reaction from 
free radicals. However, polymers may adversely affect liposome preparation, cargo 
encapsulation as well as target ligand incorporation. Therefore, a better approach 
would be to conduct the polymerization after cargo encapsulation using radical-free 
method, such as a chemoselective polymerization. 
Recently, many new strategies have been developed to stabilize liposomes via 
non-radical polymerization. For example, Ruysschaert and co-workers developed a 
method to stabilize liposomes through DNA polymerization. A 25-mer oligonucleotide 
was covalently immobilized on the surface of liposomes. Subsequent addition of an 
enzyme (terminal deoxynucleotidyl transferase) elongates the 25 bp DNA to larger 
(300-500 bp) single-stranded DNA with random sequence. The elongated DNA 
hybridizes to create a random network with short segments of double-stranded DNA. 
The random network was then reinforced by more double-stranded DNA produced by 
DNA polymerase. The resultant DNA stabilized liposomes survived after surfactant 
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treatment at a rate of 5_40%.56 Nguyen's group developed the polymer-caged 
liposomes based on chemical cross-linking between poly(acrylic acid) and 
bis(ethylamine) and applied the stabilized liposomes in drug delivery.29,57,58 However, 
the poly(acrylic acid) polymers usually contain negative charge under physiological 
conditions and this makes it unsuitable for packaging gene materials. 
Considering the pros and cons of each method, we hypothesized that new 
strategies to stabilize liposomes should be explored. We considered two new 
approaches, both involving chemoselective crosslink formation via non-radical 
polymerization. In this thesis, we aimed to develop these strategies for stabilization of 
liposomes and lipoplexes, and to demonstrate their suitability for drug/gene delivery. 
1.4 New Strategies to Stabilize Liposomes 
Our liposome stabilization strategies are based on lipid crosslinking via oximation 
chemistry (a typical type of "click chemistry" 59). Oximation is a chemospecific reaction 
between aminooxy groups and the carbonyl groups of aldehydes/ketones (Figure 7). 
Aminooxy groups react selectively with either aldehyde or ketone carbonyl groups to 
form oxime ethers CR-ON=CH-2R). The coupling process proceeds rapidly under 
aqueous conditions and thus is ideal for applications involving DNA or RNA, especially 
since these polynucleotides do not possess aldehyde or ketone functionalities. The 
resultant oxime ether linkages are robust and particularly stable to physiologic 
conditions. Importantly, aminooxy groups will not react with DNA/RNA functionality. 
Our group recently reported the attachment of a fluorescent aminooxy probe to a 
ketone-containing lipid (DMDK) by forming an oxime ether.60 We also showed that 
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lipoplexes containing aminooxy and ketone functionalities are active in gene 
transfection applications. Therefore, if a cationic lipid were to contain both aldehyde 
and aminooxy functionality, then the reaction between these two functionalities on 
neighboring lipids potentially could form crosslinks. 
Oximation + 
Aminooxy Aldehyde/Ketone Oxime Ether 
Figure 7. Oximation reaction. 
We designed two strategies to stabilize liposomes through generation of crosslinks: 
strategy A is a pH-triggered lipid polymerization and the strategy B is an external 
reagent generated crosslin king (Figure 8). 
Lipid Liposome 
~ A ~ j OQ sonicate > 0= "0 
-0 tt* O'O'd Mbb" ~ er1f B ~ 
Figure 8. Two strategies to stabilize liposomes. 
For strategy A, the lipid is fitted with both functional groups: aldehyde and 
aminooxy. To prevent spontaneous crosslinking, the aldehyde groups are masked as 
enol ethers, which are stable under neutral aqueous conditions but susceptible to 
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aqueous acid-mediated hydrolysis. We envisioned actuating the process of 
'pH-triggered lipid polymerization' in the following manner: After the polynucleotide is 
added to an aminooxy lipid formulation in water (with or without co-lipids/adjuvants) to 
generate a lipoplex, the pH can be lowered (ca. 3.0) to hydrolyze the enol ether 
sidechains and then 'incubated' for a given time to allow the aminooxy-aldehyde 
oximations to occur (step A). The fortified particles then can be (a) used directly after 
adjusting the pH or after purifying (e.g., extrusion), (b) labeled by direct addition of 
targeting elements (step B), or (c) passivated by addition of small ketone or aldehyde 
compounds (e.g., PEG-CHO). As a result of intermolecular oximation reactions, the 
lipoplex surface undergoes lipid-lipid polymerization to generate a more robust 
delivery vehicle. Furthermore, any unreacted aminooxy groups can be used to 
conveniently attach targeting elements by simple mixing with keto- or 
aldehyde-labeled components (step B). The extent of polymerization will be directly 
related to the percent of individual lipid molecules that undergo enol ether hydrolysis. 
The outer layer of the lipoplex formulation (outer leaflet of the bilayer coating) is most 
susceptible to the hydrolysis conditions; however, oximation may occur within the 
lipoplex interior (polar domains of inner leaflets) depending on reaction times and acid 
strength. The condensed polynucleotide within the lipoplex bilayers is largely shielded 
during the oximation phase. Intramolecular oximation may occur, but due to the large 
ring size formed in this event (e.g., a 21-membered ring, in the case of lipid 3.2), the 
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Figure 9. pH-triggered intermolecular polymerization. 
For strategy B, each lipid was functionalized with two aminooxy groups for reaction 
with an external crosslink reagent that contains aldehyde functionality. This strategy 
not only avoids the use of acid as in strategy A, but also simplifies the prototype lipid 
structure and synthesis. We envisioned actuating the process of 'click' stabilization in 
the following manner: After cationic aminooxy lipid formulation or lipoplex formulation 
in water to generate liposomes, an external reagent containing bis-/multi-aldehyde 
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functional groups can be added and incubated for a given time to allow 
aminooxy-aldehyde oximations. As a result of intermolecular oximation reactions, the 
liposome surface will undergo lipid-reagent polymerization to generate a stabilized 
liposome (Figure 8). Due to different equivalents of aldehyde added, the 'click' 
stabilized liposome surface may have available unreacted aminooxy or aldehyde 
functionality. Any unreacted aminooxy/aldehyde groups then can be used to 
conveniently attach targeting elements by simple mixing with keto-, aldehyde-or 
aminooxy-Iabeled components. The extent of polymerization will be directly related to 
the equivalents of aldehyde reagent/polymer added. 
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1.5 Thesis Organization 
The goal of my research is to discover new methods to stabilize liposomes or 
lipoplexes and to demonstrate their application in gene or drug delivery. 
Chapter 2 describes the synthesis and characterization of novel cationic aminooxy 
compounds. These aminooxy compounds were designed to function as the 
headgroup domains of prototype lipids as well as for other potential applications. 
Chapter 3 describes the liposome stabilization strategy A: pH-triggered lipid 
polymerization. The prototype cationic aminooxy lipids were synthesized and 
characterizated and the hypothesis of strategy A was tested. 
Chapter 4 describes the liposome stabilization strategy B: external reagent 'click' 
stabilization. The prototype cationic aminooxy lipids were synthesized and the 
hypothesis in strategy B was tested and confirmed. The 'click' stabilized liposomes 
were applied as a drug/enzyme carrier. 
Chapter 5 deals with 'click' stabilized liposomes for gene transfection. The 'click' 
stabilized liposomes were applied in in vitro gene transfections. A liver-targeted ligand 
based on lactose was synthesized for future in vivo gene transfection applications. 
Chapter 6 details all experimental procedures and compounds characterization. 
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CHAPTER 2. 
CATIONIC AMINOOXY REAGENTS 
2.1 Introduction 
As discussed in Chapter 1, the instability of liposomes is a fundamental obstacle 
that impedes liposome applications in gene/drug delivery. One promising approach to 
address this problem is liposome stabilization via a non-radical mediated lipid 
polymerization. In our proposed liposome stabilization strategies (Chapter 1.4), 
oximation was selected as an ideal polymerization reaction because it is a mild, 
selective and convenient procedure. To test the hypothesis of our proposed strategies, 
prototype cationic aminooxy lipids needed to be synthesized. The first step towards 
this type of lipid synthesis was to develop a synthesis route towards the hydrophilic 
headgroup, which contains the cationic aminooxy functionality. We designed the 
headgroup of the prototype lipid, as illustrated in Figure 10, to contain three 
functionalities: (1) an aminooxy moiety for subsequent polymerization; (2) a 
tetraalkylammonium ion to import a positive charge for DNA/RNA binding; and (3) a 
hydroxyethyl group for attachment to the hydrophobic domain of the lipid. 
Besides being applied as headgroups of prototype aminooxy lipids, these 
designed cationic aminooxy compounds can also be used as a new type of 
nucleophilic cationization reagent. 61 Cationization reagents, usually electrophilic 
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quaternary ammonium reagents, have been widely applied to react with a variety of 
materials to equip them with positive charges.62-65 This derivatization process, also 
known as cationization, can impart described properties. For example, the 
cationization of proteins is performed to enhance their intracellular delivery via 
adsorptive-mediated endocytosis.66 The cationization of cellulose fibers (e.g., cotton) 
can improve the uptake of dyes in subsequent coloring operations.67 Some 
electrophilic cationization reagents (2.3 -2.7) are shown in Figure 11.68-72 
H'N0?i)0NH' 
H2NOl ONH +J 2 ?' I-




Headgroup 2.1 2.2 
Figure 10. Cationic aminooxy lipid headgroups. 
Given the ease of oximation and the robust nature of the oxime ether linkage, 
cationic aminooxy reagents are ideal nucleophilic counterpart to the current 
electrophilic reagents. Our interest in gene transfer materials led us to prepare a 
series of cationic aminooxy compounds (2.1, 2.2 in Figure 10 and 2.8, 2.9, 2.10 in 
Figure 11). The synthesis of 2.1 and 2.2 is described in this chapter. 
OH \+/ 0 \+.....- 0 \+/ 0 CI~N" ~N, ~N~ 
CI CI CI 
2.3 2.4 2.5 
2.8 2.9 
\+/ 0 +1.....-Br~N, \S/S~N, 
./ \\ -
2.6 
Br 0 Br 
2.7 
\ / -
N + I H2NO~ ~OH 
2.10 
Figure 11. Cationization reagents and cationic aminooxy compounds. 
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2.2 Cationic Aminooxy Reagent Synthesis 
There are two common methods to introduce the aminooxy functionality (Scheme 
1). One is introduction of an N-hydroxy imide into the molecule followed by cleavage 
with hydrazine to give the aminooxy.73 The other is to displace a halide using a 
Boc-protected hydroxylamine (tett-butyl N-hydroxycarbamate) followed by 
Boc-deprotection using acid to give the aminooxy.74 Previous work in our lab 
described the synthesis of a series of aminooxy reagents. 75 In this work, a double 
halide displacement by tett-butyl N-hydroxycarbamate was troublesome; however, the 
N-hydroxy imide route was successful. Based on this experience, I opted to use the 
N-hydroxy imide route to synthesize the target cationic aminooxy compounds. 
0 0 
R-OH + c::GN- OH a O-N~ ~ R ::::-... ~ 0 0 
R-ONH2 
0 
° / R-Br + )l )l ,OH c R/O'NAO* ° N .. H H 
Scheme 1. Strategies to introduce aminooxy functionality. 
Conditions: a) N-hydroxyphthalimide, PPh3, DIAD, THF, 0 °C to rt.; b) N2H4.H20, ethanol, rt.; c) 
HONHBoc, DBN, TBAI (cat.), CH3CN, rt.; d) TFA, CH2CI2, 0 °C to rt .. 
2.2.1 Synthesis of Cationic Aminooxy Reagent 2.1 
Our retrosynthetic route to the cationic bisaminooxy compound 2.1 is shown in 
Scheme 2. Commercially available reagent triethanolamine is used as starting 
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material; no extra C-C bonds need to be installed. The synthesis route relies only on 













Scheme 2. Retrosynthetic route to aminooxy 2.1. 
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2.13 2.14 2.1 
Scheme 3. Synthesis of cationic aminooxy compound 2.1. 
Conditions: Pht = phthaloyl a) TBSCI, Et3N, CH2CI2 , 90%; b) N-hydroxyphthalimide, PPh3, DIAD, 
THF, 0 °C to rt., 12h, 82%; c) 48% aq. HF, THF, 0 °C to rt., 12h, 86%; d) CH31, sealed tube, 60°C, 
The synthesis route used to prepare compound 2.1 is shown in Scheme 3. 
Monosilylation of triethanolamine was accomplished by reaction of triethanolamine 
with 0.2 eq. of TBSCI as the limiting reagent. To favor the production of 
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mono-protected product 2.11 (90% yield based on TBSCI), the TBSCI was diluted (0.2 
M) in dichloromethane before very slow addition (dropwise overnight). The resultant 
mono-protected triethanolamine 2.11 was then transformed to the corresponding 
bis-N-(2-hydroxyethyl)-functionalized aminooxy reagent 2.12 in 82% yield through 
Mitsunobu reaction conditions. 73 
The desilylation of compound 2.12 was problematic. Standard TBAF-mediated 
deprotection of 2.12 resulted in double N-O cleavage, giving triethanolamine as the 
principal product. Other attempts (e.g., AcOH- or TsOH-mediated deprotections) were 
equally disappointing. We were gratified to find, however, that prolonged reaction with 
aqueous HF furnished the desired crude product. After recrystallization in ethyl 
acetate, compound 2.13 was obtained in 86% yield. 
The amine quaternization was best accomplished by heating the amine 2.13 in 
methyl iodide. After evaporation of the unreacted methyl iodide in the fumehood, 
compound 2.14 was obtained in 98% yield. The resultant, crude ammonium iodide 
was treated directly with hydrazine in ethanol to cleave the phthaloyl groups. After 
work-up, the aminooxy product 2.1 was obtained in 70% yield by reverse phase HPLC 
purification. In the 1 H NMR spectrum (500 MHz) of 2.1 (Figure 12), the broad signal at 
6.28 ppm and 5.26 ppm corresponds with aminooxy proton and hydroxyl proton, 
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Figure 12. 1H NMR spectrum of aminooxy compound 2.1. 
2.2.2 Synthesis of Cationic Aminooxy Reagent 2.2 
The synthesis of compound 2.2 requires extra work to generate a C-N bond due to 
the lack of a template (which was available for compound 2.1.1). (Scheme 4). The 
glycidol epoxide- ring opening by amine is an ideal reaction for this purpose. The 
selection of protection group and the purification of the hydrophilic product are two 
major concerns that need to be addressed. 
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Scheme 4. Retrosynthetic route to compound 2.2. 
(PG = Protection Group) 
The first attempt at constructing the target compound went smoothly up to the 
stage of the epoxide opening reaction (Scheme 5). Briefly, the alcohols of 
diethanolamine were first protected by TBS in 94% yield, and then amine functionality 
was Boc-protected in 79% yield. After silyl deprotection by TBAF, the diol 2.17 was 
treated with N-hydroxyphthalimide under Mitsunobu conditions to provide 2.18 in 51 % 
yield. After TFA mediated cleavage of the Boc protection group, ammonium salt 2.19 
was obtained in 99% yield. However, in subsequent chemistry, we observed that 
ammonium salt 2.19 failed to react with epoxide 1, 2-epoxyhexadecane. Under base 
conditions, the reaction was very sluggish and many byproducts formed, presumably 
due to the sensitive phthalimide group. Therefore, we explored a different route to 







































N )( • N • C14H29~ H2 
2.19 2.20 OH 
Scheme 5. First attempt to synthesize cationic aminooxy 2.2. 
Conditions: Pht = phthaloyl a) TBSCI (2.2 eq.), Et3N (2.4 eq.), CH2CI2, 12h, 94%; b) (BochO, 
Na2C03, CH2CI2, rt., 13 h, 79%; c) TBAF, THF, rt., 12 h, 100%; d) N-hydroxyphthalimide, PPh3, 





2.21 2.22 2.2 
Scheme 6. Second attempt to synthesize cationic aminooxy 2.2. 
Our second attempt involved using N,N-bis(2-phthalimidooxyethyl) -methylamine 
reacted with glycidol (Scheme 6). However, this reaction also failed, possibly due to 
steric hindrance issues. The phthalimide group is inconvenient to handle when the 
target is a hydrophilic compound. The phthalimide protecting group is readily 
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decomposed on silica gel when the eluent contains methanol. Furthermore, the 
phthalimide protecting group is unstable in the presence of a secondary or tertiary 
amine (e.g. EbN) which is often used during silica chromatography of polar amines. 
OH OH 
~ a ~ 
HN BnN 
~ ~ 



















Scheme 7. SynthesiS of Boc-protected bis-aminooxy amine 2.26. 
Conditions: Pht = phthaloyl, Bn = Benzyl. a) Benzyl chloride, CH3CN, Na2C03, reflux, 17h, 92%; b) 
N-hydroxyphthalimide, PPh3, DIAD, THF, 0 DC to rt., 12 h, 79%; c) N2H4·H20, ethanol, CH2CI2; 15 
min; d) (Boc)20, NaHC03, CH2CI2, rt., 17 h, 99% for two steps; e) H2, Pd/C, rt., 22 h, 60%. 
Due to the difficulty in handling bis-phthalimide compounds, we switched to using a 
bis-Boc protecting strategy (Scheme 7). The Boc-protected bisaminooxy amine 
compound 2.26 was synthesized according to the method described previously.75 
Briefly, diethanolamine was first protected with benzyl chloride and then followed by 
Mitsunobu reaction using N-hydroxyphthalimide to incorporate the protected 
aminooxy functionalities. The protecting groups were exchanged through hydrazine 
cleavage followed by reaction with excess Boc-anhydride. Finally, the benzyl 
protecting group of compound 2.25 was cleaved by hydrogenolysis to generate the 
bis-Boc protected 2.26 in 43% overall yield. 
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With the Boc-protected bisaminooxy amine 2.26 in hand, the C-N bond of the 
target compound should be readily formed through glycidol ring opening reaction 
(Scheme 8). Unfortunately, reaction of 2.26 with glycidol in the presence of base 
generated 2.27 in low yield (40%) with hard-to-separate byproducts (i.e. compound 
2.28) which were observed by TLC using an 12 stain. Presumably, intramolecular 
proton transfer from the initial expoxide cleavage adduct generates a primary 
oxyanion that competes with the starting amine for the remaining glycidol.76 Moreover, 
the purification of methylated product of 2.27, a quaternary ammonium, was 










































Conditions: a) 2-(trityloxy)methyloxirane, Na2C03, ethanol, 60°C, 22 h, 64%; b) CH31, CHzClz, 
sealed tube, 60°C, 24 h, 80%; c) TFA, CHzClz, triethylsilane, 0 °C to rt., 12 h, 38%. 
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To eliminate the side reactivity of the primary oxyanion, as well as to increase the 
hydrophobicity of the product, we protected glycidol using the bulky triphenylmethyl 
group. Therefore, 2-(trityloxy)methyloxirane was used as the reactant instead of 
glycidol and epoxide ring opening product 2.29 was obtained in 64% yield after Si02 
chromatographic purification. Subsequent amine quaternization was performed by 
heating 2.29 with methyl iodide in a sealed tube. The resultant crude material was 
chromatographed to give 2.30 in 80% yield. Finally, the Boc and trityl protecting 
groups were removed by treatment with TFA, and the target product 2.2 was obtained 
in 36% yield (Scheme 9). The low yield for the last step can be mainly attributed to two 
reverse phase chromatographic purification steps, and this still leaves room for overall 
synthesis improvement. 
In the 1H NMR spectrumof 2.2 in CD30D (Figure 13), the broad signal at 0 5.08 
ppm corresponds to the aminooxy protons and the hydroxyl proton. Quaternized 
amine methyl group NCH3 was observed at 3.33 ppm. With the additional information 
from COSY spectrum, the signal at 0 4.43 ppm to 0 4.52 ppm can be assigned to 
CH2-ONH2 while the signals at 0 3.92 ppm to 0 4.02 ppm can be assigned to 
NCH2CH20NH2 . The signal of 0 4.23 ppm corresponds to 1 H from NCH2CHOH. The 
signal from 0 3.45 ppm to 0 3.75 ppm corresponds to the proton from 
NCH2CHOHCH20H. The high resolution mass (HRMS) found M+ at 224.1605 
(CaH22N30/, calculated as 224.1605). 
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2.3 Future Applications 
Besides being applied as lipid headgroups for our proposed click polymerization, 
the cationic aminooxy reagents 2.1 and 2.2 may have other applications. One such 
application is for synthesis of cationic lipids for gene transfection using click chemistry 
ligation to attach hydrophobic (alkyl-chain) aldehydes (Scheme 10). Our lab already 
demonstrated that bis(oxime ether) lipid 2.31, synthesized from compound 2.9, is a 
good gene delivery Iipid.61 .77 Considering the benefit of hydroxyethylated polar 
domains in gene delivery,54.78 we believed that lipids 2.32 and 2.33, assembled from 
the headgroup 2.1 and 2.2 via click chemistry, could be promising gene delivery lipids 
as well. 
1- ONH2 1 ,+~ tetradecanal \+~o ,-; 
-N -N 
.,/N ONH2 .. ~O-N'-; '---I MeOH 
2.9 2.31 
-+~ONH2 1 
HO--../':N tetradecanal HO~N~O-N'-; 
/ ~ONH2 .-
.,/ ~O-N'-; MeOH 
2.1 2.32 
1 1 
HOp +~ONH2 tetradecanal HOpN~OVN'-; 
.,/N 
HO ~ONH2 .- HO ~OvN'-; MeOH 
2.2 2.33 
Scheme 10. Oxime ether lipids. 
Another potential application of compound 2.2 is as a part of magnetic drug 
delivery system (Figure 14). Our lab has discovered that some cationic aminooxy 
regents can attach to magnetic iron oxide (Fe304) nanoparticles and then dissociate 
from the particles when exposure to an alternating magnetic field due to induction 
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heating. For example, one aminooxy moiety of 2.2 can be conjugated with an 
aldehyde-functionalized anti-tumor drug and the other one can be conjugated with 
aldehyde-functionalized tumor targeting agent. The diol portion as well as the cationic 
ammonium ion provides non-covalent binding to the iron oxide nanoparticles. We 
envisioned that the formulated drug-nanoparticle complex, once injected into the body, 
may concentrated around the tumor site due to targeting ligand as well as magnetic 
field. Once alternating magnetic fields applied near the tumor, the induced heating 
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Figure 14. Proposed multifunctional magnetic nanoparticle for drug delivery. 
2.4 Conclusions 
In summary, this chapter presented the first synthesis of two cationic 
hydroxyethyl-functionalized bis-aminooxy reagents, 2.1 and 2.2. The general 
synthesis route can be adapted to synthesis of other similar compounds. The two 
cationic aminooxy reagents constitute the headgroups of our target 
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c1ick-polymerizable lipids. Due to the ease of oximation and the robust nature of the 
oxime ether linkage, the cationic aminooxy reagents may have other applications 
including as headgroups of gene delivery lipids as well as coatings of magnetic 
nanoparticles for drug delivery. 
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CHAPTER 3. 
CATIONIC AMINOOXY LIPIDS FOR 
pH-TRIGGERED LIPOSOME 
POLYMERIZATION 
--FIRST GENERATION CONCEPT 
3.1 Introduction 
In the early 1980s, liposome polymerization was achieved by the Regen group 
using lipids that incorporated acrylate groupS.79 Since then, an increasing number of 
lipids have been fitted with a great variety of polymerizable groups, such as styryl, 
vinyl, diacetylenyl, acryloyl, methacryloyl, butadienyl, isocyano, lipoyl and sorbyl 
(Figure 15).53 Most of these groups undergo polymerization by radical chain 
propagation except lipoyl, which uses a disulfide forming approach.8o Besides small 
molecule polymerizable groups, macromolecules, such as oligonucleotides, can be 
used as polymerizable groups once immobilized on liposome surface,56 While there is 
no question that such polymerizable molecules have been proven to be effective at 
improving liposome stability, next-generation polymerizable lipids need to be 
developed to fulfill various applications of liposomes. 
Our lab's interest in liposomes for gene/drug delivery requires polymerizable lipids 
that have certain characteristics. First, the polymerizable lipids must be biocompatible 
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and inert to various gene/drug functionalities. Next, the polymerization chemistry must 
occur in aqueous solution. Finally, the bonds generated from polymerization must be 
robust. For these reasons, we considered potential polymerizable motifs from the 
arsenal of "click chemistry" which provides many quick and reliable biocompatible 
reactions. 
9 ) c ( X \~ III 0 N+ I 0) ~ ) 
Styryl Vinyl Isocyano Acryloyl Methacryloyl Lipoyl 0 \ JVV"~~ \ O~ 
Butadienyl Sorbyl Diacetylenyl 
Figure 15. Examples of polymerizable groups for liposome polymerization. 
Click chemistry, the philosophy promoted by K. B. Sharpless in 2001, describes a 
class of chemical reactions that are "modular, wide in scope, give very high yields, 
generate only inoffensive byproducts and be stereospecific".59 Although click 
chemistry reactions such as azide/alkyne and carbonyl/aminooxy have been widely 
used, only a few examples applied to polymerization have been reported.6o.81-83 We 
set out to achieve liposome polymerization via oxime ether formation instead of the 
more widely used azide/alkyne chemistry to avoid using Cu(I). In an early application, 
the Nantz group reported a bis-keto lipid, DMBDKE, that was polymerized by reaction 
with tetra-aminooxy linker TACL as well as bisaminooxy lipid BAL (Scheme 11).75 
Although the prototype DMBDKE system successfully demonstrated that liposomes 
can be polymerized via an oximation reaction, there remained much room for 
improvement. For example, DMBDKE was hard to handle due to its low solubility in 
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aqueous solution and somewhat sluggish reactivity. Additionally, the stabilized 
DMBDKE liposomes were vulnerable to aggregation by blood proteins after dilution.75 




Scheme 11. Initial examples of lipid polymerization via oxime ether formation. 
To improve our polymerizable liposome system for gene/drug delivery, my thesis 
work addressed a novel strategy for liposome stabilization: pH-triggered liposome 
polymerization via oximation reaction (Figure 16). We postulated that aldehyde 
functionality can be masked as an enol ether group incorporated within the lipid 
hydrophobic domain. Under mild acid condition (ca. pH=3.0), the enol ether sidechain 
would be hydrolyzed and release the aldehyde group.84,85 The free aldehyde group 
could then act as polymerizable group by reaction with an adjacent aminooxy group. 
38 
Aminooxy PD 
Figure 16. pH-Triggered liposome polymerization via oximation reaction. 




with Enol Ether 
Figure 17. Structures of prototype lipids for pH-triggered lipid polymerization. 
To achieve better water solubility as well as facilitate formation of a lipid bilayer, the 
prototype lipids were designed as shown in Figure 17. Like other typical cationic lipids 
(Figure 3) , the prototype aminooxy lipid also has three parts: (1) a polar headgroup 
that contains two aminooxy moieties; (2) a hydrophobic domain that contains one or 
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two linear carbon chains where at least one contains an enol ether moiety; and (3) 
linker used to join the polar (aminooxy) domain to the hydrophobic (enol ether) domain. 
Compared to the design of DMBDKE, the new prototype lipids have the following 
advantages: first, the bisaminooxy groups are more hydrophilic than bisketo groups 
which can enhance lipid aqueous solubility; second, the tetraalkylammonium 
headgroup is smaller than the bianteniary structure in DMBDKE which may facilitate 
lipid bilayer formation; third, a pH-triggered release of aldehydes can provide control 
over the polymerization process; and last but not least, the released aldehyde group is 
more reactive than a ketone group. Based on these design considerations, 
compounds 3.1 and 3.2 were synthesized as prototype lipids to examine pH-triggered 
lipid polymerization. Since various bis-aminooxy cationic compounds had already 
been synthesized (Chapter 2), this chapter will focus on the synthesis of the enol 
ether component and the linker. 
3.2 Synthesis of Enol Ether Tail Group 
The chemical principles behind pH-triggered hydrolysis of a variety of functional 
groups have been reviewed by Cordes and Bull four decades ago. 84 Among the 
acid-cleavable functionalities, enol ethers are one of most studied acid labile 
functionalities in lipid chemistry. Thompson and associates reported several lipids 
(Figure 18) with acid-sensitive enol ether moieties.86-9o These mono- and 
bi-plasmenyl lipids have been widely used as acid labile drug/gene carriers that 
release encapsulated therapeutic agents once exposure to mildly acidic conditions 
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Figure 18. Lipids with enol ether functionality. 
Incorporating enol ether functionality into lipids is challenging work because the 
enol ether bond is sensitive toward oxidants and acidic reagents. This places great 
limitations on the types of reagents and protective groups that can be employed in the 
synthetic route. The Thompson group published many methods for synthesis of 
plasmalogen type lipids, a class of naturally occurring phospholipids with an enol ether 
in the hydrophobic domain.88,91-93 For example, lipid 3.4 was synthesized via 
paliadium(O)-catalyzed reduction of vinyl phosphates (Equation a, Scheme 12) or via 
Barbier-type reactions of vinyl acetal and alkyl halide in the lithium 
4,4-di-tert-butylbiphenyl (LiDBB) solution. (Equation b, Scheme 12)88,91 Lipid 3.6 was 
synthesized via alkylation of TBS-protected 2-iodoethanol on allyl anion, but 
undesired a-coupling byproduct is a big problem. (Equation c, Scheme 12)89,92 The 
Buchwald group also reported a synthesis of vinyl ethers by using copper-catalyzed 
C-O coupling of alcohols with vinyl iodides.94 However, this method cannot be used to 
prepare (Z)-vinyl ethers because the (Z)-vinyl iodides decomposed under the reported 
reaction conditions. (Equation d, Scheme 12) 
41 






tetramethyl-1 ,1 O-phenanthroline, 
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Scheme 12. Methods to incorporate an enol ether into a lipid sidechain. 
In our prototype lipid design, the aldehyde group, not the alcohol group, remains 
attached to the lipid backbone after acid catalyzed hydrolysis (Scheme 13). 
Moreover, a secondary alcohol was chosen as linker functionality based on synthesis 
convenience. Those structural differences between the designed prototype lipids and 
plasmalogen type lipids required us to develop new methods for synthesis of the enol 
ether domain. The new method required incorporation of an enol ether, two 
hydrophobic chains and a secondary alcohol into one molecule. We developed three 
different strategies to prepare such enol ether tail compounds. 
o 
Lipids 3.3-3.6 Lipid-OH + IIR H~ 
Lipid. OR 
Prototype Lipid ~ 
LiPi~ 
or OR HO-R 
(Z) (E) 
Scheme 13. A shift of enol ether group in the prototype lipid. 
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Acetal Elimination 
The first two strategies constructed the enol ether moiety through highly 
chemoselective deprotection of an acetal by using combinations of 
2, 6-lutid i ne--trimethyls ilyltriflate (TMSOTf) or 2,6-1 utid ine--triethylsilyltriflate 
(TESOTf).95,96 The Kita group had applied this strategy to prepare enol ether 3.7 
(Scheme 14). Considering the structural similarity of compound 3.7 and target lipid 3.9, 
we believed that the enol ether of 3.9 could be synthesized via the same strategy by 
using acetal 3.8 as starting material. 
1) TESOTf, 2,6-lutidine 




1) TESOTf, 2,6-lutidine 
CH2CI2 
----------- TESO~O/C1OH21 Present work 
3.9 
Scheme 14. Synthesis of enol ethers via TESOTf-induced elimination. 
The dual chain enol ether tail group 3.11 (Z) was synthesized from decanol in two 
parts (Scheme 15). The first involved generating an enol ether with a primary alcohol 
as linker; the second part involved conjugating to another chain. Decanol was first 
protected by reaction with dihydropyran under acid catalysis to obtain acetal 3.8 in 
98% yield.97 The resultant acetal was then treated with triethylsilyltriflate and 
2,6-lutidine to obtain enol ether 3.9 in 91 % yield. The Z:E ratio (5: 1) was determined by 
the vinyl proton integrals. Distinction between the E and Z isomers was made by 
measuring the 3 J coupling constants for vinyl protons (Figure 19). In the 1 H-NMR 
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spectrum, the RCH=CHOR' (04.32 ppm) and RCH=CHOR' (0 5.91 ppm) have a 3J 
coupling constant of 6.5Hz which is in the range expected for the Z isomer while the 
RCH=CHOR' (0 4.74 ppm) and RCH=CHOR' (0 6.22 ppm) have a 3J coupling 
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Figure 19. 1H-NMR (CDCI3 , 500 MHz) spectrum of 3.9 (Z: E=5:1). 
The TES group was removed by reaction with TBAF to give the single chain 
compound 3.10. After seperation by Si02 column chromatography, the 3.10(Z) and 
3.10(E) isomers were obtained in 60% and 9% yield, respectively. After heating the 
sodium alcoholate of 3.10(Z) with 1,2-epoxyhexadecane, the dual chain tail 3.11 (Z) 
was obtained in 83% yield (Scheme 15). It is noteworthy to mention that the 
commercially available 1 ,2-epoxyhexadecane (Sigma, 260215) is technical grade with 
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85% purity, and this reagent must be purified by Si02 chromatography to minimize 
byproduct formation. Using same method, 3.11(E) was synthesized from 3.10(E). In 














Scheme 15. Synthesis of enol ethers 3.10 and 3.11. 
Conditions: TES=Triethylsilyl a) 2,3-dihydropyran, p-TsOH, CH 2CI2 , O°C to rt. 12h, 98%; b) 
TESOTf, 2,6-lutidine, CH2CI2, O°C to rt., 12h, 91%, Z:E=5:1; c) TBAF, THF, a °C to rt, 24h, (Z, 60%, 
E 9%, separated by Si02 chromatography); d) i) NaH, DMSO; ii) 1,2-epoxyhexadecane, 50 °C, 
12h,83%. 
The second approach using this triflated-induced elimination strategy involves first 
preparing a two chain acetal and then generating the enol ether in similar manner 
using TMSOTf. As an example, enol ether 3.15 was synthesized by this method 
(Scheme 16). Firstly, the (3,4-dihydro-2H-pyran-2-yl)methanol was deprotonated by 
sodium hydride and then reacted with 1-bromododecane to generate 3.12 in 90% 
yield. Then, the compound 3.12 was reacted with 1-decanol under acid catalysis to 
give the dual chain acetal 3.13. The resultant crude acetal 3.13 was treated with 
TMSOTf and 2,6-lutidine to generate enol ether 3.14 in 77% crude yield (two steps). 
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Finally, the TMS group was removed by reaction with TBAF to give the dual chain enol 
ether 3.15(Z) after chromatography in 59% yield. In 1 H NMR spectrum, the 
RCHCHOR' (0 4.34 ppm) and RCHCHOR' (0 5.96 ppm) have a 3 J coupling constant 
of 6.0Hz which is in the range expected for the Z isomer. In a word, the dual chain tail 
3.15 has been obtained in 4 steps in 41 % overall yield from 
(3,4-dihydro-2H-pyran-2-yl)methanol. 






Scheme 16. Synthesis of enol ether tail 3.15. 
Conditions: a) i) NaH, DMF, rt., 1h; ii) 1-bromododecane, rt., 24h, 90%; b) p-TsOH, CH2CI2, rt. 14h; 
c) TMSOTf, 2,6-lutidine, CH2CI2, 0 °C to rt., 12h, 77%, two steps; d) TBAF, THF, 17h, 59%. 
Olefination Approach 
The third strategy used the Wittig reaction to generate the enol ether moiety. 98 Mr. 
Wesley Badger, an undergraduate student working with me, synthesized enol ether 
3.20 using a convergent synthesis route (Scheme 17). 
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Scheme 17. Synthesis of enol ether tail 3.20. 
Conditions: a) i) 1,4 butanediol, NaH in THF, O.5h, rt.; ii) 1 ,2-epoxytetradecane, 55°C, 24h, 97%; b) 
4-methoxy-TEMPO, KBr, NaOCI, CH2CI2, H20, O°C, 8.5 min, 72%; c) i) NaOH, chlorobenzene, H20, 
50°C, 1 h; ii) CH2Br2, TBAB, 50°C, 4h, 98%; d) i) Octanoyl chloride, ZnBr2' 4h, 45°C; ii) PPh3, 
toluene, 65°C, 12h, 69%; e) i) 3.19, KHMDS, THF, -78°C to rt., O.5h; ii) 3.17, -78°C to rt., 2.5h, 93%. 
Firstly, 1,2 epoxy-tetradecane was cleaved by mono-alkoxide of 1 ,4-butanediol to 
give 3.16 in 97% yield. Then, the primary alcohol of 3.16 was selectively oxidized to 
aldehyde 3.17 in 72% yield by using radical catalyst 4-methoxy-2,2,6,6-tetramethyl-1 
-piperidinyloxy (4-methoxy-TEMPO).99,1oo The synthesis of Wittig reagent 3.19 from 
pentanol featured reaction of dibromomethane under the phase transfer catalyst 
(tetrabutylammonium bromide) to generate formaldehyde acetal 3.18 in 98% yield.101 
The resultant formaldehyde acetal 3.18 was reacted with octanoyl chloride in the 
presence of ZnBr2 to form a-halo ether, 1-(chloromethoxy)-pentane. Due to 
carcinogenic nature of a-halo ether compound, the crude product wasn't isolated, 
rather it was directly reacted with triphenylphosphine in the same pot to generate 
Wittig reagent 3.19 in 69% (two steps) yield. Finally, the alcohol of 3.17 was 
deprotonated and then reacted with Wittig reagent 3.19 to generate enol ether 3.20. 
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The regioselectivity of the Wittig reaction was influenced by the base. For example, 
when using KHMDS the E: Z ratio of product 3.20 was 4: 1 while when using the n-BuLi, 
the E: Z ratio was 1 :1. This selectivity as well as the high yield obtained (93%) are not 
unusual under these conditions. 102,103 In summary, 3.20 was prepared in five steps in 
65% yield from 1,2 epoxy-tetradecane with 3.20(E) as major isomer. This third method 
has the highest overall yield from commercially available starting material and 
represents a convergent synthetic route design. 
3.3 Linker Study 
After completing the syntheses of cationic aminooxy headgroups and enol ether 
sidechains, the next goal was to find a suitable linker to join these domains. In the 
course of these studies, we examined many linker strategies. Here we described 
some of the chemistry to prepare lipids 3.1 and 3.2. 
3.3.1 Quaternary Ammonium Linkage 
The first designed bis-aminooxy cationic lipid 3.21 has a quaternary ammonium 
nitrogen that has dual functionality: to serve as a cation and linker atom (Figure 20). 
The two hydrophobic tail chains, including one with enol ether, are directly attached to 
the ammonium ion. 
Figure 20. Concept aminooxy enol ether lipid with quaternary ammonium. 
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To synthesize cationic lipid 3.21, a synthesis of the precursor trialkylamine 3.23 
(Scheme 18) was developed. Considering that Mel may react with the aminooxy 
groups, the aminooxy groups were protected before the quaternization reaction. 
Firstly, diethanolamine was reacted with 1-bromotetradecane to form bis-alcohol 3.22 
in 93% yield. Diol 3.22 was then transformed to the corresponding bis-protected 
aminooxy reagent 2.23 in 48% yield by treatment with N-hydroxyphthalimide under 




















Scheme 18. Synthesis of trialkylamine 3.23. 
Conditions: Pht = phthaloyl a) 1-bromotetradecane, CH3CN, Na2C03, reflux, 20 h, 93%; b) 
N-hydroxyphthalimide (2.2 eq.), PPh3 (2.2 eq.), DIAD (2.2 eq.), THF, 0 °C to rt., 12 h, 48%. 
We planned to prepare the bromo-alkyl enol ether 3.24 from alcohol 3.10(Z) by 
reaction with triphenylphosphine and tetrabromomethane (Scheme 19). However, 
bromination of alcohol 3.10(Z) failed to deliver the bromo-alkyl product 3.24. 
Cyclization product 3.8 was instead obtained in 55% yield along with 1-bromodecane 
in 41% yield. Presumably, this is due to the decomposition of the enol ether starting 
material under the given reaction conditions. Fortunately, iodo-alkyl 3.26 was obtained 
in two steps without any problem. Alcohol 3.10(Z) was converted to tosylated product 
3.25 in 86% yield and then reacted with sodium iodide to give iodo-alkyl product 3.26 
in 91% yield. 
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ClOH21-0~OH ~ ClOH21/0D ClOH21-Br 
3.10(Z) 3.8 3.24 Not formed 
3.25 3.26 
Scheme 19. Synthesis of iodoalkyl enol ether 3.26. 
Conditions: a) PPh3, CBr4, THF, rt., 12h; b) p-toluenesulfonyl chloride, Et3N, CH2CI2 , rt., 14 h, 86%; 
c) Nal, acetone, 45 DC, 12 h, 91%. 
With both iodo-alkyl 3.26 and trialkylamine 3.23 in hand, we examined the 
quaternization reaction (Scheme 20). Disappointingly, no amine alkylation accured 
since the phthalimide protection groups decomposed at the higher temperature 
needed for quaternization. The instability of phthalimide protection groups was also 





3.26 3.23 3.27 
Scheme 20. Synthesis of enol ether ammonium 3.27. 
Other quaternization attempts are described in Scheme 21. However, all reactions 
failed to produce desired products. For example, when compound 3.28 was reacted 
with 2-bromoethanol to produce the targeted product 3.29, the salt 3.30 was formed 
instead. The other two reactions towards compound 3.33 also failed to generate 
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ammonium ion before sluggish products was observed on TLC plate due to 
phthalimide protection group decomposition. Finally, the smallest alkyl halide, methyl 
iodide, was chosen because of its intrinsic high reactivity. 
PhtN-O PhtN-O ~ OH 1~ • ~+~ 
rNl'+ 
+ 
Brr ~ PhtN'o~N 10 PhtN-O 10 3.29 ~H 3.28 PhtN-O 
PhtN-O ~+~ ~ OTBS PhtN'o~N, 10 
rNl'+ + Brr ~ H 3.30 PhtN-O 10 PhtN-O 
3.31 3.32 ~+~ 
PhtN-O / PhtN'o~~ 10 ~ Br~o N~ + r OTBS 3.33 OTBS 
PhtN-O 2.12 
Scheme 21. Attempts to quaternize headgroup amine. 
3.3.2 Fused Headgroup on Amine 
The second method is based on building a protected aminooxy moiety on the 
amine, which works as a linker (Scheme 22). A similar strategy has been used to 
synthesized phospholipids with aminooxy functionality.104 Firstly, the enol ether tail 
fitted with a primary amine was synthesized; then the protected aminooxy moiety was 
directly conjugated on the amine group; finally, the target lipid will be obtained after 
methylation and deprotection. 
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Scheme 22. Fused protected aminooxy headgroup on the amine. 
To test this strategy, tetradecan-1-amine was used to mimic the enol ether 
component. First, 2-phthalimidooxyethyl bromide 3.34 was synthesized according to 
the reported methods (Scheme 23).105 Then tetradecan-1-amine was reacted with 
3.34 in anhydrous N,N-dimethylformamide in the presence of triethylamine. After 
stirring overnight at room temperature, target compound 3.35 was not observed; 
however, the dioxazine compound 3.36 was isolated. From 1 H NMR, 4 protons (04.19 
ppm (t, J=4.0 Hz, 2H), 04.44 ppm (t, J=4.0 Hz, 2H)) were identified corresponding to 
the heterocyclic ring of a dioxazine.106-108 The dioxazine structure was confirmed by 
X-ray crystallographic analysis (Figure 21). Due to this surprising result, we gave up 
this method without resorting to synthesis of amine enol ether. 
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Br Be - BrO-N~ 
o 
3.34 
Scheme 23. Synthesis of dioxazine. 




Figure 21. X-ray structure of dioxazine 3.36. 
3.3.3 Fused Headgroup via Epoxide Opening 
We envisioned a third approach to prepare lipid 3.42 (Scheme 24). Reaction of 
bis-protected diethanolamine 2.15 with 2-dodecyloxirane can be expected to form 
3.37. The addition of the three key components (enol ether, aminooxy and cationic ion) 
wou ld be accomplished step by step. First, the enol ether chain would need to be 
added to the 2° alcohol to form 3.38. After functional group interconversion (Scheme 
24, steps c, d) , the bis- protected aminooxy groups would be incorporated. The third 
step would generate the ammonium ion by methylation of the trialkylamine. Finally, the 
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prototype lipid 3.42 can be obtained after hydrazine treatment to release the free 
aminooxy groups. 
T8S0 T8S0 T8S0 R= enol ether tail ~ a ~ b ~N 
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Scheme 25. Plan for synthesis of lipid 3.43 using ether linkage approaches. 
Synthesis of 3.37 proceeded smoothly by reacting bis-protected diethanolamine 
2.15 with 2-dodecyloxirane under catalysis of lithium perchlorate in 62% yield. 
However, to conjugate the enol ether chain onto the alcohol 3.37 via an ether bond 
was difficult. The tosylated enol ether chain 3.25 was reacted with the skeleton 
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compound 3.37 but the reaction failed to produce conjugated product 3.43. The 
mesylated skeleton 3.44 also failed to deliver 3.43 when reacted with 3.10(Z). 
(Scheme 25) 
After failing to establish the ether linkage, we turned to an ester linkage strategy. 
However, direct conversion of the alcohol to a carboxylic acid group requires harsh 
oxidation conditions, a big challenge in the presence of the fragile enol ether. Many 




Scheme 26. Synthesis of cationic enol ether lipid 3.49. 
Conditions: a) 1,1'-carbonyldiimidazole, Et3N, CH2CI2 , rt., 16h, 96%; b) LiHMDS, THF, CH2CI2 , 17h, 
89%; c) TBAF, THF, rt., 16h, 78%; d) N-hydroxyphthalimide, PPh3, DIAD, THF, O°C to rt., 12h, 
69%. 
Bridging two alcohols via ester bonds can be achieved through using 
1,1 '-carbonyldiimidazole (Scheme 26). Then, the synthesis of lipid 3.48 began with 
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the reaction of 3.37 with 1,1 '-carbonyldiimidazole to obtain product 3.45 in 96% yield. 
Enol ether alcohol 3.10(Z) was deprotonated by treatment with LiHMDS and then 
reacted with 3.45 to give 3.46 in 89% yield. Removal of TBS protecting group was 
achieved by using TBAF in 78% yield. Finally the bis-protected aminooxy reagent 3.48 
was obtained in 69% yield by treatment with N-hydroxyphthalimide under Mitsunobu 
reaction conditions. Unfortunately, as noted previously, the synthesis route ended with 
a failure to quaternize. Neither methyl iodide nor trimethyloxonium tetrafluoroborate 
was effective at methylation of trialkylamine 3.48 without significant decomposition 
problems. The absence of 1H-NMR signal in the range of 5.8-6.2 ppm, which 
represents C1OH21 0CH=CHCH2-, indicated reaction of the enol ether linkage during 
methylation. Although it is highly possible to prepare compound 3.49 via methylation 
of 3.48, we didn't pursue this route since we successfully synthesized prototype enol 
ether lipid 3.1 and 3.2 using another strategy that also was under investigation at the 
time. 
3.3.4 Succinic Acid Linker 
Like 1,1 '-carbonyldiimidazole, succinic acid is another commonly used linking 
agent for tethering two alcohol compounds. With headgroup 2.13 and tailgroups 3.10, 
3.11 in hand, the synthesis of prototype lipid 3.1 and 3.2 began with joining these two 
parts together via a succinic acid linkage (Scheme 27). The protected aminooxy 
domain 2.13 was reacted with succinic anhydride in the presence of triethylamine to 
generate acid 3.50 in 81 % yield. The acid 3.50 was then reacted with alcohol 3.1 0 (or 
3.11) under DCC coupling conditions to produce ester 3.51 (or 3.52) in 66-88% yield. 
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Scheme 27. Synthesis of cationic enol ether lipids 3.1 and 3.2. 
Conditions: a) succinic anhydride, CH2CI2 , triethylamine, rt., 18h, 81 %; b) alcohol (3.10, 3.11), DCC, 
DMAP, CH2CI2, rt., 12 h, 66%-88%; c) Mel, Na2C03, CH2CI2, 50 cC, 12 h, 74% (3.53), 73% (3.54); d) 
MeNHNH2 , CH 2CI2 , ethanol, -40 cC, 1.5 h, 71 % (3.1), 60% (3.2). 
The methylation of compounds 3.51 and 3.52 were problematic, just as in the 
synthesis of compound 3.49. Decomposition of the enol ether moiety was observed 
when reacting lipids 3.51 and 3.52 with methyl iodide. We speculated that 
decomposition of the enol ether moieties is due to trace acid in methyl iodide. However, 
preincubating methyl iodide with sodium carbonate to remove trace acid also failed to 
prevent enol ether decomposition. Fortunately, we observed that adding sodium 
carbonate directly into the reaction mixture partly prevented enol ether decomposition. 
Eventually, using dichloromethane as solvent plus 0.2 eq. of sodium carbonate solved 
the problem. Quaternizations were accomplished to produce the salts 3.53 and 3.54 in 
74% and 73% yield, respectively. It is worthy to mention that the moderate yield of 
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3.53 and 3.54 is mainly due to phthalimide protection group decomposition on Si02 
when using methanol/CH2Cb as eluent. 
Removal of the phthalimide protection groups in 3.53 and 3.54 is another 
problematic step because commonly used hydrazine cleaves both phthalimide 
protection groups and ester bond at room temperature. While reducing reaction time 
did not solve the problem, reducing the reaction temperature to -40°C gave promising 
results. At this temperature, the phthalimide deprotection was accomplished at 1.5 
hours without significant ester cleavage. The solubility of salts 3.53 and 3.54 was very 
low in dichloromethane at -40°C. The solubility problem was solved by using 
ethanol/CH2Cb (1:1 v/v) as solvent. The last modification was using methylhydrazine 
instead of hydrazine to facilitate the chromatographic separation of final products 3.1 
and 3.2 from byproducts. Finally, the prototype lipid 3.1 was obtained in 71 % yield 
(25% overall yield from decanol); and the lipid 3.2 was obtained in 60% yield (13% 
overall yield from decanol). 
From the 1H NMR spectrum (500 MHz) of lipid 3.2(Z), the broad signal at 0 6.35 
ppm represents the four aminooxy protons (Figure 22 top). The quaternized amine 
methyl group NCH3 can be observed at 0 3.15 ppm. The a and ~ protons of the enol 
ether are observed at 0 6.01 ppm (J=6.5Hz) and 04.27 ppm (J=6.5Hz). The protons 
on the succinic acid linkage can be found at 0 2.60 ppm (m, 4H). With the additional 
information from COSY spectrum (Figure 22 below), the signal of 0 3.97 ppm can be 
assigned to the 4H of the headgroup CH2-ONH2 while the signal around 0 3.70 ppm 
can be assigned to 4H from NCH2CH20NH2. The signal of 04.47 ppm corresponds to 
2H from NCH2CH20COCH2 and the signal 0 3.78 ppm corresponds to the 2H from 
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NCH2CH20COCH2. Other signals belong to the protons on the hydrophobic tail. The 
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Figure 22. 1H and COSY NMR spectra of lipid (Z}-3.2. 
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3.4 Polymerization Studies 
With cationic aminooxy enol ether lipids 3.1 and 3.2 in hand , we began lipid 
polymerization studies. Ideally, the prototype lipid 3.2 would form liposomes and then 
be polymerized under mild acid conditions to give stabilized liposomes (Figure 23) . To 
establish preferred conditions for liposome polymerization, the acid-triggered enol 
ether hydrolysis ' and subsequent oximation of lipid 3.1 and 3.2 was studied. By using 
HPLC and NMR, we can observe the hydrolysis of the enol ether and follow the 





Figure 23. Polymerized liposome from enol ether lipid 3.2. 
The hydrolysis of lipid 3.1 under different pH (1 .3, 3.2, 4.3 and 6.5) conditions at 
certain time intervals was analyzed by HPLC. The amount of unhydrolyzed lipid 3.1 
was determined by monitoring the HPLC peak area using 214 nm channel. The 
preliminary data showed that lipid 3.1 hydrolyzed faster at lower pH condition. The 
lipid 3.1 is nearly intact after prolonged incubation (17 h) at room temperature under 
neutral conditions (pH 6.5) , whereas it hydrolyzes under acid conditions . However, 
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the hydrolysis required strong acid conditions (pH=1.3) instead of expected mild acid 
conditions (pH 3.0). Furthermore, the time for 90% hydrolysis required considerable 
time (ca. 17 h) even at the low pH conditions. 
:Q 100 
.9-
pH 6.5 pH 4.3 pH 3.2 pH 1.3 
Figure 24. Preliminary study on hydrolysis of lipid 3.1. 
Aliquot of Lipid 3.1 (60 IJL, 160 mg/mL in DMSO) was added to 240 IJL aqueous buffer (H20, pH 6.5; 
0.1 M acetic acid, pH 4.3; 0.1 M trifluoroacetic acid, pH 3.2) and incubated 17h at room temperature. 
The samples then were analyzed by HPLC. 
Based on the preliminary data, we then studied the enol ether lipids 
polymerization under strong acid conditions. While HPLC can only monitor the 
disappearance of lipid 3.1 due to hydrolysis, 1 H NMR can provide more detailed 
information. For example, a decrease in the signals of the enol ether vinyl proton 
represents the hydrolysis of enol ether lipids, while an increase in the signals of the 
aldoxime ether proton represents lipid polymerization. In general, the transformation 
from enol ether to aldoxime causes the ipso-carbon (Figure 25, e) of the enol ether to 
become less electronegative, effecting an upfield shift for the attached proton. For 
61 
instance, a proton shift from 0 5.8-6.3 ppm (enol ether) to 0 -7.5 ppm (aldoxime ether) 
61 indicated hydrolysis followed by oximation. 
H 
~o~ 









A N/ O" 
-7.5 ppm, J= 6.5Hz 
H~N 'O" 
-7.0ppm, J=6.5Hz 
Figure 25. 1H NMR analysis of the aCid-triggered polymerization. 
The hydrolysis samples of lipid 3.1 under acid conditions (D20ldo DMSOIDCI pH 
-1 .0) at certain time intervals were analyzed by 1H NMR (Figure 26) . The peaks 0 
-6.0 ppm (J = 12.5 Hz) and 0 -6.2 ppm (J = 6.0 Hz) represent the vinyl proton 
(RCH=CHOR) on cis- and trans- enol ethers respectively. The integrals of these two 
peaks gradually decreased to zero due to the hydrolysis of lipid 3.1 under acidic 
conditions . The integrals of the peak 0 -6.0 ppm decreased faster than the peak 0 
-6.2 ppm, which means cis-isomers hydrolyze faster. 
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Figure 26. 1H NMR spectra of lipid 3.1 under acid-triggered polymerization. 
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The intermediate aldehyde, hydrolysis product of enol ether, usually has a distinct 
proton signal at 0 9-10 ppm. However, we failed to detect any signal in this area, 
possibly due to rapid oximation or hydration. The peaks 0 -7.0 ppm and 0 -7.5 ppm 
with the same (J = 6.5 Hz) represent the oximyl proton of the (E) and (Z) isomers of the 
aldoxime ether. The gradually increasing integrals of these peaks represent the 
formation of aldoxime ether, a direct sign of lipid polymerization. It is worthy noting that 
the deuterated aldoxime ether (RCHDCH=NOCH2R) was produced in this experiment 
due to the hydrolysis was carried in deuterated buffers. That is why the doublet for the 
a proton of aldoxime ether was observed in above NMR spectrum while the triplet of 
similar aldoxime ether was reported in our previous paper.61 
The acid-triggered polymerization of lipid 3.2 was also studied by using 1H NMR 
(Figure 27). By tracing the decreasing integrals of the vinyl protons ( 0 5.96 ppm and 
6.20 ppm) of the enol ether and increasing integrals of the oximyl protons ( 0 6.90 ppm 
and 7.50 ppm) of the aldoxime ether, we studied the hydrolysis and oximation of lipid 
3.2. No hydrolysis of lipid 3.2 was observed after incubation for one week under mild 
acid conditions (pH 3.40 D20/do DMSO/d4-acetic acid). Complete hydrolysis (Figure 
27 below) under strong acid conditions (pH 1.76 D20/do DMSO/d-trifluoroacetic acid) 
took more than one week. (pH value was measured at the end of each experiment by 
pH meter.) At the end of the experiment, precipitation was observed in the NMR tube, 
a sign of polymerized lipids. 
Both HPLC and NMR analysis experiments showed that the enol ether lipids 
were more stable than we anticipated, and it required strong acid conditions (pH <2) 
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and long reaction times for complete hydrolysis to occur. Since strong acid 
pretreatment is not an ideal protocol for gene/drug delivery; we must find milder 
conditions to form stabilized liposomes. In hopes that partial polymerization of the enol 
ether lipids can still improve liposomes stability, we examined the feasibility of the 











,- ·'l-' --·'-····'r·' 1····'" ··_' -····T' -'T" ",' T' "1 r ····r···r- "Y" 1 -. 'l'··-'···-"--·f-·-'-I"""-'~·-r-r-'--'---r-"--'-r---1I--.-'---'--r·-l--'-- r- · "". r--r T·····, 
8 6 4 2 - 0 ppm ~. ~.J I .. ) .."J~.J ' .,' , l-.r-" L....,--I ~~_~.. I .. .J 
~ • ~ ~ ~ _ ~ M ~ _ ~ ~ 0 ~ ~ M ~ ~ _ _ " ~ ~ ~ ~ N ~ 0 ~ 0 
~ ~ ~ • ~ 0 ~ ~ ~ ~ _ • 0 _ • • ~ _ ~ ~ M _ _ ~ ~ ~ ~ _ 0 0 
~ ~ eo: '"": --: "": ~ t; '""! ~ "'"! ~ ~ ~ "! "'! ""'! ~ "'; ~ "": ""! I _ ~ ~ ~ ~ ~ c:: c:: 
M ~ M ~ M M M M M M M " " " " " " M M ~ "M M M OO 000 
l,__...l,L.__...l,.l..""l__... ~ l--J.,.L.~-.l. ~U---l. ___ ~ .. l. ___ L,,-S-J .. ,. ~ : J~.J.--J . ..J~ ~J~.J 
"~~:::::?::-~":::::::"""'::" :-<::'~'':::::.:;::... -''';:':'':1''' ::S:., -:::;;::::> :::::-~ 
-.......::: ..... -.....:.. . ... ~~ ............................ -... ....... -.................. ~ ....... -" After .--....;:~~ .;::~> '- i 
........ -:::::.:--':.::..-...-:: ........ --... ! 






r T"'r--, T' "T····,······1····--1 "r 'I' ··T····T....,.-,--,--·,' ..,.....-,'-I,.-,-..,-,.I·--r-r-r-r-r .,..·'T---'--r----.-r-T--T r l-"-l ml-r-r-''-' ....-r-r-r-r-
8 6 4 2 - 0 ppm 















pH4 pH 3 pH 2 pH 1.5 
Figure 28. Acid triggered liposome polymerization. 
Liposomes were formulated by sonicating a thin layer of lipid 3.2 (1.6 mg) in HEPES buffer (1.6 mL, 
20 mM, pH 7.4) for 20 minutes. The aliquots of liposome (200 iJL) were then mixed with buffer (1.8 
mL, pH 4, AcOH , 0.1 M; pH 3, AcOH , 0.1 M; pH 2, TFA 0.1 M, pH 1.5, TFA, 0.1 M). After standing 22 
h at room temperature, Triton X-100 (final concentration 0.15%, w/v) was added to solubilize any 
unstable liposomes. The light scattering signals before and after surfactant treatment were 
recorded . Normalized light scattering signal = Light scattering signals after surfactant treatmenU 
Light scattering signals before surfactant treatment. Each data point reflects the mean value of n =2 
(pH 4, 3, 1.5) and n=4 (pH 2) , and the standard deviation from the mean. 
The stability of liposomes was determined by their ability to resist 
surfactant-mediated solubilization using a reported method. 109 Surfactant 
solubilization of liposomes is a process where liposomes are disrupted to form 
surfactant-lipid micelles within a few minutes in the presence of surfactant, usually 
Triton X-100. By comparing the diameter of liposomes (-100 nm) to the 
surfactant-lipid micelles (-5 nm), one can easily see liposome disruption occur. The 
decreasing size of particles during surfactant solubilization can be observed as a 
decreasing turbidity of the liposome solution (cloudy solution turns transparent). The 
surfactant solubilization can be also quantified as a light scattering signal determined 
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by a particle size analyzer because the bigger particles (Iiposome) scatter more light 
than smaller ones (micelles). 
The liposomes from lipid 3.2 were incubated under different pH conditions, and 
their light scattering signals before and after Triton treatment were measured by 
particle size analyzer (Figure 28). As we would expect, the liposome gained extra 
stability under low pH conditions (pH=1.5, 2) and more than 50% light scattering signal 
preserved after Triton treatment, while not much light scattering signal preserved for 
the samples under mild acid condition (pH=3, 4). In another experiment, we observed 
that the liposomes made from the cationic aminooxy lipid without enol ether 
functionality (e.g. lipid 4.2), as a negative control, failed to be stabilized after mild or 
strong acid incubation. These results demonstrated that acid-triggered enol ether 
hydrolysis, which occurs under strong acid condition (pH :s; 2), is essential for lipid 
polymerization, and this is in agreement with our HPLC and NMR analysis results. 
3.5 Conclusions 
In summary, this chapter explored several methods to construct the hydrophobic 
enol ether component of our target lipids. Syntheses of the hydrophobic domains of 
lipids 3.10 and 3.11 were achieved. The general synthesis route can be adapted to 
synthesis of other acid-liable lipids which have been widely used as gene/drug 
delivery. Then, the headgroup and enol ether domain were conjugated by succinic 
acid to successfully deliver cationic aminooxy enol ether lipid 3.1 and 3.2. Finally, lipid 
polymerization study confirmed the acid-triggered strategy. However, the requirement 
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of strong acid pretreatment is not an ideal protocol for gene/drug delivery. Therefore, 
an alternative less harsh strategy was developed, as discussed in the next chapter. 
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CHAPTER 4. 
'CLICK' STABILIZED LIPOSOMES 
4.1 Introduction 
In chapter 3, we demonstrated a pH-triggered polymerization strategy and proved 
that the aldoxime crosslinking stabilized liposomes against surfactant-mediated 
disruption. However, the requirement of a strong acid pretreatment is not an ideal 
protocol for use in gene/drug delivery. To take advantage of aldehyde/aminooxy 
chemistry and avoid the use of strong acid , we explored an alternative 'click' 
stabilization strategy. Our next generation 'click' stabilization strategy uses external 
aldehydes, instead of aldehydes generated on hydrolysis of enol ethers, as the 
polymerizable functionality. This change not only avoids the use of acid, but also 
simplifies the requisite lipid structure and lipid synthesis. 
+ 
Liposomes Aldehyde reagent/polymer Stabilized liposomes 
Figure 29. 'Click' stabilized liposomes -- revised strategy. 
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We envisioned a 'click' stabilization strategy as follows: after cationic aminooxy 
lipid formulation in water to generate liposomes, an external reagent containing bis- or 
poly-aldehyde functional groups is added and followed by incubation for a given time 
to allow aminooxy-aldehyde oximations. As the result of intermolecular oximation 
reactions, the liposome surface will undergo lipid-reagent polymerization to generate a 
stabilized liposome (Figure 29). This stabilization process should proceed rapidly 
under aqueous conditions that are compatible with biological cargos. The resultant 
aldoxime ether crosslinks are expected to be robust and particularly stable to 
physiologic conditions. This chapter demonstrated our efforts to actuate this strategy. 
4.2 Synthesis of Cationic Aminooxy Lipids 
To test this hypothesis of 'click' stabilized liposomes, a series of cationic aminooxy 
lipids have been synthesized, such as cationic bisaminooxy lipid 4.1, 4.2 and cationic 
monoaminooxy lipid 4.3 (Figure 30). Among them, the lipid 4.1 was designed as a 
mimic of N, N-[bis(2-hyd roxyethyl)-N-methyl-N-[2,3-d i(tetradecanoyloxy)propyl] 
-ammonium iodide (TransFast™)54, a commercial transfection lipid previously 
developed by our lab. The difference between TransFast™ and lipid 4.1 is that lipid 4.1 
equipped with a bisaminooxy group on its hydrophilic head while TransFast™ 
possesses a bisalcohol group. The other two lipids have minor modifications, such as 
longer hydrophobic chain or monoaminooxy headgroup. 
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Figure 30. Structure of TransFaseM and cationic aminooxy lipid mimics. 
Our synthesis route of lipid 4.1 is described in Scheme 28. First, the silylation of 
diethanolamine was accomplished by reaction with TBSCI. The resultant amine 2.15 
was then reacted with glycidol under catalysis by lithium perchlorate. The principal 
adduct diol 4.4 was then acylated using myristoyl chloride to form the hydrophobic 
domain. Silyl ether deprotection using TBAF gave diol4.6 in good yield. The resultant 
diol 4.6 was reacted with N-hydroxyphthalimide under Mitsunobu conditions 73 to 
generate amine 4.7 with bis-protected aminooxy groups. Amine quaternization was 
best accomplished by heating the amine with methyl iodide in a sealed tube. Finally, 
the ammonium iodide 4.8 was treated with hydrazine to cleave the phthaloyl groups. 
After chromatography, product 4.1 was isolated as a white solid in 7 steps, 12% 
overall yield from diethanolamine. Following the same synthesis route, lipid 4.2 was 
synthesized using palmitoyl chloride without any problem (7 steps, 10% overall yield 
from diethanolamine) (Scheme 29). 
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Scheme 28. Synthesis of cationic aminooxy lipid 4.1. 
Conditions: Pht = phthaloyl a) glycidol, LiCI04 , ethanol, 0 DC to rt., 16 h, 85%; b) Et3N, DMAP, 
myristoyl chloride, CH2CI2 , 0 DC to rt., 16 h, 50%; c) TBAF, THF, 0 DC to rt., 12 h, 71%; d) 
N-hydroxyphthalimide, PPh3, DIAD, THF, 0 DC to rt., 12h, 86%; e) CH31, sealed tube, 60 DC, 48 h, 
4.4 4.9 
4.11 4.12 




Conditions: Pht = phthaloyl a) Et3N, DMAP, palmitoyl chloride, CH2CI2, 0 DC to rt., 16 h, 61%; b) 
TBAF, THF, 0 DC to rt., 12 h, 60%; c) N-hydroxyphthalimide, PPh3, DIAD, THF, 0 DC to rt., 12 h, 86%; 
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From the 1H NMR spectrum (400 MHz, CDCI3) of lipid 4.1, the broad signal at is 
6.07 ppm represents the four aminooxy proton (Figure 31). The quaternized amine 
methyl group NCH3 can be observed at is 3.43 ppm. The a and ~ protons of two esters 
can be found at is 2.30-2.37 ppm as two triplets and around is 1.57 ppm as broad peak 
respectively. The protons on the hydrophobic tail can be found at is 0.86 ppm and is 
1.24-1.58 ppm. The signal at is 5.66 ppm can be assigned to NCH2CH(O)CH2 . The 
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Figure 31. 1H NMR spectrum of cationic aminooxy lipid 4.1. 
The monoaminooxy lipid 4.3 was synthesized by Mr. Ralph Knipp, my colleague 
(Scheme 30). First, the silylation of 2-(methylamino)ethanol was accomplished by 
treatment with TBSCI. The resultant amine 4.13 was then reacted with glycidol to 
obtain diol 4.14, which was then bis-esterified with palmitoyl chloride to generate 
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compound 4.15. After the TBS protection group was cleaved using TBAF, alcohol 4.16 
was reacted with N-hydroxyphthalimide under Mitsunobu conditions 73 to generate 
amine 4.17. The Pht protection group was cleaved by reaction with hydrazine to afford 
4.18. In another route, the cationic lipid 4.3 was obtained after methylation and 
hydrazinolysis (7 steps, 6% unoptimized overall yield from 2-(methylamino)ethanol) . 
Scheme 30. Synthesis of aminooxy lipid 4.3. and 4.17. 
Cond itions: Pht = phthaloyl a) TBSCI , Eh N, imidazole(cat.) , CH 2CI2, O°C to rt., 12h, 100%; b) 
glycidol, LiCI04 , ethanol , O°C to rt ., 16h, 43%; c) Et3N, DMAP, myristoyl chloride, CH2CI2, O°C to rt., 
12h, 85%; d) TBAF, THF, O°C to rt., 12h, 74%; e) N-hydroxyphthalimide, PPh3, DIAD, THF, O°C to 
rt. , 12 h, 64%; f) N2H4oH 20 , CH 2CI2, O°C to rt ., 2h , 69%; g) 1) CH31, sealed tube, 45°C, 22 h, 67%; 
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4.3 Liposome Stabilization Study 
4.3.1 Liposome Formulation and Bis-aldehyde Stabilization Attempts 
With cationic aminooxy lipids in hand, we started to examine the feasibility of 'click' 
stabilized liposomes using external aldehydes. First, a thin layer of lipid 4.1 was 
sonicated in water to formulate liposomes (diameter 119 nm; zeta potential 59 meV). 
The high zeta potential (surface surcharge) kept the liposomes from aggregating -- no 
precipitation was observed even after storage at room temperature for one week. 
Similarly, liposomes with -100 nm diameter were produced from lipid 4.2, whereas no 
liposomes were formed from lipid 4.3 using the same protocol. 
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Figure 32. Effect of glutaric dialdehyde on liposome stabilization. 
Liposomes were formulated by sonicating a thin layer of lipid 4.1 (19.5 mg) in water (4.87 mL) for 20 
minutes. The liposome solution (200 IJL) was mixed with water (3.8 mL). After incubated with 
glutaric dialdehyde (0 , 1, 2, 4, 8 eq. , aldehyde to aminooxy) for 0.5 h at room temperature, the 
liposome mixture was treated with Triton X-100 (final concentration 0.12%, w/v). The light 
scattering signals before and after surfactant treatment were recorded. 
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The stabilities of liposomes from 4.1 before and after addition of different eq. of 
dialdehyde reagents were measured using the surfactant solubilization method 
discussed previously. For untreated liposomes, the light scattering signals 
disappeared almost completely on Triton X-1 00 treatment due to surfactant-mediated 
solubilization (Figure 32). Disappointingly, the bis-aldehyde reagent (glutaric 
dialdehyde) treated liposomes also had little light scattering signal remaining after 
Triton X-100 treatment, indicating that glutaric dialdehyde failed to stabilize the 
liposome formulation (Figure 32). This is possibly due to insufficient crosslinks on the 
liposome surface even excess glutaric dialdehyde (e.g., 8 eq.) was added. Due to the 
negative results from this one time experiment, we decided to abandon this approach. 
We hypothesized that a poly-aldehyde polymer may provide more crosslinks and 
consequently impart stability. 
4.3.2 DPA Synthesis and Aldehyde Titration 
Since hydrophilic polyaldehyde compounds are not commercially available, we set 
out to synthesize a panel. Polysaccharide derivatives were selected as polyaldehyde 
candidates due to their good biocompatibility, availability and wide application in 
biological studies.41 ,11o,111 The first polysaccharides we studied were dextrans, a class 
of polysaccharides with molecular weights ~1 ,000 Dalton.112 Dextrans have a linear 
backbone of a-linked D-glucopyranosyl repeating units. Due to different production 
resources, the glucose units can be linked through a(1-2), a(1-3), a(1-4) and 
a(1-6) linkage (Figure 33). 
76 
Dextran PolyAldehyde 
Figure 33. Structure of dextran and dextran polyaldehyde. 
A panel of dextran polyaldehydes (DPAs) was synthesized from dextran (sigma, 
MW 6kD) by using reported protocols (Figure 33).63 Briefly, dextran (1.62 g) was first 
reacted with varying ratios of Nal04 overnight at room temperature. The reactions 
were stopped by passing the reaction solution through a column filled with Dowex 
1 x8-400 ion exchange resins. The resultant light yellow solutions then were 
extensively dialyzed against distilled water for 3 days at 4 cC. After concentration 
under reduced pressure and lyophilization, the purified DPAs were obtained as white 
powders (1.32-1.37 g). 
DPA Glu:Na104 Aldehyde Oxidized Glucose 
(mmol/g) (%) 
A 1:1 8.4 68 
B 3:1 3.0 24 
C 10:1 0.6 4.9 
D 30:1 0.3 2.3 
E 100:1 0.16 1.2 
Table 1. DPA aldehyde density as a function of Nal04 stoichiometry. 
Glu:Na104 = glucose units (mole) : Nal04 (mole) 
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Aldehyde content was determined by the hydroxylamine hydrochloride method 
according to the work of Zhao, et al.. 113 In brief, DPA (0.1 g) was dissolved in an 
aqueous solution of hydroxylamine hydrochloride (25 mL, 0.25 M, pH 4.0). The 
mixture was stirred for 2 h at room temperature and then titrated with aqueous sodium 
hydroxide (0.1 M) until the pH returned to 4.0 (Digital pH meter: Thermo Orion, model 
410). The aldehyde concentration was calculated by the equation: 
CHO on DPA (mmol/g)= VolNaoH mLxO.25mol/L I Weight of sample (g) 
By using different molar ratios of dextran to NaI04, DPAs with different molar ratios 
of aldehydes were synthesized (Table 1).The greater equivalents of Nal04 used, 
more was used, more aldehyde groups generated on the DPA sample. For example, 
the DPA-A was calculated to possess 8.4 mmol of -CHO groups per gram of polymers. 
4.3.3 DPA-Stabilized Liposome Study 
The liposomes formulated from lipid 4.1 were incubated with 4 eq. (aldehyde to 
aminooxy ratio) of DPA-A at room temperature for 30 minutes. The resultant 'treated' 
liposomes had a similar diameter and surface charge (DH= 117 nm, ~= 62 meV) as the 
untreated aminooxy liposomes derived from lipid 4.1. The surfactant solubilization 
experiments showed that DPA-A incubation dramatically increased liposome stability. 
In the negative control experiments, incubation of liposomes with unoxidized dextran 
(no polyaldehyde groups) or with DPA-A that had been pretreated with hydroxylamine 
(polyaldehydes capped as oximes) were not stabilized. In the positive control 
experiments, incubation of liposomes with dextran sulfate (a polyanion polymer) and 
hydroxylamine pretreated dextran sulfate improved liposome stability through 
electrostatic forces. These results clearly demonstrated that the DPA-A can stabilize 
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liposomes (fromulated lipid 4.1) and the polyaldehyde functional group is essential for 
the stabilization effect. The stabilized liposomes also have remarkably long term 
stability. For example, stabilized liposomes were resistant to precipitation f9r more 
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Conditions Expected Results Observed Results 
Untreated No stabilization since no oximation possible. No stabilization liposomes 
observed 
Liposomes + No stabilization since no oximation possible. No stabilization Dextran observed 
Liposomes Stabilization due to oximation . Stabilized 
+DPA-A liposomes formed 
Liposomes + No stabilization since no oximation possible. 
(DPA-A + Hydroxylamine converts all RCHO groups into No stabilization 
H2NOH) RCH=NOH rendering them inactive with observed aminooxy. 
Liposomes + Stabilization due to electrostatic coating of Stabilized 
Dextran sulfate polymer onto liposome. liposomes formed 
Liposomes + Stabilization due to electrostatic coating of Stabilized (Dextran sulfate polymer onto liposome because the presence liposomes formed 
+ H2NOH) of hydroxylamine do not destabilize liposome. 
Figure 34. Results of liposomes treated with Triton X-100. 
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os: Dextran sulfate. Liposomes formulated from lipid 4.1 in water (1 mL, 0.2 mg/mL) were treated 
with the indicated reagents (4 IJL, 60mg/mL) for 30 min prior to addition of Triton X-100 (final 
concentration 0.15% w/v) . Hydroxylamine pretreatment was carried out by incubation of DPA-A or 
OS (4 IJL, 60mg/mL) with hydroxylamine (8 IJL, 0.25 mol/L) at room temperature for 30 min. The 
light scattering signals of samples before and after Triton treatment were measured. Normalized 
light scattering signal = Light scattering signals after surfactant treatment! Light scattering signals 
before surfactant treatment. Each data point reflects the mean value of n = 3, error bars show 
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Figure 35. Effect of DPA-A on liposome stabilization. 
Liposomes formulated from lipid 4.1 in water (1 mL, 0.2 mg/mL) were treated with the indicated eq. 
of DPA-A for 1 h prior to addition of Triton X-100 (final concentration 0.15% w/v) . The light 
scattering signals of samples before and after Triton treatment were measured. Normalized light 
scattering signal = Light scattering signals after surfactant treatment! Light scattering signals 
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Figure 36. Effect of incubation time on liposome stabilization. 
Liposomes formulated from lipid 4.1 in water (1 mL, 0.2 mg/mL) were treated with the DPA-A (4 IJL, 
60 mg/mL) for indicated time intervals prior to addition of Triton X-100 (final concentration 0.15% 
w/v). The light scattering signals of samples before and after Triton treatment were measured. 
Normalized light scattering signal = Light scattering signals after surfactant treatment! Light 
scattering signals before surfactant treatment. 
In preliminary liposomes stabilization conditions study, liposomes formulated from 
lipid 4.1 were reacted with varying equivalents of DPA-A (from 0 eq. to 12 eq. , 
aldehyde to aminooxy ratio) and then treated with various equivalent of surfactant 
Triton X-100. (Figure 35) The preliminary data shows that the untreated liposomes 
is not stable under the surfactant treatment and consequently the light scattering 
intensity decreases by an order of magnitude after addition of 10 eq. (final 
concentration 0.15% w/v) of Triton X-100. While incubation with DPA-A can stabilize 
liposomes in dose depended way and normalized light scattering intensity increased 
when more DPA-A was added . It shows that 4 equivalent of DPA-A can achieve good 
liposome stabilization result. In another prelim inary study, the liposomes were 
incubated at various time internals with DPA-A (4 eq.) at room temperature before the 
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addition of Triton X-1 00. The preliminary data (Figure 36) shows that 4 equivalents of 
DPA-A can fully stabilize liposomes within 30 minutes, and this stabilization condition 
was used in more controlled experiment. (Figure 34, liposomes+DPA-A) 
Two synthesized DPAs with different aldehyde density (DPA-A 8.4mmol/g CHO; 
DPA-B 3.0 mmol/g CHO) were tested for the abil ity to stabilize liposomes formulated 
from lipid 4.1 (Figure 37) . The results show that both DPAs stabilized liposomes in a 
dose dependent way. Moreover, the DPA-A provided the better stabilization effect 
than DPA-B when using identical equivalents .This is possible due to higher density of 































Figure 37. Liposomes stabilized by DPA-A and DPA-B. 
Liposomes formulated from lipid 4.1 in AcOH buffer (2 mL, 0.2 mg/mL, pH 5) were incubated with 
the DPA-A or DPA-B (eq. aldehyde to aminooxy) at room temperature. Triton X-100 (final 
concentration 0.15% w/v) was added after incubation for 4 h. The light scattering signals of 
samples before and after Triton treatment were measured. Normalized light scattering signal = 
Light scattering signals after surfactant treatment! Light scattering signals before surfactant 
treatment. Each data point reflects the mean value of n = 3, error bars show standard deviation 
from the mean. 
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Liposome stabilization under different pH conditions was also studied. We 
observed that liposome stabilization proceeds slightly faster when the incubation of 
liposome and OPA was performed under mild acid buffer rather than neutral buffer 
presumably because the oximation is catalyzed by acid . Considering that oximation is 
a fast reaction and most that biological cargos prefer neutral conditions , we conducted 
the majority of experiments in neutral conditions. In summary, liposomes made from 
lipid 4.1 can be stabilized by simply adding OPA-A (4 eq.) to the liposome suspension 


































Figure 38. Liposomes stabilized by polyaldehyde compounds. 
Liposomes formulated from lipid 4.1 (2 mL, 0.2 mg/mL, HEPES 12mM, pH 7.4) were mixed with 
the indicated polyaldehyde compounds (4eq. aldehyde to aminooxy). Then Triton X-100 (final 
concentration 0.15% w/v) was added after incubation after 1 h at room temperature. The light 
scattering signals of samples before and after Triton treatment were measured. Normalized light 
scattering signal = Light scattering signals after surfactant treatment! Light scattering Signals 
before surfactant treatment. Each data point reflects the mean value of n = 2, and error bars show 
standard deviation from the mean. 
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Because click stabilization is based on oximation chemistry, there should be no 
reason why this strategy cannot be applied to other polysaccharides. Therefore, 
dextrans with different molecular weight (40 kd, 100 kd) and other polysaccharides 
(maltoheptaose, cyclodextrin) were oxidized by Nal04 in similar fashion to produce the 
corresponding polyaldehyde polymers. The resultant DPA-F (from 40 kd dextran, 
CHO 11.6 mmol/g), DPA-G (from 100 kd dextran , CHO 10.75 mmol/g) , Oxidized 
maltoheptaose (CHO, 8.8 mmol/g) and l3-cyclodextrin (CHO, 8.8 mmol/g) were then 
used to stabilize liposomes using the same protocol mentioned above. The data show 
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Figure 39. Aggregation behavior of liposomes and DPA stabilized liposomes. 
The stabilized liposomes were prepared by incubating liposomes formulated from lipid 4.1 (1 mL, 1 
mg/mL lipid , HEPES 20 mM, pH 7.4) and DPA-A (1 0 IJL, 60 mg/mL) overnight at room 
temperature. The untreated liposomes and the stabilized Liposomes were then incubated with 
10% FBS at room temperature. The particle sizes (mean hydrodynamic diameter) of the samples 
were recorded at the indicated time. Each data point reflects the mean value of n = 3, error bars 
show standard deviation from the mean. 
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Considering dextran has been widely applied in intravenous usages, we believed 
that addition of DPA gives liposomes a coating that provides a "stealth" barrier against 
serum-induced aggregation. A liposome aggregation study showed that the particle 
size of untreated liposomes derived from lipid 4.1 increased very fast due to 
aggregation in 10% FBS (Fetal Bovine Serum); precipitations were observed in 1 h. In 
contrast, the particle size of DPA-A stabilized liposomes increased slowly to around 
300 nm diameter; no precipitation was observed even after one day (Figure 39). This 
resu lt proved that the DPA-A can help protect liposomes against 10% FBS-induced 
aggregation . 
In previous experiments, we observed that even partial oximation between DPA 
and liposomes provided some measure of stability to liposomes. We also observed 
that incubation with 4 eq . of DPA-A can provide extra stability to the liposomes that 
have at least 25% of lipid 4.1 in total lipids. Therefore, the cationic aminooxy lipid 4.1 
could be applied as a co-lipid for liposome stabilization. 
4.3.4 IR Characterization 
For aminooxy compounds , the oximation reaction can be confirmed by analyzing 
the NMR spectra of adducts (described in chapter 3.4). However, it is difficult to follow 
the oximation reaction of liposomes using NMR. Fortunately, our collaborator, Prof. 
Donald P. Land (Department of Chemistry, University of California , Davis) , has 
cutting-edge methods using Fourier Transform Reflection Absorption Infrared 
Spectroscopy, that can obtain IR absorption spectra of liposomes absorbed on the 
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surface of an ATR crystal. 11 4 By recording the IR spectrum during liposome incubation 









Figure 40. IR spectra of the lipid 4.1 and corresponding liposome. 
First, the IR spectrum of dry cationic aminooxy lipid 4.1 on the surface of the ATR 
crystal (Figure 40 above) and the cation ic aminooxy liposome freely floating in the 
solution above the surface of the ATR crystal (Figure 40 below) were obtained . We 
can see the characteristic -CH and -NH absorption bands between 3500 - 2800 cm-1. 
The fingerprint region within both spectra display the carbonyl absorption at 1730 cm-1, 
primary amine bending 1640 -1560 cm-1, methylene bending 1465 cm-1, and the ester 
at 1175 cm-1 . 
Then, at certain time intervals the IR spectrum of the reaction mixtures of cationic 
aminooxy liposomes and DPA-A were recorded . The time dependent fingerprint 
reg ion of the cationic liposomes are shown superimposed (Figure 41 left) . The 
decreasing primary amine absorption band found at 1650 cm-1 is attributed to the 
ongoing chemical reaction between the aminooxy present on the lipid headgroups 
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with the aldehyde groups on the OPA-A. The plot shows the integrated absorbance for 
that absorption band as a function of time, where the changes in absorbance no longer 
occur after 60 minutes of monitoring the liposome solution (Figure 41 right) . 
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Figure 41. IR spectra of the cationic aminooxy liposome during reaction and integrated IR 
absorbance around 1650cm·1 as a function of time. 
From the IR spectrum analysis , more than 80% of aminooxy absorbance 
disappeared within 30 min , meaning that most of the aldoxime bonds are generated in 
the first 30 min of incubation. It is interesting that 'click' liposome stabilization needed 
30 minutes to stabilize liposomes against surfactant solubilization (Figure 36) . 
Therefore, we can get a tentative conclusion : 'click' liposome stabilization requires 
around 80% of aminooxy functional groups crosslinking. 
4.4 Permeability Study of 'Click' Stabilized Liposomes 
The permeability of 'click' stabilized liposomes was studied by the encapsulated 
calcein leakage experiment. 115 Calcein is a small molecular fluorescent dye with an 
excitation and emission wavelength of 495/515nm , respectively. Under high 
concentration (e.g , 50 mM) , calcein emits a minimal fluorescent signal due to 
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self-quenching. Thus, very low fluorescence is observed when calcein is entrapped in 
liposomes (50 mM). However, once leaked from liposomes, an intensive fluorescent 
signal of calcein can be observed (Figure 42) , since the probe dilutes into the bulk 
buffer. Therefore, liposome permeability can be determined through monitoring 
fluorescence generated from leaked calcein.116 The relative fraction (RF) of released 
calcein can be calculated using the formula below: 
RF (%) = 1 OOX(lt - lo)/(Imax - 10) 
Where 10 is fluorescence intensity at time 0, It is fluorescence intensity at time t, Imax 
is maximum fluorescence intensity and represents all calcein released. 
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Figure 43. Calcein release study. 
Liposomes formulated from lipid 4.1 and containing encapsulated calcein (50 mM) in HEPES 
buffer (20 mM, pH 7.4) were treated with the indicated reagents prior to addition of Triton X-100 
(final concentration 0.15% w/v) at 75h. The release of calcein from the liposome samples was 
measured fluorometrically at certain time intervals. The relative fraction (RF %) was calculated 
using the formula: RF (%) = 100 X {It-Io}/{lmax-Io}. The RF (%) was plotted as a function of time. 
Each data point represents the mean value of n = 2, error bars show standard deviation from the 
mean. 
Briefly, a thin lipid layer of 4.1 was first hydrated using a calcein buffer (50 mM, pH 
7.4) by vortex mixing and sonication. Then the resultant liposomes containing calcein 
were separated from free calcein using a Sephadex G-100 column. The aliquot of 
calcein liposomes samples then was incubated with different reagents and the 
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fluorescent signal was recorded at certain time intervals. The effect of different 
reagents on the permeability of liposomes is shown in Figure 43. The result showed 
that DPA-A stabilized liposomes release calcein at the slowest rate --less than 25% of 
calcein had leaked out of DPA-A stabilized liposomes. The dextran and dextran 
sulfate treated liposomes, like untreated liposomes, released almost all calcein 
payload during the same timeframe. This result clearly showed that the sugar coating 











Figure 44. Calcein released from DPA-B stabilized liposomes. 
Liposomes formulated from lipid 4.1 containing encapsulated calcein (50 mM) in HEPES buffer 
(20 mM, pH 7.4) were incubated with the DPA-B (4 eq. aldehyde to aminooxy) for 30 min at room 
temperature. The stabilized liposomes were purified by Sephadex G-100 column using buffer B 
(10 mM HEPES, 150 mM NaCl, pH 7.4) as eluent. The aliquot of liposomes was incubated with 
dextranase (10 U) at 37°C for 12h or buffer only, and then Ttriton X-100 was added to release 
entrapped calcein . The release of calcein from the liposome samples was measured 
fluorometrically at the given time intervals. The relative fraction (RF %) was calculated using the 
formula: RF (%) = 100 X {It-Io}/(Imax-Io} . a} The RF (%) was plotted as a function of time. Each data 
point at figure b represents the mean value of n = 3, error bars show standard deviation from the 
mean . 
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In a final demonstration, an enzyme-mediated liposome permeability change was 
examined using the same technique. We believed that the hydrolysis of dextran by 
dextranase may remove some of the polymer from the liposome surface or decrease 
crosslin king and consequently increase liposome permeability. Since the enzymatic 
activity of dextranase is strongly affected by the cross-linking density of dextran, 117 the 
less crosslinked DPA-B was used in this experiment. The experimental results (Figure 
44 ) confirmed that the calcein release rate of 'click' stabilized liposomes increased 
round 3 fold in the presence of dextranase. 
The liposome permeability study showed that the dextran coating of 'click' 
stabilized liposome effectively decreases cargo leakage while incubation with 
dextranase can increase cargo leakage. Considering the anaerobic Gram-negative 
intestinal bacteria produce dextranase111,118, our 'click' stabilized liposomes have a 
potential to be a colon-specific drug carrier. 
4.5 'Click' Stabilized Liposomes as Nano-reactors 
Enzyme-containing liposomes have been studied as nano-reactors for medical 
and non-medical applications.11 9 The lipid layer of nano-reactors not only offers 
protection to encapsulated enzymes against denaturation or proteolysis, but also 
provides additional substrate selectivity due to different membrane permeability of 
external substrates. 12o The enzyme-containing liposomes can serve as nanoreactor 
and the entrapped enzymes can catalyze specific substrates which permeate across 
the lipid bilayer(s). Those enzyme containing liposomes have great potential in 
bio-catalysis as nano-bioreactor and signal generator/amplifier in analytical 
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chemistry.121-124 Considering the simplicity and ease to get click stabilized liposomes 
and their super stability, we believe this approach can offer great advantages when 
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Figure 45. The activity of phosphatase encapsulated within liposomes. 
The liposomes were formulated from lipid 4.1 and encapsulated within alkaline phosphatase. The 
stabilized liposomes were prepared by addition of DPA-A (1eq, aldehyde to aminooxy) followed by 
incubation overnight at room temperature. Unencapsulated enzyme was removed by repeated 
centrifugation , and the pelleted liposomes were resuspended in buffer (5 mM Tris, 5mM MgCI2, 
0.1 mM ZnCI2, pH 8) . The redispersed liposomes then were treated with Triton X-100 (final 
concentration 0.15% w/v). The released enzymes were separated by repeated centrifugation. The 
alkal ine phosphatase activity then was measured using the fluorogenic substrate 
4-methylumbelliferyl phosphate. Normalized phosphatase activity = phosphatase activity / loaded 
phosphatase activity. Each data point represents the mean value of n = 2, error bars show 
standard deviation from the mean. 
In our click stabilized nano-reactor, the enzyme (alkaline phosphatase) was 
encapsulated in the aqueous core domain and its activity was measured by cleavage 
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of the fluorogenic substrate 4-Methylumbelliferyl phosphate that diffuses through the 
lipid wall. Both liposome- and click stabilized liposome- encapsulated alkaline 
phosphatase were made. The free enzyme and liposomes were separated by 
repeated centrifugation . After Triton X-1 00 treatment, the disrupted liposomes and 
intact liposomes were separated by repeated centrifugation again. Final precipitation 
pellet were resuspended into the buffer and test their enzyme activity. The normal 
nano-reactor made from untreated liposomes was disrupted on surfactant treatment 
(no measured enzyme activity after treatment) whereas the click-stabilized 
nano-reactor preserved a significant amount of enzyme activity (6 .5 ± 3.1 % of total 
loaded enzyme activity) (Figure 45) . This proof-of-concept experiment 
demonstrated that the 'click' stabilized liposomes can work as nano reactor under 
harsh conditions such as the presence of surfactant due to its enhanced stability. 
4.6 Aminooxy Lipids as 'Clickable' Co-lipids 
The bis-aminooxy functionality on the cationic aminooxy lipid not only provides 
reactive groups for stabilization but also provides 'clickable' functionality for liposome 
surface modification . By using a cationic aminooxy lipid as a co-lipid , a formulated 
liposome is formed that is now equipped with aminooxy functionality on the surface for 
future modification, such as conjugation to target ligands, fluorescent groups or PEG 
groups. 
Our collaborator, Dr. Anu Puri (NCI-Frederick Center for Cancer Research 
Nanobiology Program) has developed a method to incorporate keto functionality on 
the antibody through site-specific protein glycosylation. 125 Considering the keto and 
93 
aminooxy group are an ideal conjugation pair, they plan to use our cationic aminooxy 
lipid as a co-lipid for conjugation of an antibody to the liposome through ketoximation . 
The preliminary results demonstrated that the cationic lipid 4.2 can labeled with 
anti-HER2 scFv antibody, an antibody targeting breast cancer (Figure 46) . 
Figure 46. Antibody conjugated with aminoxy-lipid. 
SOS-PAGE gel of the anti HER2 scFv with 2-keto-Gal before (left) and after (right) 
Besides the cationic lipids 4.2, the mono-aminooxy lipids 4.18 and bis-aminooxy 
lipids 4.19 and 4.20 are also synthesized in 94% and 30% unoptimized yield 
respectively, at the request of our collaborator (Scheme 31). 
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Scheme 31. Synthesis of aminooxy lipid 4.19 and 4.20. 
4.7 Conclusions 
In summary, we have demonstrated a convenient method to stabilize aminooxy 
liposomes via click chemistry of the aminooxy surface using externally added 
aldehyde-polymers. The resultant liposomes have super stability against surfactant 
solubi lization and serum mediated aggregation. The stabilized liposomes also have 
reduced permeability compared with untreated liposomes. Moreover, the stabilized 
liposomes can be permeablized by treatment with an enzyme, such as dextranase. 
The stabilized liposomes may be useful in two potential applications: as a colon 
targeted drug carrier and as a robust nanoreactor. The aminooxy lipids we 




'CLICK' STABILIZED LIPOSOMES FOR 
GENE TRANSFECTION 
5.1 Introduction 
Gene therapy is a promising approach for the treatment of liver diseases including 
cancer.126-128 Compared to viral vectors, liposomal-directed gene delivery systems are 
nearly non-immunogenic, relatively safer, have a lower production cost and can carry 
multiple genetic materials. But the transfection efficiency of liposomal-directed gene 
delivery still needs to be improved. To achieve a high in-vivo, liver-targeted gene 
transfection efficiency, intact liposome vectors need to be efficiently delivered to the 
surface of liver cells . However, there are two hurdles that decrease delivery efficiency: 
off-target delivery (e.g, lungs) and instabil ity in the blood. 129 In this chapter, we attempt 
to overcome these two hurdles using a liver-targeted 'click' stabilized liposome. 
The ligand we chose is targeted to the asialoglycopretein receptor, which is 
predominantly expressed on the sinusoidal surface of mammalian hepatocytes and 
specifically recognizes ligands fitted with terminal galactose or N-acetylgalactosamine 
residues .13o It has been reported that the incorporation of the natural ligand for this 
receptor, asialofetuin, onto liposome exteriors can enhance liver uptake and gene 
delivery.131 ,132 However, the protein-based ligand suffers from a tedious purification 
procedure and potential immunoresponse. Thus, other ligands (i.e, galactose, lactose) 
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that also are recognized by the asialoglycopretein receptor have been investigated . 
Many synthetic compounds with galactosylated residues have been developed to 
achieve liver targeting , such as galactosylated cholesterol133, galactosylated 
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Figure 47. Pre- and Post-modification formulation . 
Currently, most researchers use the premodification formulation process where 
galactosylated lipids are formulated to encapsulate a drug/gene payload (Figure 
47) .1 38,139 The resultant lipoplexes have galactosylated molecules distributed on both 
sides of the lipid bilayer. However, the presence of galactosylated functionality in the 
inner leaflet of lipoplexes is not preferred because it reduces the interior volume 
(carrying capacity) of the liposomes and may interfere with the interaction between 
lipid and cargos. The postmodification formulation process can overcome those 
drawbacks by incorporating galactosylated functionality on lipoplexes after lipoplexes 
formulation . Therefore, we plan adopt postmodification formulation strategy to create 
a liver-targeted , stabilized liposomal carrier. 
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The newly developed 'click' stabilized liposomes are ideal vectors to overcome 
these hurdles. First, DPA stabilized liposomes are super stable and do not 
disassemble even under surfactant treatment. Second , DPA provides a dextran-like 
surface layer as "stealth" barrier against serum-induced aggregation. Last but not 
least, the unreacted aldehyde groups on the DPA exterior provide 'clickable' groups 
for attachment of a liver targeted ligand . Moreover, in this approach, the covalently 
conjugated ligands cannot dissociate from the liposomes, which is a major problem of 
other postmodification formulation strategies using absorbed targeted-lipids or 
targeted-polymers. 14o 
We envisioned postmodification formulation of liver-targeted 'click' stabilized 
lipoplexes as follows (Figure 47) : first, the cationic aminooxy lipid 4.1 is sonicated in 
aqueous buffer to generate liposomes; second , the liposomes are mixed with plasmid 
DNA to form lipoplexes; the resultant lipoplexes are then stabilized by incubation with 
DPA; finally, the stabilized lipoplexes are incubated with a 'clickable' liver-targeting 
element. 
5.2 In-vitro Gene Transfection 
It is well known that the chemical structure of cationic lipids can strongly influence 
the transfection potency of formulated lipoplexes. Although the lipid 4.1 is a mimic of 
commercial gene transfection vector TransFast™, the effect of headgroup 
functionality changing from alcohol (TransFast™) to aminooxy (4.1) on its potency as 
gene transfection vector is unknown. We evaluated the gene transfection potency of 
lipoplexes in MCF-7 breast cancer cells using a luciferase reporter plasmid 
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(pCMV-Luc) . The data (Figure 48) indicated that the lipoplexes is roughly equivalent 
or slightly higher than that of the transfection agent Lipofectamine ™ 2000 (positive 
control) at various lipids:pONA charge ratios , while uncomplexed pONA (negative 
control) did not show significant transfection . 
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Figure 48. Transfection of MCF-7 cells using lipoplexes from lipid 4.1. 
The resu lts are expressed as Relative Light Units (RLU) . MCF-7 cells were plated at 1 X 10s/well in 
a 24 well plate 24 h prior to transfection in DME/10% FBS. Transfections were performed using 
0.025 mg luciferase reporter construct (pCMVLuc) per well with 39 h transfection time. Each data 
point reflects the mean value of three separate transfections. Error bars show the standard 
deviation from the mean. DNA: uncomplexed pDNA; LFT: Lipofectamine™ 2000 (Invitrogen). 
The above lipoplexes were formulated using equimolar lipid 4.1 and 
dioleoylphosphatidylethanolamine (DOPE), a 'helper' lipid to facilitate H11 phase 
organization that promotes cytoplasmic release of plasm ids. From preliminary 
experiments, we observed that DOPE did not significantly affect liposome 
stabilization. 
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Compared to the liposomes from the lipid 4.1 only (diameter 119 nm; zeta potential 
59 meV), the liposomes formulated from the lipid 4.1 and DOPE have smaller size and 
lower zeta potential (diameter 82 nm, 19 meV). Then the formulated liposomes mixed 
with calf thymus DNA (Invitrogen) at 3:1 lipid:DNA charge ratio to get the resultant 
lipoplexes which have larger size and lower zeta potential (diameter 190 nm; zeta 









. No DPA-B 
.0.2 eq DPA-B 
00.5 eq DPA-B 
. 1 eq DPA-B 
D2eq DPA-B 
7 LFT DNA 
I 
Lipids/pDNA (charge ratio) 
Figure 49. Transfection of MCF-7 cells using stabilized lipoplexes. 
The results are expressed as thousand Relative Light Units (kRLU). MCF-7 cells were plated at 1X 
10s/well in a 24 well plate 24 h prior to transfection in DME/10% FBS. Transfections were 
performed in 24-well tissue culture plates using 0.025 mg luciferase reporter construct (pCMVLuc) 
per well with 39 h transfection time. Each data point reflects the mean value of three separate 
transfections. Error bars show the standard deviation from the mean. DNA: uncomplexed pDNA; 
LFT: Lipofectamine ™ 2000. 
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The gene transfection potency of DPA-B stabilized lipoplexes was then evaluated 
in MCF-7 breast cancer cells using a luciferase reporter plasmid (pCMV-Luc). The 
formulated liposomes from lipid 4.1 and DOPE (1:1 molar ratio) were first incubated 
with pDNA at various lipids:pDNA charge ratios for 20 min and then incubated with 
various eq. of PDA-B for stabilization. The resultant lipoplexes were then mixed with 
DMEM media and added to MFC7 cells for transfection. The data (Figure 49) 
indicated that the stabilized lipoplexes (e.g. lipids: pDNA charge ratio 3:1, stabilized 
by 1 eq. DPA-B) still preserved transfection potency, yet at a slightly lower level than 
that of the transfection agent Lipofectamine ™ 2000 (positive control). However, it also 
observed that the following trend of gene transfection potency: 0 eq DPA-B > 
Lipofectamine™ 2000 > 0.2 eq DPA-B > O.Seq DPA-B > 1eq DPA-B > 2eq DPA-B > 
pDNA only. The gene transfection efficiency decreases with an increasing amount of 
DPA-B. This is possible due to the more stable lipoplexes formulated, the slower 
pDNA releasing from lipoplexes. 
5.3 Synthesis of Aminooxy Functionalized Lactose 
We felt that a mild, quick and convenient procedure for directly conjugating a 
galactosylated ligand to the liposomes would constitute a promising postmodification 
method. The oximation, which has been widely applied to conjugate carbohydrates to 
peptides 141, proteins 142 and Iipids44,75, was chosen due to the ease of reaction and the 
robust nature of the oxime ether linkage. Gur'eva reported the synthesis of aminooxy 
functionalized D-Iactose 5.1 as an intermediate compound towards neoglycolipids 
(Figure 50).143 However, their conjugation strategy is DCC catalyzed amine and acid 
101 
coupling reaction which is not compatible to physiological conditions. The lack of linker 
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Figure 50. Aminooxy functionalized D-Iactose. 
Our designed ligand 5.2 has three parts (Figure 50), the 'clickable' aminooxy 
group which can conjugate on ketone or aldehyde carbonyl groups on the surface of 
liposomes or lipoplexes (e.g, DPA stabilized lipoplexes); the lactose as a liver-targeted 
ligand and the flexible linker provides extra space between two parts. By combining 
the aminooxy functionalized lactose and postmodification formulation, we simplify lipid 
synthesis by avoiding a lengthy glycolipid synthesis required for a premodification 
formulation. We also guarantee that the galactosylated functionality is present only on 
the outer layer of the liposomes/lipoplexes. 
The aminooxy functionalized lactose 5.2 was prepared as described in Scheme 
32. First, diethylene glycol was reacted with N-hydroxyphthalimide under Mitsunobu 
conditions to generate 5.3 in 90% yield. 144 The Pht protection group was cleaved by 
reaction with hydrazine to afford bis-aminooxy linker 5.4 in 87% yield. Mono-Boc 
protection of 5.4 was accomplished by reaction with Boc20 as the limiting reagent. 
The resultant, mono-Boc protected linker 5.5 was then condensed with lactose in 
pyridine, catalyzed using a solid phase acid catalyst, at 65 L for 4 h. All hydroxyl 
groups were then acetylated by adding acetic anhydride to generate 
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Ac-lactose-Iinker-Boc 5.6 (Ell 4:1) in 65% yield. The Boc group was removed by 
addition of acid (TFA) to afford the Ac-lactose-Iinker-aminooxy 5.7 (Ell 57:43) in 91 % 
yield. Finally, all acetyl protection groups were removed by treating in methanol with 
catalytic CH30Na to give lactose-linker-aminooxy 5.2 (Ell 73:27) in 96% yield. It is 
worth noting that we had a difficult time to get pure deacetylation product 5.2 by using 
NH3 aqueous solution as deprotection reagent. Due to variations of reaction and work 
up conditions, the Ell ratio may vary from batch to batch. 
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Scheme 32. Synthesis aminooxy functionalized D-Iactose 5.2. 
Conditions: Pht = phthaloyl a) N-hydroxyphthalimide, PPh3, DIAD, THF, ODC to rt., 20 h, 90%; b) 
N2H4·H20, CH2CI2, rt., 14 h, 87%; c) di-tert-butyl dicarbonate, CHCI3, 0 DC to rt., 14 h, 90%; d) (1) 
lactose monohydrate, pyridine, Amberlyst-15 resin, 65 DC, 12 h; (2) (CH3COhO, 0 DC to rt., 12 h, 
65%; e) TFA, H20, CH2CI2, 0 DC to rt., 12 h, 83%; f) CH30Na/methanol, rt.,12 h, 96%. 
103 
From the 1H NMR (400 MHz, CD30D) spectrum of aminooxy lactose 5.2, the 
duplet signals of 0 7.55, 6.87 ppm represent the E and Z aldoxime ether aminooxy 
proton respectively (Figure 51). The acetal proton can be found at 4.95 ppm. The 
HRMS found M+Na + at 483.1797 (C16H32N2Na013 + calculated as 483.1797). The 
obtained aminooxy functionalized D-Iactose 5.2 has the following potential 
applications: 1) can be applied to the DPA stabilized lipoplexes for in-vivo liver 
targeted gene delivery (Figure 47); 2) can be applied as a lactosylation reagent for 
liver-targeted lipid or polymer syntheses; 3) can be applied as a lactosylation reagent 
in postmodification formulation of other liver-targeted nano-carriers including micelles, 
nanoparticles, dendrimers and polysomes as long as these possess carbonyl groups 
at their exterior. 
\ 
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Figure 51. 1H NMR spectrum of aminooxy functionalized O-Iactose 5.2. 
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5.4 Conclusions 
Initial results of in vitro transfection studies revealed that the lipid 4.1 has roughly 
equivalent or slightly higher gene transfection efficiency than that of the commercial 
transfection agent Lipofectamine ™ 2000 at various lipids:pDNA charge ratios. The 
stabilized lipoplexes formulated from lipid 4.1, DOPE and DPA-B can successfully 
transfect MCF-7 cells, but with lower transfection potency than Lipofectamine™ 2000. 
It is important to note that these results are preliminary and require further optimization 
to achieve ideal transfection efficiency. We feel that formulation lipoplexes with 
co-lipids having control-release function or incorporate control-release function on the 
lipid 4.1 may provide efficient way for pDNA releasing in the cells. Those 
control-release functions could be pH-sensitive, temperature-sensitive, 
redox-potential sensitive, light-sensitive or other external stimuli sensitive (e.g. 
magnetic field, ultrasound, enzyme etc.)145-147. 
An aminooxy-functionalized lactose-based ligand was synthesized in 0.863 gram 
with 35 % overall yield from biethanol amine. This targeting ligand is suitable for use in 
in vivo liver targeted gene delivery. The clickable ligand may be also applied to 
functionalize lipids polymers and nano carriers (Iiposomes, polysomes, micelles and 
nanoparticles) via click chemistry. 
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CHAPTER 6. 
EXPERIMENTAL PROCEDURES, NMR 
SPECTROSCOPY 
6.1 General Experimental Procedures 
Unless otherwise noted, all reagents were purchased from commercial suppliers 
and were used as without further purification. The progress of reactions was 
monitored by thin-layer chromatography (TLC) using silica gel 60 F254 TLC plates. 
Visualization was accomplished by staining the plates with iodine or PMA (3% 
phosphomolybdic acid/ethanol solution) stain. Silica gel 60 (230-400 mesh) was used 
for flash column chromatography. 1 H NMR spectra were recorded at 400 or 500 MHz, 
and 13C spectra were recorded at 100 or 125 MHz, respectively, in the indicated 
solvents. The chemical shifts are reported in ppm values relative to the solvent 
residual peak CDCI3 (7.26 ppm for 1H NMR and 77.26 ppm for 13C NMR); CD30D 
(3.31 ppm for 1H NMR and 49.00 for 13C NMR); (CD3hSO (2.50 ppm for 1H NMR and 
39.52 for 13C NMR) and TMS (0.00 ppm). Coupling constants are reported in hertz 
(Hz). High resolution ESI-MS were obtained using a MS-FTICR-MSn system (LTQ FT, 
Thermo Electron Corp.) at the CREAM Mass Spectrometry Facility, University of 
Louisville, Kentucky. ST-IR cards (thermo Electron Co.) were used to determine the IR 
absorptions. Melting points are uncorrected. All sonications were performed in a bath 
106 
sonicator (Laboratory Supplies Inc.). Dynamic light scattering was carried by 
Brookhaven 90 Plus Nanoparticle Size Analyzer. 
6.2 Chapter 2. Cationic Aminooxy Reagent 
6.2.1 2-(N-(2-tert-butyld imethylsilyloxyethyl)-2-hydroxyethylamino) 
ethanol (2.11) 
6.2.2 N, N-bis(2-phthalimidooxyethyl)-2-(tert-butyldimethyl-silyloxy) 
ethyl amine (2.12) 
6.2.3 2-(N, N-bis(2-phthalimidooxyethyl)amino )ethanol (2.13) 
6.2.4 N, N-bis(2 -phtha I im id ooxyethyl)-N-(2 -hyd roxyethyl)-N-methyl-ammon iu m 
iodide (2.14) 
6.2.5 N,N-bis(2-aminooxyethyl)-N-(2-hydroxyethyl)-N-methyl-ammonium iodide 
(2.1) 
6.2.6 bis(2-( (tert-butyldimethylsilyl)oxy)ethyl)amine (2.15) 
6.2.7 di-tert-butyl(( ((2-hydroxy-3-(trityloxy)propyl)azanediyl)bis( ethane-2, 1-diyl) )bis 
(oxy»dicarbamate (2.29) 
6.2.8 N, N-bis(2-( (( tert-butoxycarbonyl)am inc )oxy)ethyl)-2-hyd roxy-N-methyl-3-(trit 
yloxy)propan-1-aminium iodide (2.30) 





To a solution of triethanolamine (5.96 g, 40.0 mmol) and triethylamine (5.6 mL, 
40 mmol) in CH2Cb (10 mL) at 0 °C was added slowly via cannula a solution of 
teri-butyldimethylsilyl chloride (1.21 g, 8.03 mmol) in CH2Cb (40 mL). The reaction 
mixture was stirred 1 h at 0 °C and then allowed to warm to room temperature. After 12 
h, the reaction solvent was removed by rotary evaporation. The crude residue was 
dissolved in ethyl acetate (40 mL) and washed successively with saturated aq. 
NaHC03 (2 x 40 mL) and brine (40 mL). The organic layer was dried (Na2S04), filtered, 
and the solvent was removed by rotary evaporation. The crude product was purified by 
flash chromatography (Si02) using 19:1 CH2Cb: MeOH as eluent (product Rf = 0.25) 
to obtain 2.11 (1.90 g, 90%) as a colorless oil. IR (neat) 3389, 2928, 2858,1472 cm-1; 
1H NMR (CDCI3, 500 MHz) 0 3.59 (t, J = 5.0 Hz, 2H), 3.50 (t, J = 5.5 Hz, 4H), 3.04 (br, 
2H), 2.65 (m, 6H), 0.82 (s, 9H), 0.00 (s, 6H); 13C NMR (CDCI3, 125MHz) 0 62.0, 60.0, 
57.1, 56.5, 26.1, 18.5, -5.2. 
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6.2.2 N,N-bis(2-phthalimidooxyethyl}-2-(tert-butyldimethyl-siIyloxy}ethyl amine 
2.11 2.12 
To a solution of diol 2.11 (2.38 g, 9.03 mmol), N-hydroxyphthalimide (3.23 g, 
19.8 mmol) and PPh3 (5.19 g, 19.8 mmol) in THF (50 mL) at 0 °C was added DIAD 
(3.93 mL, 19.8 mmol) over 5 min. The reaction was stirred at 0 °C for 0.5 h and then 
warmed to room temperature. After 12 h, the reaction solvent was removed by rotary 
evaporation. The orange residue was dissolved in ethyl acetate (150 mL) and washed 
successively with saturated aq. NaHC03 (3 x 100 mL), brine (100 mL) and cold aq. 5% 
HCI (2 x 120 mL). The organic layer was stored at 0 °C for 2h (or overnight) to effect 
precipitation of the product as its hydrochloride salt. The solids were collected by 
filtration and washed with cold ethyl acetate. The collected hydrochloride salt was 
suspended in a 1:1 mixture of ethyl acetate: saturated aq. NaHC03 and stirred for 0.5 
h. The organic layer was separated and washed successively with saturated aq. 
NaHC03, brine, and then dried (Na2S04)' The solvent was removed by rotary 
evaporation and the crude product was purified by flash chromatography (Si02) 
eluting with a 2: 1 hexanes: ethyl acetate (product Rf = 0.23) to obtain 2.12 (4.10 g, 
82%) as a light yellow solid. mp = 56-58°C; 1H NMR (CDCI3, 500 MHz) 0 7.78 (m, 4H), 
7.70 (m, 4H), 4.32 (t, J = 6.0 Hz, 4H), 3.71 (t, J = 6.0 Hz, 2H), 3.16 (t, J = 6.0 Hz, 4H), 
2.86 (t, J = 6.0 Hz, 2H), 0.84 (s, 9H), 0.02 (s, 6H); 13C NMR (CDCI3, 125 MHz) 0 163.6, 




To a solution of bis-phthalimide 2.12 (2.77 g, 5.00 mmol) in THF (15 mL) at 0 °C 
was added a mixture of HF (2 mL of 48% aq. HF) in THF (14 mL) over 2 min. The 
reaction mixture was stirred at 0 °C for 1 h before warming to room temperature. After 
12 h, the solvents were removed by rotary evaporation. The crude residue was 
dissolved in ethyl acetate (100 mL) and washed successively with saturated aq. 
NaHC03 (3 x 100 mL), brine (100 mL) and then dried (Na2S04). The solvent was 
removed by rotary evaporation and the crude product was recrystallized in ethyl 
acetate to yield 2.13 (1.88 g, 86%) as a light yellow solid. mp = 136-138 °C; IR 3066, 
1731 cm-1; 1H NMR (CDCI3, 500 MHz) (5 7.80 (m 4H), 7.72 (m 4H), 4.36 (t, J = 5.0 Hz, 
4H), 3.65 (t, J = 5.0 Hz, 2H), 3.13 (t, J = 5.0 Hz, 4H), 2.91 (t, J = 5.0 Hz, 2H); 13C NMR 
(CDCI3, 125 MHz) (5163.7,134.7,129.1,123.8,77.4,59.4,57.6,53.0; Anal. calcd. for 






~N~OH -.. ~N~OH 
PhtN-O PhtN-O 
2.13 2.14 
In a sealed tube, bis-phthalimide 2.13 (0.88 g, 2.0 mmol) was dissolved in 
iodomethane (5 mL). The reaction mixture was degassed using a stream of N2 before 
sealing the tube. After stirred 3 h at 50 DC, the reaction was cooled and the 
iodomethane was evaporated (Caution: fume hood required) to afford the 
corresponding ammonium iodide 2.14 (1.14 g, 98%). mp = 201 DC (dec); IR 3256, 
2921, 1583 cm-1; 1 H NMR (OMSO-d6 , 500 MHz) 0 7.87 (s, 8H), 5.36 (t, J = 4.5 Hz, 1 H), 
4.74 (t, J = 4.5 Hz, 4H), 4.06 (s, 4H), 3.92 (s, 2H), 3.78 (t, J = 4.5 Hz, 2H), 3.42 (s, 3H); 
13C NMR (OMSO-d6 , 125 MHz) 0164.0,135.9,129.4,124.4,72.1,65.5,61.7,55.7, 
50.7. 
111 
6.2.5 N,N-bis(2-aminooxyethyl)-N-(2-hydroxyethyl)-N-methyl-ammonium iodide 
2.14 2.1 
To a solution of the ammonium iodide 2.14 (1.05 g, 1.8 mmol) in a 19:1 mixture of 
EtOH: H20 (8.0 mL) at room temperature was added via syringe hydrazine 
monohydrate (0.20 mL, 4.1 mmol). After stirring 12 h at room temperature, the 
solvents were removed by rotary evaporation. The residue was dissolved in H20 (100 
mL) and washed with ethyl acetate (3 x 100 mL). The aqueous layer then was 
concentrated to -2mL and loaded onto HPLC (reverse phase, C18) using H20 as the 
eluent to obtain 2.1 as a colorless oil (0.40 g, 70%). IR (neat) 3256, 3135, 2921, 1583, 
1203, 1149, 1052,950 cm -1; 1H NMR (DMSO-d6 , 500 MHz) 0 6.29 (br, 4H), 5.26 (s, 
1 H), 3.97 (br, 4H), 3.87 (s, 2H), 3.69 (m, 4H), 3.54 (t, J = 5.0Hz, 2H), 3.16 (s, 3H); 13C 
NMR (DMSO-d6 , 125 MHz) 0 69.1,64.9,61.5,55.7,50.4; Anal. calcd. for C7H201N303: 
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13C NMR spectrum of compound 2.1 
114 
6.2.6 bis(2-((tert-butyldimethylsilyl)oxy)ethyl)amine 
TBso1 fOTBS --~~ ~N 
H 
2.15 
To a solution of diethanolamine (4.20 g, 40.0 mmol) and triethylamine (20 g, 200 
mmol) in CH2CI2 (30 mL) was slowly added a solution of teri-butyldimethylsilyl chloride 
(13.3 g, 88.0 mmol) in CH2Cb (30 mL). The reaction mixture was stirred 48 h at room 
temperature and then washed by two times of brine (100 mL). The organic layer was 
dried, filtered, and the solvent was removed by rotary evaporation. The crude product 
was purified by flash chromatography (Si02) using 19:1 CH2Cb:MeOH as eluent 
(product Rf=0.30) to afford 2.15 (12.50 g, 94%) as a clear oil. The product have also 
been purified by distillation 148. 1H NMR (CDCb, 500 MHz) 0 3.72 (t, J = 5.0 Hz, 4H), 2.72 
(t, J = 5.0 Hz, 4H), 1.88 (br, 1 H), 0.90 (m, 18H), 0.05 (s, 12H); 13C NMR (CDCb, 125 
MHz) 0 62.9, 52.1,26.3, 18.7, -5.0. 
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6.2.7 di-tert-butyl ((((2-hydroxy-3-(trityloxy)propyl)azanediyl) 
bis(ethane-2,1-diyl))bis(oxy))dicarbamate 
2.26 





To a solution of 2-(trityloxy)oxirane (0.316 g, 1.0 mmol) in ethanol (5 mL) was 
added amine 2.26 (0.335 g, 1.0 mmol) and Na2C03 (0.106 g, 1.0 mmol). The reaction 
was stirred 17 h at rt. and then at 60°C for 22h. After evaporated ethanol, the crude 
residue was dissolved in CH2CI2 (20 mL) and then washed successively with saturated 
aq. NaHC03 (2 x 20 mL) and brine (20 mL) and dried (Na2S04). After evaporated 
solvent, the crude product was purified by flash chromatography (Si02) using 9:1 
CH2CI2:MeOH as eluent (product Rf=0.43) to afford 2.29 (0.42 g, 64%) as a clear oil. 
1H NMR (CDCI3, 500 MHz) 0 8.15 (s, 2H), 7.49 (d, J = 7.5 Hz, 6H), 7.30 (t, J = 7.5 Hz, 
6H), 7.22 (t, J = 7.0 Hz, 3H), 3.87-3.96 (m, 5H), 3.22 (m, J = 5.0 Hz, 1 H), 3.11 (m, J = 
5.0 Hz, 1 H), 2.90 (m, 2H), 2.75 (m, 2H), 2.66 (m, 1 H), 2.59 (m, 1 H), 1.48 (s, 18H); 13C 
NMR (CDCI3, 125 MHz) 0 156.9,143.9,128.6,127.7,126.9,86.4,81.3,74.2,67.6, 
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13C NMR spectrum of compound 2.29 
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6.2.8 N, N-bis( 2-( « tert-butoxycarbonyl)am i no )oxy)ethyl) 
-2-hydroxy-N-methyl-3-(trityloxy)propan-1-aminium iodide 








N ......... I TrtO~ 
OH 
2.30 
In a sealed tube, the amine 2.29 (1.70 g, 2.6 mmol) was dissolved in CH2CI2 (5 
mL) then iodomethane (2 mL) was added. The reaction mixture was stirred at 60°C for 
24 h. The colorless solution turned to yellow and finally to brown color. After 
iodomethane and CH2Ch was removed by rotary evaporator, the crude product was 
purified by flash chromatography (Si02) using 24:1 CH2CI2:MeOH as eluent (product 
Rf = 0.70 in 9:1 CH2CI2:MeOH) to afford the corresponding ammonium iodide 2.30 
(1.65 g, 80%) as a yellow oil. 1H NMR (CDCI3 500 MHz) 0 8.41 (d, 2H), 7.37 (d, J = 7.5 
Hz, 6H), 7.26 (t, J = 7.5 Hz, 6H), 7.17 (t, J = 7.0 Hz, 3H), 4.49 (s, 1 H), 4.25 (m, 4H), 
4.07 -4.15 (m, 5H), 3.64 (s, 2H), 3.42 (s, 3H), 3.23 (m, 1 H), 3.25 (m, 1 H), 1.36 (s, 18H); 
13C NMR (CDCI3, 125 MHz) 0156.5, 143.2, 128.4, 127.9, 127.0,87.0,81.9 (2 signals), 
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13C NMR spectrum of compound 2.30 
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To a solution of the ammonium iodide 2.30 (0.50 g, 0.63 mmol) in CH2Cb (7 ml) 
was added triethylsilane (2 mL) and trifluoroacetic acid (1 mL) at 0 °C. The reaction 
mixture was stirred at 0 °C for 2 h and then stirred 2.5 h at room temperature. After 
solvent was removed by rotary evaporation, the yellow residue was dissolved in H20 
(10 mL) and washed with CH2CI2 (3 x 10 mL). The red aqueous layer was 
concentrated to -2 mL and purified by flash chromatography (reverse phase, C1a) two 
times using water as eluent to afford the corresponding ammonium iodide 2.2 (83 mg, 
38%) as red liquid. 1H NMR (CD30D, 500 MHz) 0 5.08 (br, 6H), 4.50 (m, 2H), 4.44 (m, 
2H), 4.23 (m, 2H), 4.02 (m, 3H), 3.94 (m, 1 H), 3.62-3.75 (m, 2H), 3.58 (m, 1 H), 3.50 (m, 
1 H); 3.33 (s, 3H) 13C NMR (CD30D, 125MHz) 069.7,67.3,66.9,65.1,63.3,63.0,51.7; 
HRMS (ESI): calcd. for CaH22N30/ [M+]: 224.1605, found: 224.1605. 
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1H NMR spectrum of compound 2.2 
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6.3 Chapter 3. Cationic Aminooxy Lipids for 
pH-Triggered Liposome Polymerization--First Generation 
Concept 
6.3.1 2-(decyloxy)tetrahydro-2H-pyran (3.8) 
6.3.2 ((5-( decyloxy)pent-4-en-1-yl)oxy)triethylsilane (3.9) 
6.3.3 5-( decyloxy)pent-4-en-1-ol (3.10) 
6.3.4 (Z)-1-( (5-( decyloxy)pent-4-en-1-yl)oxy)hexadecan-2-ol (3.11) 
6.3.5 2-( (dodecyloxy)methyl)-3,4-dihydro-2H-pyran (3.12) 
6.3.6 (Z)-6-( decyloxy)-1-( dodecyloxy)hex-5-en-2-ol (3.15) 
6.3.7 2-(5,6-dihydro-1 ,4,2-dioxazin-3-yl)-N-tetradecylbenzamide (3.36) 
6.3.8 4-(2-(bis(2-((1,3-dioxoisoindolin-2-yl)oxy)ethyl)amino)ethoxy)-4-oxobutanoi 
c acid (3.50) 
6.3.9 2-(bis(2-( (1,3-dioxoisoindolin-2-yl)oxy)ethyl)am inc )ethyl( 5-( decyloxy)pent-4 
-en-1-yl) succinate (3.51) 
6.3.10 2-( (4-( (5-( decyloxy)pent-4-en-1-yl)oxy)-4-oxobutanoyl)oxy)-N, N-bis(2-( (1,3-
dioxoisoindolin-2-yl)oxy)ethyl)-N-methylethanaminium iodide (3.53) 
6.3.11 2-( am inooxy)-N-(2-( am inooxy)ethyl)-N-(2-( (4-( (5-( decyloxy)pent-4-en-1-yl) 
oxy)-4-oxobutanoyl)oxy)ethyl)-N-methylethanaminium iodide (3.1) 
6.3.12 2-(bis(2-( (1,3-dioxoisoindolin-2-yl)oxy)ethyl)amino )ethyl(1-( (5-( decyloxy)pe 
nt-4-en-1-yl)oxy)hexadecan-2-yl) succinate (3.52) 
6.3.13 N, N-bis(2-( (1,3-dioxoisoindolin-2-yl)oxy)ethyl)-N-methyl-4,7 -dioxo-9-tetrad 
ecyl-3,8,11,17-tetraoxaheptacos-15-en-1-aminium iodide (3.54) 




To a solution of decanol (7.90 g, 50 mmol) and p-toluenesulfonic acid in CH2Ch 
(50 ml) was added 3,4-dihydro-2H-pyran (8.40 g, 100 mmol) at 0 °C. The reaction 
mixture was stirred at 0 °C for 1 h and then warm up to room temperature. After 12 h, 
the solvent was removed by rotary evaporation. The crude residue was dissolved in 
EtzO (200 mL) and then washed successively with saturated aq. NaHC03 (2 x 100 mL) 
and brine (100 mL). The organic layer was dried (Na2S04), filtered, and the solvent 
was removed by rotary evaporation. The crude product was purified by flash 
chromatography (Si02) using 19: 1 hexanes: ethyl acetate as eluent (product Rf = 0.35) 
to afford 3.8 (11.83 g, 98%) as a colorless liquid. 1H NMR (CDCI3, 500 MHz) (54.56 (t, 
J = 2.0 Hz, 1 H,), 3.86 (m, 1 H), 3.72 (m, 1 H), 3.49 (m, 1 H), 3.37 (m, 1 H), 1.82 (m, 1 H), 
1.70 (m, 1 H), 1.50-1.58 (m, 6H), 1.25-1.34 (m, 14H), 0.86 (t, J=7.0 Hz, 3H); 13C NMR 
(CDCI3, 125 MHz) (5 99.2,68.0,62.7,32.2,31.1,30.1,29.9 (2 peaks), 29.8, 29.7, 26.6, 
25.9,23.0, 20.0, 14.4. 
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6.3.2 «5-(decyloxy)pent-4-en-1-yl)oxy)triethylsilane 
To a solution of acetal 3.8 (0.242 g, 1.0 mmol) and 2,6-lutidine (0.428 g, 4.0 
mmol) in dry CH2CI2 (10 ml) was added triethylsilyltriflate (0.473 g, 2.0 mmol) dropwise 
at 0 ac. The reaction mixture was stirred at 0 ac for 0.5 h and then at room 
temperature for 12 h. The yellow reaction mixture was quenched by saturated aq. 
NaHC03 (20 mL) and the CH2CI2 was removed by rotary evaporation. The crude 
residue was dissolved in ethyl acetate (30 mL) and then washed successively with 
saturated aq. NaHC03 (30 mL), brine (30 mL) and dried (Na2S04). After filtration, the 
solvent was evaporated and then dried by oil pump. The crude product was purified by 
flash chromatography (Si02) using 49:1 hexanes: ethyl acetate as eluent (product Rf = 
0.20) to afford 3.9 (0.323 g, Z:E=5:1, 91%). 1H NMR (CDCI3, 500 MHz) 0 6.22 (d, J = 
12.5 Hz, 0.16H), 5.91 (dt, J = 6.5 Hz, 1.0 Hz, 0.94H), 4.74 (dt, J = 12.5,5.5 Hz, 0.16H), 
4.32 (dt, J = 6.5, 2.0 Hz, 0.94H), 3.68 (t, J = 6.5 Hz, 2H), 3.59 (m, 2H), 2.10 (m, 1.88H), 
1.80 (m, 0.32H), 1.59 (m, 4H), 1.26-1.34 (m, 14H), 0.94-0.97 (m, 9H), 0.88 (t, J= 7.0 
Hz, 3H), 0.59 (m, 6H); 13C NMR (CDCI3, 125 MHz) 0 146.8, 145.5 (2 peaks), 106.4, 
103.7, 72.5, 69.6, 63.0, 62.5, 34.2, 33.4, 32.3, 30.1, 29.9, 29.7 (2 peaks), 26.4, 26.2, 
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To a solution of 3.9 (6.41 g, 18.0 mmol) was added TBAF (27 mL, 1M in THF) 
dropwise at 0 DC. The reaction mixture was stirred at 0 DC for 12 h and then warm up to 
room temperature. After 12 h, the solvent was removed by rotary evaporation and the 
yellow crude residue was dissolved in ethyl acetate (100 mL). The organic solution 
was washed successively with saturated aq. NaHC03 (100 mL x 3), brine (100 mL) 
and dried (Na2S04)' After filtration, the solvent was removed and the crude product 
was purified by flash chromatography (Si02) using 5:1 hexanes: ethyl acetate as 
eluent (product E Rf=0.21, Z Rf=0.31) to afford 3.10(Z) (2.63 g, 60%) and 3.10(E) 
(0.41 g, 9.4%) as white solid. 1H NMR (CDCI3, 500 MHz) 3.10(Z) (5 5.98 (d, J = 6.5 Hz, 
1 H), 4.33 (dt, J = 6.5 Hz, 2.5 Hz, 1 H), 3.71 (t, J = 6.5 Hz, 2H),3.62 (t, J = 6.5 Hz, 2H), 
2.16 (m, J = 7.0 Hz, 2H), 2.09 (br, 1H), 1.60 (m, 4H), 1.25-1.34 (m, 14H), 0.87 (t, J = 
7.0 Hz, 3H); 3.10(E) (5 6.24 (d, J = 12.5 Hz, 1H), 4.76 (dt, J = 12.5,7.5 Hz, 1H), 
3.61-3.67 (m, 4H), 2.02 (t, J = 7.0 Hz, 2H), 1.61 (m, 4H), 1.26-1.35 (m, 14H), 0.88 (t, J 
= 7.0Hz, 3H); 13C NMR (CDCI3, 125 MHz) 3.10(Z) (5 146.2,105.6,72.7,62.0,32.2 (2 
peaks), 30.0, 29.9, 29.7, 29.6, 26.1, 23.0, 20.0, 14.4; 3.10(E) (5 147.0, 103.5,69.7, 
62.7, 33.9, 32.2, 29.9 (2 peaks), 29.7 (2 peaks), 29.6, 26.3, 24.5, 23.0, 14.4. HRMS 

















L=-5~ ~~~4 ,-~-,......---------:\ ...... 5.981 
-4.360 
_4.347 













































s: w 0 if N 
146.158 
_ ____ .105.606 
77.616 











... ----- 32.161 ~ ____________________________________________ ~--------~~30.033
~--- .29.674 29.623 ... 26.085 22.996 
_20.028 
14.420 
































l;:::-.. ____ ..... __ -.... .'--' 3.667 3.653 
r 




I 1.637 1. 630 I 
\ ~;;;~~.;;;;;;;;;!iliiil!.!!!!!!!!!!!!!!!!!!!!!II!!!.I!!!!!!!!!!!!!!!!!!!II!!!!!!!!!!!!!!!!!!!!.JJ!!!I ..... 1. 533 r~=-;~~-"- ="""'":=======;;;;;:;;:;:;;;:;;;;;:;:::::::::::~~~_"".1;;;;.;;;;34;;;8~~~~=~~o-.!lp·43~43~ " '._1.331 
.'.-1.308 
>c:-=-.--:'>.CCC'-"' .. =~ ________ ~~----- -------------c\~~: ~:: 
\ .. 0.890 
'-~0.876 
-0.862 













































The commercial available 1,2-epoxyhexadecane (Sigma, 260215) is technical 
grade with 85% purity and requires purification by Si02 chromatograph using 9:1 
hexanes: ethyl acetate as eluent. After evaporated the solvents, the purified epoxy 
was dried overnight by oil pump. 
To a solution of 3.10 (2.03 g, 8.38 mmol) in dry DMSO (20 mL) was added NaH 
(0.40 g, 60%, 10.1 mmol) at room temperature. After 1 h, purified 
1 ,2-epoxyhexadecane (2.22 g, 9.22 mmol) in dry DMSO (10 mL) was added and the 
reaction mixture was stirred at 50°C for 12 h. The reaction was quenched by adding 
saturated aq. NaHC03 (100 mL). The mixture was extracted by EhO (30 mL x 3) and 
the combined organic layer was washed successively with saturated aq. NaHC03 
(100 mL x 3), brine (100 mL) and dried (Na2S04). After filtration, the solvent was 
removed by rotary evaporation. The crude product was then purified by flash 
chromatography (Si02) using 9:1 hexanes: ethyl acetate as eluent (product Rf=0.55 
4:1 hexanes: ethyl acetate) to afford 3.11(Z) (2.11 g, 83%) as grease and unreacted 
3.10(Z) (0.76 g) was recovered. Using the same method, the 3.11(E) isomer was 
synthesized from 3.10(E). 1H NMR (CDCI3, 500 MHz) 3.11 (Z) 0 5.94 (d, J = 6.0 Hz, 
1 H), 4.30 (dt, J = 7.0 Hz, 7.0Hz, 1 H), 3.75 (m, 1 H), 3.70 (m, 2H), 3.50 (m, 3H), 3.23 (t, 
J = 9.0 Hz, 1 H), 2.43 (br, 1 H), 2.13 (m, 2H), 1.60 (m, 4H), 1.25-1.35 (m, 40H), 0.88 (t, 
J = 7.0 Hz, 6H); 3.11 (E) 0 6.21 (d, J = 12.5 Hz, 1 H), 4.71 (dt, J = 12.5,7.5 Hz, 1 H), 3.76 
(m, 1 H), 3.60 (t, J = 6.5 Hz, 2H), 3.44 (m, 3H), 3.22 (t, J = 9.0 Hz, 1 H), 2.44 (br, 1 H), 
136 
1.97 (t, J = 8.0 Hz, 2H), 1.57-1.63 (m, 4H), 1.24-1.41 (m, 40H), 0.86 (t, J = 7.0Hz, 6H); 
13C NMR (CDCb, 125 MHz) 3.11(Z) 0145.8,106.1,75.5,72.6,71.2,70.7,33.5,32.3, 
30.1,30.0 (2 peaks), 29.9, 29.7 (2 peaks), 26.1,25.9,23.0,20.8,14.5; 3.11(E) 0146.9, 
103.3, 75.5, 70.8, 70.6, 69.5, 33.5, 32.2 (2 peaks), 30.8, 30.0, 29.9 (2 peaks), 29.7 
(2peaks), 29.6, 26.3, 25.9, 24.7, 23.0, 14.4; HRMS (ESI): calcd. for C31 H62Na03+ 
[M+Na+]: 505.4591, found: 505.4598. 
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To a solution of sodium hydride (57.6 mg, 2.4 mmol) in dry DMF (10 mL) was 
added (3,4-dihydro-2H-pyran-2-yl)methanol (0.228 g, 2.0 mmol). After the reaction 
mixture was stirred at room temperature for 1 h, 1-bromododecane (0.784 g, 3.0 mmol) 
was added and the reaction mixture was stirred at room temperature for 24 h. The 
reaction was quenched by adding saturated aq. NaHC03 (50 mL). The mixture was 
extracted by Et20 (40 mL x 2) and the combined organic layer was washed 
successively with saturated aq. NaHC03 (100 mL x 3), brine (100 mL) and dried 
(Na2S04). After filtration, the solvent was removed by rotary evaporation. The crude 
product was then purified by flash chromatography (Si02) using hexanes as eluent 
(product Rf=0.74 4:1 hexanes: ethyl acetate) to afford 3.12 (0.51 g, 90%) as colorless 
liquid. 1H NMR (CDCI3, 500 MHz) 0 6.38 (d, J = 5.5Hz, 1 H), 4.67 (s, 1 H), 3.97 (m, 1 H), 
3.54 (m, 1 H), 3.47 (m, 3H), 2.10 (m, 1 H), 1.98 (m, 1 H), 1.86 (m, 1 H), 1.56-1.68 (m, 3H), 
1.25 (m, 18H), 0.87 (t, J = 6.5Hz, 3H), 13C NMR (CDCI3, 125 MHz) 0 144.0,100.7,74.4, 
73.6,72.2,32.6,30.0 (3 peaks), 29.8, 29.7, 26.4, 25.0, 23.0,19.7,14.4. 
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6.3.6 (Z)-6-(decyloxy)-1-(dodecyloxy)hex-5-en-2-ol 
QO'C12H25 - C10H21'oRo'C12H25 
3.12 3.13 
3.14 3.15 (Z) 
To a solution of 3.12 (0.282 g, 1.0 mmol) and decan-1-01 (0.316 g, 2.0 mmol) in 
CH2CI2 (10 ml) was added p-toluenesulfonic acid monohydrate (5.7 mg, 0.03 mmol). 
After stirred at room temperature for 14 h, the solvent was removed. The residue was 
purified by flash chromatography (Si02) using 49:1 hexanes: ethyl acetate as eluent 
(product Rf=0.53 9: 1 hexanes:ethyl acetate) to afford crude 3.13 (0.44 g). 
To a solution of above crude 3.13 and 2,6-lutidine (0.321 g, 3.0 mmol) in dry 
CH2CI2 (5 ml) was added trimethylsilyltriflate (0.222 g, 1.2 mmol) dropwise at 0 °C. The 
mixture was stirred at 0 °C for 0.5 h and then at room temperature for 12 h. Saturated 
aq. NaHC03 (20 mL) was added to yellow mixture to quench reaction. After the 
solvent was removed by rotary evaporation, the crude residue was dissolved in ethyl 
acetate (50 mL). The solution was washed successively with saturated aq. NaHC03 
(50 mL x 2), brine (50 mL) and dried (Na2S04). After filtration, the solvent was 
removed by rotary evaporation. The crude product was purified by flash 
chromatography (Si02) using 49:1 hexanes:ethyl acetate as eluent (product Rf=0.20) 
to afford crude 3.14 (0.392 g, 77%). 
To a solution of 3.14 (0.38 g, 0.74 mmol) was added TBAF (0.89 mL, 1 Min THF) 
dropwise at 0 °C. After stirring 12 h at room temperature, the solvent of yellow reaction 
mixture was removed by rotary evaporation. The crude residue was dissolved in ethyl 
143 
acetate (20 mL) and then washed successively with saturated aq. NaHC03 (20 mL x 3) 
and brine (20 mL). Then the combined aqueous layer was extracted by ethyl acetate 
(20 mL). The organic layer was combined, washed by brine (20 mL) and dried 
(Na2S04). After filtration, the solvent was removed by rotary evaporation. The crude 
product was then purified by flash chromatography (Si02) using 9:1 hexanes: ethyl 
acetate as eluent (product Rf=0.45, 4:1 hexanes: ethyl acetate) to afford 3.15(Z) 
(0.192 g, 59%) as white solid. 1H NMR (CDCb, 500 MHz) 3.10(Z) 05.96 (br, 1H), 4.34 
(d, J = 6.0 Hz, 1 H), 3.80 (t, J = 3.0 Hz, 1 H), 3.70 (2H), 3.45 (m, 3H), 3.30 (m, 1 H), 2.52 
(s, 1 H), 2.20 (m, 2H), 1.47-1.63 (m, 7H), 1.26 (m, 33H), 0.88 (m, 6H); 13C NMR (CDCI3, 
125 MHz) 0145.9, 106.0,75.3,72.7,71.9,70.1,33.4,32.2,30.1,30.0 (2 peaks), 29.9, 
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13C NMR spectrum of compound 3.15 (Z) 
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6.3.7 2-{5,6-dihydro-1 ,4,2-dioxazin-3-yl)-N-tetradecylbenzamide 
A solution of N-hydroxyphthalimide (3.26 g, 20 mmol) in DMF (50 mL), ethylene 
bromide (9.4 g, 50 mmol) and Et3N (2.52 g, 25 mmol) was stirred at rt. for 17 h. The 
precipitation product was filtered off, washed with water and then recrystallized in 70% 
ethanol to afford compound 3.34 as colorless needles (1.53 g, 28%). 
To a solution of 3.34 (568 mg, 2.1 mmol) and tetradecan-1-amine (214 mg, 1.0 
mmol) in DMF (7.0 ml, dry) was added EhN (638 mg, 6.3 mmol). The reaction was 
stirred at rt. for 13 h. The white precipitation was come out after water (50 ml) was 
added. The precipitation was filtered and dissolved in ethyl ether (100 ml). The 
aqueous phase was extracted with ethyl ether (2 x 50 ml). The combined organic layer 
was washed with Brine (60 ml), dried (Na2S04) and filtered. After the solvent was 
removed by rotary evaporation, the residue was purified by flash chromatography 
using 1:1 hexanes:ethyl acetate as eluent (product Rf=O.4) to afford the product 3.36 
(340 mg, 84%) as white solid. m.p. 358--359 K; IR (cm-\ 3272 (N-H), 3263, 3069, 
2955,2914,2851,1634,1540,1475,1357,1341,1106, 1045,911,765; 1H NMR (500 
MHz, CDCI3): 0.88 (t, J =7.0 Hz, 3H), 1.35 (m, 22H), 1.61 (m, J= 7.5, 7.5Hz, 2H), 3.41 
(dd, J= 7.5, 7 Hz, 2H), 4.19 (t, J = 4.0 Hz, 2H), 4.44 (t, J = 4.0 Hz, 2H), 5.99 (s, 1 H, NH) , 
7.44 (m, 2H), 7.50(m, 1 H), 7.60 (m, 1 H); 13C NMR (125 MHz, CDCI3): 14.2, 22.8, 27.1, 
29.5,29.7,29.8,32.0,40.3,63.7, 65.0,127.9,129.2,129.3,129.8,130.4,136.7,155.8, 
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13C NMR spectrum of compound 3.36 
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6.3.8 4-(2-(bis(2-{{1,3-dioxoisoindolin-2-yl)oxy) 




N~ 'j---/ 'b r LO 
PhtN-O 
3.50 
A solution of compound 2.13 (1.0 g, 2.27 mmol), succinic anhydride (0.683 g, 
6.83 mmol) in CH2Cb (10 mL) was added triethylamine (0.68 g, 6.83 mmol). After 
stirred for 18h at rt., the colorless reaction mixture turned to black color. After solvent 
was removed by rotary evaporation, aq. NaHP04 (100 mL, 0.5 M, pH 7.0) was added. 
The aqueous solution was then extracted by CH2CI2 (50mL x 3). The combined 
organic layer was washed by brine (50 mL), dried (Na2S04). The crude product was 
purified by column chromatography (Si02) eluting with 0% to 5% Methanol in CH2CI2 
(product Rf= 0.33 Methanol:CH2Cb=1 :12) to afford 3.50 (0.99 g, 81%) as yellow solid. 
1H NMR (CDCI3, 500 MHz) 08.95 (br, 1 H), 7.77 (m, 4H), 7.71 (m, 4H), 4.33 (t, J = 5.5 
Hz, 4H), 4.23 (t, J = 5.5 Hz, 2H), 3.16 (t, J = 5.5 Hz, 4H), 3.06 (J = 5.5Hz, 2H), 2.62 (t, 
J = 3.0 Hz, 4H); 13C NMR (CDCb, 125 MHz) 176.8,172.5,163.6,134.7,129.0,123.7, 
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13C NMR spectrum of compound 3.50 
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6.3.9 2-(bis(2-((1 ,3-dioxoisoindolin-2-yl)oxy)ethyl)amino)ethyl 
(S-(decyloxy)pent-4-en-1-yl) succinate 
PhtN-O OH 
~ 0, ri 








A solution of compound 3.S0 (0.81 g, 1.5 mmol), DMAP (0.037 g, 0.030 mmol), 
DCC (0.37 g, 1.8 mmol), in CH2CI2 (20 mL) was added 3.10(E) (0.36g, 1.5 mmol). 
After reaction mixture was stirred for 12h at room temperature, the percipataion was 
filetered off and the solvent was removed by rotary evaporation. The crude product 
was purified by column chromatography (Si02) eluting with 1:1 hexanes:ethyl acetate 
(product Rf=0.34) to afford 3.S1(E) (1.0 g, 88%) as light yellow solid. 1H NMR (CDCI3, 
500 MHz) 7.77 (m, 4H), 7.71 (m, 4H), 6.20 (d, J = 12.5 Hz, 1H), 4.68 (dt, J = 12.5, 
7.0Hz, 1 H), 4.31 (t, J = 5.5 Hz, 4H), 4.21 (t, J = 5.5 Hz, 2H), 4.04 (t, J = 7.0 Hz, 2H), 
3.58 (t, J = 6.5 Hz, 2H), 3.14 (t, J = 5.5 Hz, 4H), 3.03 (t, J = 6.0 Hz, 2H), 2.60 (m, 4H), 
1.93 (dt, J = 7.0, 7.0 Hz, 2H), 1.55-1.64 (m 4H), 1.21-1.31 (m, 14H), 0.85 (t, J = 7.0 Hz, 
3H); 13C NMR (CDCI3, 125 MHz) 172.6, 163.6, 147.3, 134.7, 129.3, 123.7, 102.7,77.2, 
69.6, 64.3, 63.2, 53.4, 53.1, 32.2, 29.8 (3 peaks), 29.7, 29.6, 29.4, 26.3, 24.4, 22.9, 
14.5. 3.S1(Z) can be synthesized from 3.10(Z) using the same method with 81% 
yield. 1H NMR (CDCI3, 500 MHz) 7.73 (m, 4H), 7.66 (m, 4H), 5.87 (d, J = 5.5 Hz, 1 H), 
4.17-4.28 (m, 7H), 3.99 (t, J = 7.0 Hz, 2H), 3.62 (t, J = 7.0 Hz, 2H), 3.10 (t, J = 5.0 Hz, 
4H), 2.98 (t, J = 6.0 Hz, 2H), 2.55 (m, 4H), 2.03 (m, J = 6.5 Hz, 2H), 1.51-1.61 (m 4H), 
1.18 (m, 14H), 0.80 (t, J = 7.0 Hz, 3H); 13C NMR (CDCI3, 125 MHz) 172.3, 163.4, 145.3, 
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13C NMR spectrum of compound 3.51 (E) 
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6.3.1 0 2-((4-((5-(decyloxy)pent-4-en-1-yl)oxy)-4-oxobutanoyl)oxy)-







A solution of compound 3.51 (0.76 g, 1.0 mmol), sodium carbonate (0.021 g, 0.2 
mmol) in CH2CI2 (5 mL) was added CH31 (2.28 g, 16.1 mmol). After stirred in 55°C for 
12h, the solvent was removed by rotary evaporation. The crude product was purified 
by column chromatography (Si02) eluting with 1 :24 methanol: CH2CI2 (product 
Rf=0.25) to afford compound 3.53 (0.67 g, 74%, Z:E = 0.78:0.22) as yellow solid. 1H 
NMR (CDCI3, 500 MHz) 7.83 (m, 4H), 7.77 (m, 4H), 6.21 (d, J = 13.0 Hz, 0.22H), 5.92 
(d, J = 6.0 Hz, 0.78H), 4.86 (m, 4H), 4.78 (m, 2H), 4.69 (m, 0.22H), 4.57 (m, 4H), 4.49 
(m, 2H), 4.26 (m, 0.88H), 3.96 (m, J = 7.0 Hz, 2H), 3.88 (s, 3H), 3.68 (t, J = 6.5 Hz, 
1.56H), 3.6 (t, 0.44H), 2.68 (m, 4H), 2.08 (dt, J = 7.5, 6.5 Hz, 1.56H), 1.93 (dt, J = 8.0 
Hz, 0.44H), 1.54-1.64 (m, 4H), 1.20-1.28 (m, 14H), 0.87 (t, J = 7.5 Hz, 3H); 13C NMR 
(CDCI3, 125 MHz) 172.7, 172.1, 163.4, 146.0, 135.3, 128.8, 124.2, 105.1,72.5,72.4, 
64.9, 63.9, 62.3, 58.2, 51.3, 32.1, 30.0, 29.8, 29.6, 29.5, 29.4, 29.2, 28.9, 28.8, 26.1, 
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A solution of compound 3.53 (1.27 g, 1.4 mmol) in CH2CI2 (20 mL) and ethanol 
(20 mL) was added methylhydrazine (0.387 g, 8.4 mmol) at -40°C. The reaction 
mixture was stirred in for 1.5h at -40°C. The solvent was removed by rotary 
evaporation and the crude product was purified by column chromatography (Si02) 
eluting with 8:92 methanol: CH2CI2 (product Rf=0.10) to afford 3.1 (0.64 g, 71%, Z:E = 
0.92:0.08) as yellow solid. 1H NMR (CD30D, 500 MHz) 6.24 (d, J = 13.0 Hz, 0.92H), 
5.98 (d, J = 6.5 Hz, 0.08H), 4.82 (s, 4H), 4.69 (m, 0.92H), 4.55 (m, 2H), 4.28 (m, 
0.08H), 4.06 (m, 6H), 3.88 (t, J = 4.5 Hz, 2H), 3.79 (m, 4H), 3.69 (t, 0.16H), 3.60 (t, J = 
6.5 Hz, 1.84H), 3.26 (m, 4H), 2.66 (m, 4H), 2.08 (m, 0.16H), 1.96 (dt, J = 6.5 Hz, 
1.84H), 1.56-1.66 (m, 4H), 1.27(m, 14H), 0.87 (t, J = 7.5 Hz, 3H); 13C NMR (CD30D, 
125 MHz) 172.7, 172.1, 163.4, 146.0, 135.3, 128.8, 124.2, 105.1,72.5,72.4,64.9, 
63.9, 62.3, 58.2, 51.3, 32.1, 30.0, 29.8, 29.6, 29.5, 29.4, 29.2, 28.9, 28.8, 26.1, 26.0, 
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6.3.12 2-(bis(2-((1 ,3-dioxoisoindolin-2-yl)oxy)ethyl)amino)ethyl 
(1-( (5-( decyloxy)pent-4-en-1-yl)oxy)hexadecan-2-yl) succi nate 
PhtN,o C1OH21 
-- ), ~o0dC"H" 
PhtN,o \......0 0 
PhtN-O OH 
~ Q, ri 




A solution of compound 3.50 (0.189 g, 0.35 mmol), DMAP (7 mg, 0.058 mmol), 
N,N'-Dicyclohexylcarbodiimide (0.072 g, 0.35 mmol) in CH2CI2 (1.0 mL) was added 
3.11 (E) (0.14g, 0.29 mmol). After stirred for 12h at rt., the reaction mixture was filtered. 
The solution was concentrated by rotary evaporation. The crude product was purified 
by column chromatography (Si02) eluting with 1:1 hexanes:ethyl acetate (product 
Rf=0.40) to afford 3.52(E) (0.19g, 66%) as light yellow solid. 3.52(Z) can be 
synthesized from 3.11(Z) using the same method in 68% yield. 1H NMR (CDCI3, 500 
MHz) 3.52(E) 7.74 (m, 4H), 7.67 (m, 4H), 6.16 (d, J = 12.5 Hz, 1H), 4.92 (m, J = 5.5 Hz, 
1 H), 4.66 (dt, J = 12.5, 7.5 Hz, 1 H), 4.28 (t, J = 5.5 Hz, 4H), 4.18 (t, J = 5.5 Hz, 2H), 
3.55 (t, J = 6.5 Hz, 2H), 3.30-3.42 (m, 4H), 3.11 (t, J = 5.5 Hz, 4H), 3.00 (t, J = 5.5 Hz, 
2H), 2.58 (s, 4H), 1.89 (dt, J = 7.5, 7.5 Hz, 2H), 1.55 (m, 6H), 1.28 (m, 38H), 0.81 (t, J 
= 6.5 Hz, 6H); 3.52(Z) 7.76 (m, 4H), 7.70 (m, 4H), 5.88 (d, J = 6.5 Hz, 1 H), 4.95 (m, J 
= 5.0 Hz, 1 H), 4.30 (m, 5H), 4.20 (t, J = 5.5 Hz, 4H), 3.65 (t, J = 6.5 Hz, 2H), 3.35-3.44 
(m, 4H), 3.14 (t, J = 5.5 Hz, 4H), 3.02 (t, J = 5.5 Hz, 2H), 2.60 (s, 4H), 2.06 (dt, J=7.0, 
7.0 Hz, 2H), 1.55 (m, 6H), 1.28 (m, 38H), 0.84 (t, J = 6.5 Hz, 6H); 13C NMR (CDCI3, 125 
MHz) 3.52(E) 172.4,172.1,163.5,146.8,134.6,129.1,123.6,103.2, 77.0, 73.3, 71.9, 
70.7,69.3,53.3,52.9,32.1 (2 peaks), 31.1,30.7,29.9 (2peaks), 29.8, 29.7, 29.6, 29.5 
(2 peaks), 29.3, 26.2, 25.4, 24.5, 22.9, 14.3. 64.5, 63.0, 53.2, 52.8, 31.9, 29.8, 29.6, 
29.4,29.3,29.2,28.7,28.6,25.8,22.7,20.4,14.2; 3.52(Z) 172.5,172.2,163.6,145.5, 
164 
134.6, 129.2, 123.7, 106.0, 77.1, 73.5, 72.4, 71.9, 71.3, 63.1, 53.4, 53.0, 32.1 (2 
peaks), 31.1, 30.0, 29.9 (2 peaks), 29.8 (2 peaks), 29.7, 29.6 (2 peaks), 29.5, 29.4, 
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13C NMR spectrum of compound 3.52 (Z) 
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6.3.13 N,N-bis(2-((1 ,3-dioxoisoindolin-2-yl)oxy)ethyl)-N-methyl-4, 7 -dioxo 
-9-tetradecyl-3,8, 11,17 -tetraoxaheptacos-15-en-1-aminium iodide 
PhtN-o 
~+/ 1- 0 0 ~C1OH21 
PhtN O~N,-- )lJ-( ~r.or-/~ ,C10H 21 
- 000 
3.54 
A solution of compound 3.52 (1.00 g, 1.0 mmol), sodium carbonate (0.21 g, 2.0 
mmol) in CH2CI2 (10 mL) was added methyl iodide (2.0 g, 14.0 mmol). The reaction 
mixture was stirred in 50°C for 21 h. The solvent was removed by rotary evaporation 
and the crude product was purified by column chromatography (Si02) eluting with 0% 
to 10% gradient methanol in CH2CI2 (product Rf = 0.33 in 1:9 MeOH: CH2CI2) to afford 
3.54 (0.84 g, 73%) as yellow solid. m.p. 119-121°C; HRMS (ESI): calcd. for 
C58H88N3012 + [M +]: 1018.6363, found:1 018.6383. 
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6.3.14 N,N-bis(2-(aminooxy)ethyl)-N-methyl-4, 7 -dioxo-9-tetradecyl 
-3,8,11,17 -tetraoxaheptacos-15-en-1-aminium 
PhtN-o 
'- _ C10H21 
\+/ 10 0 ~ 




'- _ C10H21 
\+/ 10 0 ~ H2N_Or-JN~ )\J\\ ~"o,r--/~ ,C10H21 
000 
3.2 
A solution of 3.54(Z) (0.82 g, 0.71 mmol) in CH2Cb:ehtanol (20 mL, 1:1 v/v) was 
added methylhydrazine (0.198 g, 4.3 mmol) at -40°C. After stirred in -40°C for 1.5h, 
the solvent was removed by rotary evaporation. The crude product was purified by 
column chromatography (Si02) eluting with 0% to 10% gradient methanol in CH2CI2 
(product Rf=0.18 1:9 MeOH: CH2Cb) to get product 3.2(Z) (0.38 g, 60%) as white 
grease. 1 H NMR (d6-DMSO, 500 MHz) 6.35 (br, 4H), 6.01 (d, J = 6.5 Hz, 1 H), 4.89 (m, 
J = 6.0 Hz, 1 H), 4.47 (s, 2H), 4.27 (dt, J = 6.5 Hz, 1 H), 3.97 (s, 4H), 3.77 (d, 2H), 3.70 
(s, 6H), 3.41 (t, 2H), 3.15 (s, 3H), 2.60 (m, 4H), 2.00 (m, J = 7.0 Hz, 2H), 1.49 (m, 6H), 
1.24 (m, 38H), 0.87 (t, J = 6.0 Hz, 6H); 13C NMR (d6-DMSO, 125 MHz) 171.5, 171.4, 
145.5, 104.8, 72.5, 71.2, 70.9, 70.1, 68.0, 60.8, 60.4, 57.6, 49.3, 40.0, 31.3, 30.3, 
29.2, 29.0 (2 peaks), 28.8, 28.7 (2 peaks), 28.5, 25.2, 24.5, 22.1, 20.2, 18.8, 13.9; 
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13C NMR spectrum of compound 3.2 (Z) 
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6.4 Chapter 4. 'Click' Stabilized Liposomes 
6.4.1 3-[N,N-[Bis-[2-(tert-butyl-dimethyl-silyloxy)ethyl]]-amino ]-1 ,2-propanediol 
(4.4) 
6.4.2 3-(bis(2-( (tert-butyldimethylsilyl)oxy)ethyl)amino )propane-1 ,2-d iyld itetradec 
anoate (4.5) 
3-(bis(2-( (tert-butyldimethylsilyl)oxy)ethyl)am inc )propane-1 ,2-d iyldipalmitat 
e (4.9) 
6.4.3 3-(bis(2-hydroxyethyl)amino)propane-1 ,2-diyl ditetradecanoate (4.6) 
3-(bis(2-hydroxyethyl)amino )propane-1 ,2-diyl dipalmitate (4.10) 
6.4.4 3-(N,N-Bis-(2-phthalim idooxyethyl)amino )propane-1 ,2-diylditetradecanoate 
(4.7) 
3-(N,N-Bis-(2-phthalimidooxyethyl)amino )propane-1 ,2-d iyldipalmitate 
(4.11 ) 
6.4.5 N,N-bis(2-phthalimidooxyethyl)-N-methyl-N-[2,3-di(tetradecanoyloxy)propyl 
]-ammonium iodide (4.8) 
N, N-bis(2 -phth a Ii m idooxyethyl)-N-methyl-N-[2, 3-d i(pa 1m ityloxy) propyl]-am 
monium iodide (4.12) 
6.4.6 N,N-bis(2-( am inooxy)ethyl)-N-methyl-2,3-bis(tetradecanoyloxy)propan-1-a 
minium iodide (4.1) 
N, N-bis(2 -( am inooxy)ethyl)-N-methyl-2, 3-bis(pa 1m ityloxy)propan-1-am i n i u 
m iodide (4.2) 
6.4.7 2-( (tert-butyldimethylsilyl)oxy)-N-methylethanamine (4.13) 
6.4.8 3-( (2-( (tert-butyld imethylsilyl)oxy)ethyl)( methyl)amino )propane-1 ,2-diol 
(4.14) 
6.4.9 3-( (2-( (tert-butyld imethylsilyl)oxy)ethyl)(methyl)am inc )propane-1 ,2-diyl 
dipalmitate (4.15) 
6.4.10 3-«2-hydroxyethyl)(methyl)amino)propane-1 ,2-diyl dipalmitate (4.16) 
6.4.11 3-«2-phthalimidooxyethyl)(methyl)amino)propane-1 ,2-diyldipalmitate (4.17) 
6.4.12 3-«2-hydroxyethyl)(methyl)amino)propane-1 ,2-diyl dipalmitate (4.18) 
6.4.13 N-(2-(aminooxy)ethyl)-N,N-dimethyl-2,3-bis(palmitoyloxy)propan-1-aminiu 








3-(bis(2-(aminooxy)ethyl)amino)propane-1 ,2-diyl ditetradecanoate (4.19) 
3-(bis(2-(aminooxy)ethyl)amino)propane-1 ,2-diyl dipalmitate (4.20) 
Synthesis of DPA and other polysaccharides 
Liposome formulation and stabilization 
Calcein experiment 




T8S0 OT8S \~ l 
NH I OH r -----.. ~N~OH 
T8S0 T8S0 
2.15 4.4 
To a mixture of glycidol (1.56 g, 21 mmol) and lithium perchlorate (1.06 g, 10 
mmol) in absolute ethanol (30 mL) was added the amine 2.15 (6.70 g, 20 mmol) in O°C. 
The reaction mixture was warmed to room temperature and allowed to stir for -16 
hours. Determine reaction completeness by TLC (silica, Ethyl acetate: Hexane=1:1, 12 
stain). When complete, the reaction solvent was evaporated (in vacuo), redisolved in 
thyl acetate (50 mL) and washed with saturated aqueous sodium bicarbonate (50 
mLx3) and brine (50 mL). The organic layer was dried (Na2S04) and the solvent was 
evaporated (in vacuo) to afford crude product. The compound was purified via silica 
chromatography (33%-67% ethyl acetate in hexanes) to afford 4.4 as yellow oil (6.94g, 
85%). Rf=0.34 (ethyl acetate: hexane=1:1, 12 stain). 1H-NMR (400 MHz, CDCb) 0 ppm 
0.02 (s, 12H), 0.85 (s, 18H), 2.61 (m, 2H), 2.69 (s, 4H), 3.44 (m, 1 H), 3.63 (m, 6H); 
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13C NMR spectrum of compound 4.4 
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6.4.2 3-(bis(2-«terl-butyldimethylsilyl)oxy)ethyl)amino)propane-1 ,2-diyl 
ditetradecanoate & 
3-(bis(2-«terl-butyldimethylsilyl)oxy)ethyl)amino)propane-1 ,2-diyl dipalmitate 
OTBS 




To a mixture of diol4.4 (5.93 g, 14.5 mmol), Et3N (4.40 g, 43.5 mmol) and DMAP 
(0.177 g, 1.45 mmol) in CH2CI2 (100 mL, dry) at O°C was slowly added myristoyl 
chloride (8.94 g, 36.3 mmol) in CH2Cb (30 mL, dry). After addition, the pink color 
reaction mixture was stirred in room temperature for 16 hours. Determine reaction 
completeness by TLC (silica, 5% ethyl acetate in hexanes, 12 stain). Upon completion, 
the reaction mixture was washed with saturated aq. NaHC03 (250 mLx 3) and (250 mL) 
and dried (Na2S04). After the solvent was evaporated (in vacuo), the crude product 
was purified by flash chromatography (Si02) using (1 %-5%) ethyl acetate in hexanes 
as eluent to afford compound 4.5 as colorless solution (5.96 g, 50%). (product Rf=0.33 
ethyl acetate: hexane=1 :19). 1H-NMR (400 MHz, CDCb) 0 ppm 0.04 (s,12H), 0.88 (m, 
24H), 1.25-1.57(m, 40H), 1 .60(m, 4H), 2.27 (m, J = 7.2 Hz, 4H), 2.69 (m,6H), 3.63 (t, J 
= 6.4 Hz,4H), 4.11 (dd, J = 11.8, 3.2 Hz, 1 H), 4.37(d, t = 11.6 Hz, 1 H), 5.08(m, J = 3.2 
Hz, 1H); 13C-NMR (100 MHz, CDCI3) 0 ppm -5.23,14.25,18.38,22.83,25.09,25.12, 
26.06, 29.29, 29.31, 29.47, 29.51, 29.66, 29.81, 29.84, 32.07, 34.35, 34.59, 55.81, 
57.75, 62.06, 63.80, 70.34, 173.23, 173.61; HRMS (ESI) calcd. for C47H9sN06Si2+ 
[M+Ht:828.6927, found: 828.6928. 
179 
Using the same method, compound 4.9 can be made from palmitoyl chloride in 
61% yield. 1H-NMR (500 MHz, CDCb) 0 ppm 0.04 (s,12H), 0.88 (m, 24H), 1.25-1.29 
(m, 48H), 1.59 (t, J = 7.0 Hz, 4H), 2.28 (m, J = 7.5 Hz, 4H), 2.69 (m, 6H), 3.62 (t, J = 
6.5 Hz, 4H), 4.11 (dd, J = 12.0, 6.0 Hz, 1 H), 4.37 (dd, t = 12.0, 3.0Hz, 1 H), 5.08 (m, J = 
3.0 Hz, 1 H); 13C-NMR (125 MHz, CDCb) 0 ppm -5.04, 14.44, 18.56, 23.03, 25.29, 
25.31, 26.25, 29.48, 29.50, 29.65, 29.70, 29.85, 30.00, 30.04, 32.27, 34.54, 34.79, 
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6.4.3 3-(bis(2-hydroxyethyl)amino)propane-1 ,2-diyl ditetradecanoate 







To a solution of amine 4.5 (3.66 g, 4.42 mmol) in THF (20 mL, dry) at O°C was 
added TBAF (9.72 mL, 1 M in THF) dropwise. After addition, the reaction mixture was 
stirred in room temperature for 12 hours. The solvent was removed by rotary 
evaporation and ethylacetate (100 mL) was added. The reaction mixture was washed 
with saturated aq. NaHC03 (100 mLx 3), brine (100 mL) and dried (Na2S04). The 
solvent was removed by rotary evaporation and the crude product was purified via 
silica chromatography (30%-50% ethyl acetate in hexanes) to afford compound 4.6 as 
white waxy solid (1.89 g, 71 %). (Rf=0.45, ethyl acetate). 1H-NMR (400 MHz, CDCI3) 0 
ppm 0.85 (m, 6H), 1.25-1.26 (m, 40H), 1.57 (t, J = 6.4 Hz, 4H), 2.28 (m, 4H), 2.69 (m, 
6H), 3.14 (s, 2H), 3.57 (t, J = 5.2 Hz, 4H), 4.09 (dd, J = 12.0,6.0 HZ,1H), 4.34 (dd, 
J=12.0, 2.8 Hz, 1H), 5.15 (m, J = 3.2 Hz,1H); 13C-NMR (100 MHz, CDCI3) 0 ppm 14.17, 
22.75, 24.94, 24.95, 29.18, 29.21, 29.37, 29.43, 29.57, 29.71, 29.72, 29.74, 29.76, 
31.99, 34.20, 34.45, 55.80, 57.33, 59.88, 63.66, 70.11, 173.73, 173.83. HRMS (ESI): 
calcd. for C35H70N06+ [M+Hr: 600.5198, found: 600.5205. 
Using the same method, compound 4.10 can be made from compound 4.9 in 
60% yield. 1H-NMR (500 MHz, CDCI3) 0 ppm 0.85 (t, J = 6.5 Hz, 6H), 1.23-1.26 (m, 
48H), 1.59 (t, 4H), 2.29 (m, J=7.5Hz, 4H), 2.69 (m, 6H), 3.03 (s, 2H), 3.57 (t, 4H), 4.09 
(dd, J = 12.0, 6.0 HZ,1 H), 4.34 (d, J = 12.0 Hz, 1 H), 5.15 (m, J = 3.0 HZ,1 H); 13C-NMR 
183 
(125 MHz, GOGh) 0 ppm 14.40,22.98,25.17,29.43,29.59,29.66,29.80,29.96,29.99, 
32.22, 34.43, 34.68, 56.10, 57.55, 60.12, 63.89, 70.36, 173.96, 174.09. HRMS (ESI) 
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6.4.4 3-(N,N-Bis-(2-phthalimidooxyethyl)amino)propane-1 ,2-diyl 
ditetradecanoate 
& 3-(N,N-Bis-(2-phthalimidooxyethyl)amino)propane-1 ,2-diyl dipalmitate 
4.6,4.7 R=C13H27 
4.10,4.11 R=C15H31 
To a solution of diol 4.6 (0.650 g, 1.10 mmol), N-hydroxyphthalimide (0.391 g, 
2.40 mmol) and triphenylphosphine (0.629 g, 2.40 mmol) in THF (30 mL) at 0 °C was 
added diisopropyldiazodicarboxylate (0.485 g, 2.40 mmol) over 5 min. The reaction 
was stirred at 0 °C for 0.5 h and then warmed to room temperature. Determine 
reaction completeness by TLC (silica, ethyl acetate: hexanes=1:1, UV light and b 
stain). When completed (-12 h), the reaction solvent was removed by rotary 
evaporation. The orange residue was dissolved in ethyl acetate (30 mL) and washed 
successively with saturated aq. NaHC03 (3 x 30 mL), brine (30 mL) and dried 
(Na2S04)' After the solvent was evaporated, the crude product was dissolved in hot 
hexanes and slowly cooled down to room temperature and the side product was 
crystallized and removed through filtration. The solvent was evaporated and purified 
via silica chromatography (20%-35% ethyl acetate in hexanes) to afford light yellow 
liquid (0.83g, 86%). (Rf =0.74 ethyl acetate: hexanes=1:1). IR(neat) 2922,2852,1789, 
1187, 1151,992,701cm-1; 1H-NMR (CDCb400 MHz) is ppm 0.88 (m, 6H),1.23 (s, 
40H), 1.58 (m, 4H), 2.29 (t, J = 6.4 Hz, 4H), 2.93 (dd, J = 11.2, 4.8Hz, 1 H), 3.00 (dd, J 
= 11.2,4.8 Hz, 1 H), 3.16 (m, 4H), 4.18 (dd, J = 9.6, 4.8 Hz, 1 H), 4.33 (t, J = 4.4 Hz, 4H), 
4.43 (dd, J = 4.8,2.4 HZ,1 H), 5.17 (ddd, J = 9.6, 4.8, 2.4Hz, 1 H), 7.74 (m 4H), 7.79 (m 
187 
4H); 13C-NMR (100 MHz, CDCI3) 0 ppm 14.11, 22.67, 24.92, 29.11, 29.14, 29.30, 
29.32, 29.35, 29.49, 29.64, 29.66, 29.68, 31.90, 34.17, 34.37, 52.94, 54.93, 63.52, 
69.79,77.16,123.44,128.94,134.39,163.29,173.17, 173.42. HRMS (ESI) Calcd. for 
C51H75N301ONa+ [M+Na+]: 912.5350, found: 912.5339. 
Using the same method, compound 4.11 can be made from compound 4.10 in 
86% yield. 1H-NMR (CDCI3 500 MHz) 0 ppm 0.86 (t, J = 7.0 Hz, 6H), 1.23 (5, 48H), 
1.56 (m, 4H), 2.28 (t, J = 7.0 Hz, 4H), 2.94 (m, 2H), 3.16 (m, 4H), 4.18 (dd, 1 H), 4.33 (t, 
J = 4.0 Hz, 4H), 4.43 (dd,1H), 5.19 (m, 1H), 7.71 (m 4H), 7.78 (m 4H); 13C-NMR (125 
MHz, CDCb) 0 ppm 14.41, 22.88, 24.98, 25.22, 29.45, 29.63, 29.66, 29.81, 29.96, 
30.00,32.22,34.48,34.69,53.24,55.25,63.84,70.09, 77.10,123.76,129.27,134.69, 
163.63, 173.52, 173.78. HRMS (ESI) Calculated for C55H83N301ONa+ [M+Na+]: 
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6.4.5 N,N-bis(2-phthalirnidooxyethyl}-N-rnethyl-N-[2,3-





~ O)lR 4.7,4.8 R=C13H27 
N/ lOR 4.11,4.12 R=C15H31 PhtNO~_~ If 
I 0 
4.8/4.12 
In a sealed tube, to the amine 4.7 (0.712 g, 0.8 mmol) dissolved in 3 mL 
dichloromethane was added Mel (2 mL). The reaction mixture was degassed using a 
stream of N2 before sealing the tube. The reaction was heated to 60°C for 48 hand 
the solvent was evaporated (Caution: fume hood required). The product was purified 
via silica chromatography (ethyl acetate) to afford compound 4.8 as yellow solid 
(0.611 g, 74%). (Rf =0.10 ethyl acetate) m.p. = 95-9rC. 1H-NMR (400 MHz, CDCI3) 0 
ppm 0.85 (t, J = 6.4 Hz, 6H), 1.22 (s, 40H), 1.52 (t, J = 6.4 Hz, 2H), 1.62 (t, J = 6.4 
HZ,2H), 2.29 (t, J = 7.6 Hz, 2H), 2.42 (dt, J = 6.4 Hz, 2H), 3.79 (s, 3H), 4.15 (dd, J = 
12.0, 4.4Hz, 1 H) 4.42 (dd, J = 14.8,8.8 Hz, 1 H), 4.51-4.67 (m, 6H), 4.87 (s, 4H), 5.78 
(m, 1H), 7.78 (m, 8H) 13C-NMR (100 MHz, CDCI3) 0 ppm 14.27,22.84,24.78,24.88, 
29.26, 29.29, 29.47, 29.51, 29.68, 29.81, 29.84, 29.85, 32.07, 34.07, 34.49, 51.25, 
62.13,62.44,63.25,64.93,65.96,72.27, 124.21, 128.63, 135.25, 163.21, 163.25, 
173.02, 173.32. 
Using the same method, compound 4.12 can be made from compound 4.11 in 
67% yield. 1H-NMR (500 MHz, CDCI3) 0 ppm 0.84 (t, J = 7.0 Hz, 6H), 1.19-1.24 (m, 
48H), 1.50 (t, J = 6.5 Hz, 2H), 1.60 (t, J = 6.5 Hz, 2H), 2.28 (t, J = 7.5 Hz, 2H), 2.39 (m, 
191 
J = 8.5 Hz, 2H), 3.78 (s, 3H), 4.13 (dd, J = 12.0,4.5 Hz, 1 H) 4.42 (dd, J = 14.5, 5.5 Hz, 
1 H), 4.49-4.54 (m, 5H), 4.62 (d, J= 9.0Hz, 1 H), 4.86 (s, 4H), 5.77 (m, 1 H), 7.76 (m, 4H), 
7.79 (m, 4H); 13C-NMR (125 MHz, CDCI3) 0 ppm14.35, 22.91, 24.85, 24.96, 29.37, 
29.56, 29.59, 29.76, 29.89, 29.94, 32.15, 34.15, 34.57, 51.29, 62.20, 62.50, 63.33, 
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m iodide & N,N-bis(2-(aminooxy)ethyl)-N-methyl-2,3-
bis(palmityloxy)propan-1-aminium iodide 
4.8/4.12 4.1/4.2 
To the ammonium salt 4.8 (0.601 g, 0.583 mmol) in CH2Cb (10 mL) was added 
hydrazine (177 mg, 3.50 mmol) at O°C and the white percipatition come out. When 
reaction complete (- 2h), the percipatition was filtered off. After the solvent was 
removed by rotary evaporation, the crude residue was purified via silica 
chromatography using 1:9 MeOH:CH2CI2 as elutent (product Rf=0.28) to afford 4.1 as 
white solid (0.311 g, 67%). IR(neat) 2955, 2850, 1736, 1467, 1277, 1145, 569, 548 
cm-1; m.p. = 125-12rC; 1H-NMR (400 MHz, CDCb) 0 ppm 0.86 (t, J = 6.4 Hz, 6H), 
1.25 (40H, s), 1.58 (br, 4H), 2.30 (t, J = 7.2 Hz, 2H), 2.35 (t, J = 7.2 Hz, 2H), 3.43 (s, 
3H), 3.90-3.98 (m, 3H), 4.03-4.10 (m, 3H), 4.19 (m, 2H), 4.27-4.31 (m, 3H), 4.53 (d, J 
= 9.6 Hz, 1 H), 5.66 (s, 1 H), 6.07 (br, 4H); 13C-NMR (100 MHz, CDCI3) 0 ppm 14.31, 
22.88, 24.90, 24.95, 29.33, 29.37, 29.54, 29.57, 29.75, 29.88, 29.92, 32.12, 34.25, 
34.51, 51.31, 62.50, 63.49, 65.81, 69.08, 65.74, 173.17, 173.54. HRMS (ESI) calcd. 
for C36H74N306+ [M+]:644.5572, found: 644.5582. 
Using the same method, compound 4.2 can be made from compound 4.12 in 
52% yield. 1H-NMR (500 MHz, CDCI3) 0 ppm 0.86 (t, J = 6.5 Hz, 6H), 1.24(48H, s), 
1.58 (m, 4H), 2.30 (t, J = 7.0 Hz, 2H), 2.35 (t, J = 7.0 Hz, 2H), 3.44 (s, 3H), 3.91-4.10 
195 
(m, 6H), 4.18 (t, J = 9.0 Hz, 2H), 4.28 (m, 3H), 4.53 (d, J = 11.5 Hz, 1 H), 5.66 (5, 1 H), 
6.08 (br, 4H); 13C NMR (125 MHz, CDCI3) (5 ppm 14.41, 22.70, 22.74, 23.00, 25.02, 
25.06, 29.44, 29.49, 29.68, 29.87, 30.04, 32.23, 34.37, 34.62, 51.43, 62.60, 62.89, 
63.60, 65.91, 69.22 173.28, 173.66; HRMS (ESI) calcd. for C4oH82N306+ 
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NH NH r ----. r 
HO TBSO 
4.13 
Add 2-methylaminoethanol (5.0 g, 66.6 mmol), dichloromethane (220 mL), 
triethylamine (11.2 mL, 79.9 mmol), and imidazole (11.33 g, 166.4 mmol) to a round 
bottom flask fitted with a stir bar, N2 sweep, and an addition funnel. Cool to O°C with an 
ice water bath. Dissolve the TSSCI (12.1 g, 79.9 mmol) in dry DCM and add dropwise to 
the reactor through the addition funnel. Keep temperature between 0-10 °C. After 
addition is complete, let the reaction warm to room temperature and stir for -12 hours. 
Determine reaction completeness by TLC (silica, 10% MeOH-DCM, 12 stain). When 
complete, add 200 mL 01 water to the cooled reaction through the addition funnel. 
Separate off the water and wash the organic phase with saturated NaHC03 (aq.) solution. 
Separate the layer and combine the water layers. Extract the water layer twice with diethyl 
ether and combine extractions with the organic phase. Wash organic phase with brine and 
dry over Na2S04. Rota-vap off solvent. Flash distill product to afford product 4.13 in 102% 
yield (a pot temperature of 89°C, the head temperature at 64°C, and the pressure at -33 
torr, ended at a pot temperature of 113°C.). Estimated b.p. -157°C at 760 torr. (Rf = 0.34, 
TLC, silica 10% MeOH-DCM) 1 H NMR (400 MHz, CDCI3) 8 3.67-3.64 (dd, J = 4.8, 4.0 Hz, 
2H OCH2CH2), 2.62-2.59 (dd, J = 5.0, 5.0 Hz, 2H, CH2CH2NH), 2.39-2.35 (d, J = 4.0 Hz, 
3H, NCH3), 0.85-0.81 (m, 9 H, SiC(CH3h), 0.01--0.02 (m, 6 H, Si(CH3h). 
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6.4.8 3-((2-((tert-butyldimethylsilyl)oxy)ethyl)(methyl)amino)propane-1 ,2-diol 
\ 
NH I OH r -----.. ~N~OH 
TBSO TBSO 
4.13 4.14 
To a mixture of glycidol (6.47 g, 87.30 mmol) and LiCI04 (3.49g, 32.84 mmol) in 
absolute ethanol (100 mL) the protected amine 4.13 was added dropwise with stirring 
and an ice water bath. Allow the reaction to warm to room temperature and stirred for 
-16 hours. Determine reaction completeness by TLC (silica, 10% MeOH-DCM, 12 
stain). When complete, rota-vap off the ethanol then add ethyl acetate (170mL). 
Wash with saturated NaHC03 (aq.) solution (3x100mL) and then wash with brine 
(1 x1 OOmL). Dry over Na2S04 the rota-vap off solvent. Flash chromatography on 
silica using 4 ~ 10% MeOH-DCM gave the aminodiol (7.44g, 43.0% over two columns) 
as a yellow oil (Rf = 0.35, TLC, silica 10% MeOH-DCM, b stain). 1H NMR (400 MHz, 
CDCI3) 6 3.76-3.72 (m, 1 H, CH(OH», 3.68-3.66 (dd, J = 5.6, 5.6 Hz, 2H, OCH2), 
3.62-3.58 (dd, J = 8.0, 3.6 Hz, 1 H, CH(H)OH}, 3.46-3.43 (dd, J = 6.4, 5.2 Hz, 1 H, 
CH(H)OH}, 3.35 (s, 2 H, 2 x OH), 2.69-2.65 (dd, J = 6.8, 6.4 Hz, 1 H NCH(H)CHOH}, 
2.61-2.56 (dd, J = 7.2, 5.8 Hz, 2H, CH2CH2N), 2.50-2.46 (dd, J = 8.4, 1 H 4.0 Hz, 




To a round bottom flask add diol 4.14 (2.09 g, 7.94 mmol), DMAP (0.10 g, 0.79 
mmol), Et3N (3.35 mL, 23.8 mmol), and DCM (68 mL) and cool with an ice water bath. 
Add palmitoyl chloride (5.46 g, 19.9 mmol) in solution with DCM (22 ml) to the reaction 
dropwise. Allow to warm to room temperature and stir overnight. Determine reaction 
completeness by TLC (silica, 5% EtOAc-Hexanes, 12 stain). When complete, dilute 
product with hexane and wash 3x with NaHC03(aq.) solution. A rag will form. 
Separate off rag layer and add a small amount of HCI(aq.) and stir to break rag. Keep 
pH -7. Extract the rag layer 2x with hexanes and combine with the organic phase. 
Wash organic with brine and dry over Na2S04. Rota-vap off hexanes. Flash 
chromatography on silica using 4 -+ 14% EtOAc-Hexanes gave the diester 4.15 (4.97 
g, 84.5%) as a yellow oil (Rf= 0.28, TLC, silica 5% EtOAc-Hexanes, b stain). 1H NMR 
(400 MHz, CDCI3) 8 5.12 (m, 1 H, CH(02C16), 4.34-4.31 (dd, J = 12.0 Hz, 1 H, 
CH(H)02C16), 4.08-4.06 (m, 1 H, CH(H)02C16), 3.63-3.62 (dd, J = 3.2, 2H, 
OCH2CH2N), 2.54-2.53 (m, 4H, CH2NCH2), 2.27 (s, 3H, NCH3), 2.24 (m, 4H, 2 x 
C02CH2), 1.56 (m, 4H, 2 x C02CH2CH2), 1.22 (m, 48H, 2 x (CH2)12), 0.85 (m, 6H, 2 x 
(CH2)12CH3), 0.84 (s, 9H, SiC(CH3h), 0.01-0.00 (m, 6H, Si(CH3h). 
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6.4.10 3-«2-hydroxyethyl}(methyl)amino)propane-1 ,2-diyl dipalmitate 
4.15 4.16 
Dissolve the amine 4.15 (2.43 g, 3.28 mmol) in THF (49 mL) and cool with an ice 
water bath. Add 1 M TBAF solution in THF (4.27 mL, 4.27 mmol) dropwise through an 
addition funnel, then stir overnight while allowing to warm to room temperature. 
Determine reaction completeness by TLC (silica, 50% EtOAc-Hexanes, 12 stain). 
When complete, dilute reaction with diethyl ether and wash with NaHC03(aq) solution 
(3x75 mL). Extract the water layer with EhO, then wash combined organic layers with 
brine (75mL). Rota-vap off solvent. Flash chromatography on silica using 40 ~ 70% 
EtOrHexanes gave the deprotected alcohol 4.16 (1.50 g, 74.1%) as a white 
amorphous powder (Rf = 0.53, TLC, silica 50% EtOAc-Hexanes, 12 stain). 1H NMR 
(400 MHz, CDCh) 85.23-5.21 (dd, J = 3.2,2.8 Hz, 1 H, CH(C02), 4.37-4.33 (dd, J = 8.8, 
3.0 Hz, 1 H, CHCH(H)O), 4.14-4.10 (dd, J = 6.0, 5.8 Hz, 1 H, CHCH(H)O), 3.60-3.58 
(dd, J = 5.0, 5.0 Hz, 2H, HOCH2), 2.64-2.60 (m, 4H, CH2NCH2), 2.35 (s, 3H, NCH3), 
2.34-2.32 (m, 4H, 2 x C02CH2), 1.66-1.63 (dd, J = 6.6, 6.6 Hz, 4H, 2 x C02CH2CH2), 
1.46 (s, 1 H, OH), 1.32-1.29 (m, 48H, 2 x (CH2h2), 0.93-0.90 (dd, J = 6.8, 6.8 Hz, 6H, 
2 x (CH2)12CH3); 13C NMR (100 MHz) 8172.2, 172.0, 69.6, 64.0, 60.1, 59.1, 58.2, 
43.3,35.3,35.0,32.8,30.7,30.6,30.6,30.5,30.3, 30.3, 30.1, 30.1, 26.0, 25.9, 23.8, 
15.3. 
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6.4.11 3-( (2-phthalimidooxyethyl)(methyl)amino)propane-1 ,2-diyl dipalmitate 
Alcohol 4.16 (1.90 g, 3.0 mmol), N-hydroxyphthalimide (645 mg, 3.95 mmol), and 
triphenylphosphine (1.04 g, 3.95 mmol) in THF (30 mL) was added DIAD (0.78 mL, 
3.95 mmol) dropwise at O°C under N2. The reaction was then reacted at room 
temperature overnight. Determine reaction completeness by TLC (silica, 50% 
EtOAc-Hexanes, UV light and 12 stain). When complete, the THF was evaporated and 
the residue was dissolved with EtOAc (60 mL). The organic layer was washed with 
NaHC03 (aq.) solution (3x60 mL) and then extract the combined water layers with 
EtOAc. The combine organic layers were washed with brine (60 mL) and dried 
(Na2S04). After evaporated solvent, the product was purified by flash chromatography 
on Teldyne CombiFlash with silica using 1 0 ~ 25% EtOAc-Hexanes gave the amino 
phthalimide 4.17 (1.50 g, 64%) as a white amorphous powder (Rf = 0.80, TLC, silica 
50% EtOAc-Hexanes, UV light and 12 stain). 1H NMR (400 MHz, CDCI3) 8 7.82-7.80 (m, 
2H, ArH), 7.73-7.71 (m, 2H, ArH), 5.18-5.16 (m, 1H, CH(02C16)), 4.36-4.33 (dd, J=8.8, 
3.2 Hz, 1 H, CHCH(H)02C16), 4.27-4.25 (dd, J=5.4, 5.4 Hz, 2H, OCH2CH2), 4.11-4.06 
(dd, J=6.4, 5.2 Hz, 1 H, CHCH(H)02C16), 2.89-2.86 (m, 2H, CH2CH2N), 2.68-2.64 (m, 
2H, NCH2CH), 2.38 (s, 3H, NCH3), 2.29-2.25 (m, 4H, 2 x C02CH2), 1.59-1.54 (dd, 
J=6.8, 6.8 Hz, 4H, 2 x C02CH2CH2), 1.22 (m, 48H, 2 x (CH2)12), 0.87-0.83 (dd, J = 6.8, 
6.8 Hz, 6H,2 x CH2CH3); 13C NMR (100 MHz) 8 172.2, 171.9, 162.3, 133.8, 128.3, 
123.0, 76.5, 69.7, 64.2, 57.9, 56.4,43.9, 35.3, 35.1, 32.9, 30.7, 30.6, 30.6, 30.6, 30.5, 
30.3, 30.3, 30.1, 30.1, 26.0, 26.0, 23.8, 15.3. 
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6.4.12 3-((2-hydroxyethyl)(methyl)amino)propane-1 ,2-diyl dipalmitate 
The amine 4.17 (522 mg, 0.68 mmol) in dichloromethane (90 mL) was added 
N2H4·H20 (170 mg, 3.39 mmol) at O°C. After stirred at O°C for two hours, the reaction 
mixture was washed with NaHC03 (aq.) solution (3x60 mL) then with brine (60 mL). 
After dried over Na2S04 and rota-vap off solvent, the residue was purified by flash 
chromatography on Teldyne CombiFlash with silica using 10 ~ 25% EtOAc-Hexanes 
gave the aminooxy compound 4.18 (0.36g, 69%) as a white amorphous powder 
(Rf=0.28, TLC, silica 1:1 EtOAc-Hexanes, UV light and b stain). 1H NMR (400 MHz, 
CDCI3) 8 5.20-5.18 (dddd, J = 3.2,3.2,3.2,3.2 Hz, 1 H, CH(02C16), 4.39-4.35 (dd, J = 
8.8,3.0 Hz, 1 H, CHCH(H)02C16), 4.13-4.09 (dd, J = 5.2, 6.4 Hz, 1 H, CHCH(H)02C16), 
3.75-3.72 (dd, J = 5.4, 5.4 Hz, 2H, OCH2CH2), 2.66-2.63 (dd, J = 5.4, 5.4 Hz, 2H, 
CH2CH2N), 2.58-2.57 (dd, J = 6.4, 6.4 Hz, 2H, NCH2CH), 2.33 (s, 3H, NCH3), 
2.32-2.28 (dd, J = 7.6, 7.6 Hz, 4H, 2 x C02CH2), 1.62-1.59 (dd, J=6.8, 6.8 Hz, 4H, 2 x 
C02CH2CH2), 1.28-1.25 (m, 48H, 2 x (CH2)12), 0.89-0.86 (dd, J=6.6, 6.6 Hz, 6H, 2 x 
CH2CH3); 13C NMR (100 MHz) 8 173.8, 173.4, 73.5, 69.6, 64.1, 57.9, 56.6,43.6, 34.6, 
34.4, 32.1, 29.9, 29.9, 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 25.2, 25.1, 22.9, 14.3; 
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To a solution of the amine 4.17 (500 mg, 0.65 mmol) in CH2CI2 (3 mL) in a sealed 
tube was added CH31 (888 ).lL, 14.3 mmol). The tube was then sealed and heated to 
40-50°C for 29 hours. After the solvent was removed, CH2CI2 (10 mL) and hydrazine 
(168 ).lL, 3.47 mmol) was added at O°C. The mixture was stirred overnight while slowly 
warming to room temperature. Mixture turned from opaque yellow to opaque white 
upon addition of hydrazine. Determine reaction completeness by TLC (silica, 10% 
MeOH-DCM, UV light and PMA stain). When complete, filter off solids and rota-vap off 
solvent. Flash chromatography with silica using 4-10% MeOH in DCM gave the salt 
4.3 (0.278 g, 55 %) as a white amorphous powder (Rf=0.29 1:9 MeOH:CH2Cb, UV 
light and PMA stain). 1H NMR (400 MHz, CDCI3) 8 5.98 (br s, 1 H), 5.65 (s, 1 H), 
4.54-4.51 (dd, J = 12.0 Hz, 1 H), 4.44-4.40 (dd, J = 14.0 Hz, 1 H,), 4.28-4.22 (dd, J = 7.6, 
6.2 Hz, 1 H), 4.14-4.11 (dd, J = 8.0, 4.4 Hz, 1 H), 4.09-4.06 (dd, J = 6.6, 6.6 Hz, 2H), 
4.02-3.97 (dd, J = 8.8, 5.4 Hz, 1 H), 3.94-3.89 (dd, J = 8.6, 6.0 Hz, 1 H), 3.51 (s, 3H), 
3.49 (s, 3H), 2.38-2.32 (dd, J = 8.4, 7.6 Hz), 1.61-1.59 (d, J = 6.8 Hz, 4H), 1.25 (m, 
48H), 0.89-0.86 (dd, J = 6.6, 6.6 Hz, 6H); 13C NMR (100 MHz) 8 171.9, 171.5, 69.1, 
65.9,64.2,63.5,53.7,35.1,34.9,32.9,30.7,30.6, 30.5, 30.5, 30.3, 30.3, 30.2, 30.1, 





Sample 10. Ra1pbX_20100628_01 
File. Ra1pbX_20100628_01/data/protoD_Ol.fid 
Pulse Sequence: B2pul 
Solvent; cdel3 




Relax. delay 1.000 .ee 
pulae 45.0 degrees 
Aeq. time 2.048 8ec 
Width 4006.4 Hz 
16 repetitions 
OBSERVE HI. 399.7698128 MHz 
DATA PROCESSING 
Resol. enhancement -0.0 Hz 
FT size 65536 
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6.4.14 3-(bis(2-(aminooxy)ethyl)amino)propane-1 ,2-diyl ditetradecanoate 
To a solution of the amine 4.7 (0.67 g, 0.75 mmol) in dichloromethane (3 mL) was 
added hydrazine (0.225 g, 4.5 mmol) at O°C. After filter off precipitation, the organic 
solution was washed by sat. NaHC03, brine and then dried (Na2S04). After removed 
solvent by rota-vap, the crude product was purified by column chromatography (Si02) 
eluting with 3% MeOH in OCM and give product 4.19 (0.44 g, 94%) as white solid. (Rf 
= 0.29, ethylacetate). 1H NMR (400 MHz, COCI3) 8 5.45 (br s, 1 H), 5.11 (m, 1 H), 4.38 
(d, J = 12.0 Hz, 1 H), 4.08 (dd, J = 12.0, 6.4Hz, 1 H), 3.67 (t, J = 6.4 Hz, 4H), 2.73 (m, 
4H), 2.64 (d, J = 6.4 Hz, 2H), 2.24 (t, J = 7.6 Hz, 4H), 1.55 (t, J = 6.4 Hz, 4H), 1.22 (m, 
40H), 0.82 (t, J = 6.4 Hz, 6H); 13C NMR (100 MHz) 8 173.5, 173.2, 73.7, 70.0, 63.8, 
55.1,53.8,34.4,34.2,31.9,29.7 (4 peaks), 29.5, 29.4, 29.3, 29.2, 29.1,24.9 (2 peaks), 
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13C NMR spectrum of compound 4.19 
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6.4.15 3-(bis(2-(aminooxy)ethyl)amino)propane-1 ,2-diyl dipalmitate 
To a solution of the amine 4.11 (2.69 g, 2.93 mmol) in dichloromethane (10 mL) 
was added hydrazine (0.88 g, 17.6 mmol) at O°C. After filter off precipitation, the 
organic solution was washed by sat. NaHC03, brine and then dried (Na2S04). After 
remove solvent by rota-vap, the crude product was purified twice by column 
chromatography (Si02) using 0-5% MeOH in OCM as eluent to afford product 4.19 
(0.60 g, 30%) as white solid. (Rf=0.29, ethylacetate). 1H NMR (400 MHz, COCI3) 8 
5.43 (br s, 1 H), 5.13 (m, J = 6.4, 2.8Hz, 1 H), 4.38 (dd, J = 12.0, 2.8Hz, 1 H), 4.08 (dd, 
J = 12.0, 6.4Hz, 1 H), 3.69 (t, J = 5.6 Hz, 4H), 2.65-2.78 (m, 6H), 2.26 (td, J = 7.6, 2.8 
Hz, 4H), 1.55 (m, J = 6.8 Hz, 4H), 1.25 (m, 48H), 0.83 (t, J = 6.8 Hz, 6H); 13C NMR (100 
MHz) 8 173.6, 173.3, 73.8, 70.1, 63.8, 55.2, 53.9, 34.5, 34.3, 31.9, 29.7 (4 peaks), 
29.6, 29.4 (2 peaks), 29.2 (2 peaks), 25.0 (2 peaks), 22.8, 14.2; HRMS calcd. for 
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13C NMR spectrum of compound 4.20 
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6.4.16 Synthesis of DPA and other polysaccharides 
Dextran Polyaldehyde A (DPA-A) was prepared through oxidation of 
polysaccharide dextran by using reported protocols with minor modification.63 Dextran 
(6kD, 1.62 g, 10 mmol of glucose units) was dissolved in 50 mL distilled water and 
then sodium periodate (2.14 g, 10 mmol) was added. The mixture was stirred 
overnight in the dark at room temperature to get afford yellow solution. After gravity 
passing through Dowex 1 x8-400 ion exchange chromatography (20 g), the resultant 
colorless solution was extensively dialyzed against 6x5 L distilled water (2kD cutoff 
cellulose tubing from sigma) for 3 days at 4°C. The purified DPA was concentrated 
under reduced pressure and lyophilized to obtain a white solid. For DPA-B, DPA-C, 
DPA-D, DPA-E, the same protocol was followed with different molar ratio of sodium 
periodate. DPA-F (from 40kd dextran, CHO 11.6mmol/g) and DPA-G (from 100kd 
dextran, CHO 10.75 mmol/g) were prepared and titrated as the same way as DPA-A. 
Usually, 1.32-1.37 g DPA can be obtained by this way. The oxidized Maltoheptaose 
(CHO, 8.8mmol/g) and r3-cyclodextrin (CHO, 8.8mmol/g) were prepared and titrated 
as DPA-A with minor change. (100 Da cut off dialysis membrane was used due to 
product's relatively small molecular weight.) 
6.4.17 Liposome formulation and stabilization 
Liposome formulation 
The lipid 4.1 (10 mg) was dissolved in -1 mL chloroform solutions to 20mL sample 
vials. The chloroform was removed via rotary vacuum evaporation. The resulting thin 
lipid film was placed under vacuum for at least 2 hours to ensure that all traces of 
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solvent were removed. The dry lipid films were hydrated in water (4 mL) followed by 20 
min's sonication to form transparent liposome stock solution (lipid concentration 3.24 
mM). We observed that the required sonication time to get liposomes (- 100 nm 
diamter) was depended on the life/power of sonicator. The brand new sonicator can 
make liposomes in 5 minutes while the older one may need longer time to get the 
same results. The solution contain liposomes with a mean hydrodynamic diameter of 
119 nm (~=59 eV) as determined by dynamic light scattering (DLS) measurements 
(Brookhaven 90 Plus Nanoparticle Size Analyzer). 
Liposome stabilization study 
Glutaric dialdehyde was diluted by water to get 0.5 M final concentration. Dextran 
polyaldehyde A (DPA-A, 60 mg) was dissolved in water (1 mL) to get DPA-A (50 mM 
aldehyde concentration) solution. Dextran and dextran sulfate was dissolved in water 
to get 60 mg/L concentration. Hydroxylamine pretreatment was carried by mixture 
hydroxylamine (8 IJL 0.25 M) with DPA-A or Dextran sulfate (4 IJL, 60 mg/mL) in room 
temperature for 30min. 
The liposome stock solution (77 IJL) was mixed with water (923 IJL) in cuvettes 
and stabilize reagents (4 IJL) or hydroxylamine pretreatment stabilize reagent (12 IJL) 
were added to each cuvettes. Then Triton X-1 00 (final concentration 0.15% w/v) was 
added after incubated the indicated time intervals at room temperature. The light 
scattering signals were recorded before and after. 
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6.4.18 Calcein experiment 
The lipid 4.1 (2.0 mg) was dissolved in -1 mL chloroform solutions. The chloroform 
was removed via rotary vacuum evaporation. The resulting thin lipid film was placed 
under vacuum for at least 2 hours. The dry lipid films were hydrated in calcein solution 
(2.0 mL, 50 mM calcein and 20mM HEPES pH 7.4) by 30 seconds vortex mixing and 
followed by 10 min's sonication. The solution was then purified by Sephadex G-100 
column using HEPES buffer (50mM, pH 7.4) as eluent. The free calcein passed 
through column first and the later fraction was collected as liposome encapsulated 
calcein. 
The aliquot (200 IJL) of calcein liposome samples were then mixed with HEPES 
buffer (1.8mL, 50mM, pH 7.4) and stabilization reagents (5 IJL, 60 mg/mL). The 
release of calcein from the liposomes was measured fluorometrically (excitation 495 
nm and emission 515 nm, respectively, the slit widths were 5 nm) at certain time 
intervals. The relative fraction of released calcein was calculated using the formula: 
RF (%) = 100 X (It - lo)/(Imax - 10) 
Where 10 is fluorescence intensity at time 0, It is fluorescence intensity at time t, Imax 
is maximum fluorescence intensity and represents all calcein released. 
Dextranase-mediated calcein release from stabilized liposomes 
The liposome encapsulated calcein was incubating with 4 eq. DPA-B for 30 mins 
and the resultant stabilized liposomes were purified by Sephadex G-1 00 column using 
buffer B (10mM HEPES, 150mM NaCI, pH 7.4) as eluent. The aliquot of liposomes (1 
mL) was treated with dextranase (sigma D4668, 10 U) and incubated at 37°C. At the 
220 
given time intervals, samples (100 uL) were taken out and mixed with buffer B (2 mL). 
Their fluorescent signal of samples was recorded and relative fraction of released 
calcein was calculated using the same formula. 
6.4.19 Liposome encapsulated phosphatase 
The lipid 4.1 (8 mg) was dissolved in -1 mL chloroform solutions to 20 mL sample 
vials. The chloroform was removed via rotary vacuum evaporation. The resulting thin 
lipid film was placed under vacuum for 2 hours. The dry lipid films were hydrated in 
alkaline phosphatase (from Sigma P0114) solution (4 mL, 0.5 mg/mL alkaline 
phosphatase in buffer A (Tris 5 mM pH 8, MgCI2 5 mM, ZnCI2 0.1 mM) followed by 20 
min's sonication to form transparent liposome solution. To generate stabilized 
liposomes, 2 mL of liposomes were incubated with 1 equivalent of DPA-A (20 j..IL, 60 
mg/mL) overnight at room temperature. The free enzyme and liposomes were 
separated by repeated centrifugation (16,100 g, 30 min, 4°C). The pelleted liposomes 
are resuspended in buffer A. The redispersed liposomes are then treated by Triton 
X-100 (final concentration 0.15% w/v) and separated free enzyme from liposomes. 
The alkaline phosphatase activity was tested before and after triton X-100 treatment. 
The alkaline phosphatase activity was measured using fluorogenic substrate. 
Within 1.98 mL of Buffer A, 4-methylumbelliferyl phosphate disodium salt (Sigma, 
M8168, 10 j..IL, 10 mM) and phosphatase contain liposome sample (10 j..IL) was added 
and incubate in 3rC for 1 h. Detection of the products of the enzymatic reaction is 
performed with a fluorescence spectrometer (PerkinElmer, LS55 Fluorescence 
Spectrometer) with an excitation 360 nm and emission 440 nm. 
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6.5 Chapter 5. 'Click' Stabilized Liposomes for Gene 
Transfection 
6.5.1 Lipoplexes formulation and in-virto gene transfection 
6.5.2 2, 2'-diphthalimidooxy diethyl ether (5.3) 
6.5.3 2,2'-diaminooxy diethyl ether (5.4) 
6.5.4 tert-butyl 2-(2-(aminooxy)ethoxy)ethoxycarbamate (5.5) 
6.5.5 2,3,4,6-tetra-O-acetyl-~-D-Glucopyranosyl-(1 ~4)-2,3,5,6-tetraacetate-~-D-
glucose {7 -[(9H-9-tert-butoxycarbonyl)amino]-1 ,4,7 -trioxaheptyimine (5.6) 
6.5.6 2,3,4,6-tetra-O-acetyl-~-D-Glucopyranosyl-(1 ~4)-2, 3,5,6-tetraacetate-
~-D-glucose(7-amino-1 ,4,7-trioxaheptyl)imine (5.7) 
6.5. 7 ~-D-Glucopyranosyl-(1 ~4)-~-D-glucose(7 -amino-1 ,4,7 -trioxaheptyl)imine 
(5.8) 
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6.5.1 Lipoplexes formulation and in-vitro gene transfection 
Human breast cancer cells (MCF-7) were purchased from American Type Culture 
Collection VA, USA. Cells were grown to 50-60% confluency in DMEM and 1 % 
Pennstrep (Mediatech, Inc, VA) with 10% FBS (Valley Biomedical, Winchester, VA). 
Luciferase transfections were performed in triplicate using 0.025 mg of pDNA (pCMV 
Luc)/well in MCF-7 cells. 
The lipid 4.1 (11.5 j..IL, 10mg/mL in chloroform) and DOPE (11.2 j..IL, 10mg/mL in 
chloroform) was added to -0.2 mL chloroform solutions to 2 mL sample vials. The 
chloroform was removed via rotary vacuum evaporation. The resulting thin lipid film 
was placed under vacuum for at least 2 hours to ensure that all traces of solvent were 
removed. The dry lipid films were hydrated in HEPES buffer (0.2 mL, 20mM, pH 7.4) 
followed by 10 min's sonication to form transparent liposome solution. 
Lipoplex was prepared by adding the required volume of liposomes (fresh made) 
to a pDNA solution (lipids:pDNA charge ratios of 3, 5, 7). After brief mixing (votex 5 
seconds), the samples were incubated at room temperature for 20min to gave the 
lipoplexes. For stabilized lipoplexes, required volume of DPA-B (0.752mM) was added 
to the mentioned lipoplexes and incubated 3 h at 37.5 °C. 
The lipoplexes and stabilized lipoplexes were then mix with serum free DMEM 
media and added to cell culture (200 j..ILlwell). After 2h, the DMEM media with 20% 
FBS (200 j..ILlwell) was added to cell culture. After 39 h incubation at 37.5 °C, the cells 
were lysed and luciferase gene expression was quantified using a commercial kit 
(Promega) and luminometer according to the vendor's protocol. Lipofectamine 2000 
(Invitrogen) was used as a positive control while pDNA was used as negative control. 
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6.5.22, 2'-diphthalimidooxy diethyl 
HO~O~OH - PhtNO~O~ONPht 
5.3 
To a solution of diethylene-glycol (3.0 g, 28.3 mmol), PPh3 (18.5 g, 70.8 mmol), 
and N-hydroxyphthalimide (11.5 g, 70.8 mmol) in THF (200 mL, dry) was added DIAD 
(14.0 mL, 70.8 mmol) at O°C. After 30min, the reaction solution was warmed to room 
temperature and stirred for -20 hours. The solid was filtered and washed by ethyl 
acetate (40 mL) twice to give compound 5.3 as a white solid in (10.04 g, 90%). Rf = 
0.38 (CH2Cb: MeOH=49:1, v/v); 1H-NMR (500 MHz, CDCI3) 0 ppm 3.83 (t, J = 4.0 Hz, 
4H), 4.23 (t, J = 4.0 Hz, 4H), 7.69 (m, 4H), 7.74 (m, 4H); 13C_NMR (125 MHz, CDCI3) 
o ppm 69.73,77.18,123.66,129.11,134.64,163.54. 
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To a solution of compound 5.3 (10.04 g, 25.3 mmol) in dichloromethane (150 mL) 
was added N2H4 ·H20 (12.4 mL, 253 mmol). The reaction mixture was stirred at room 
temperature for -14 hours. The percipetation was seperated and washed with 
dichloromethane (20 mL x 2) and then dissolved in water (-100 mL). The aqueous 
buffer was extracted by dichloromethane (50 mL x 3). The combined organic solvent 
was concerated by rotary evaporation. The residual oil was filtered again and then 
purified by silica gel column chromatography (CH2CI2: MeOH=10:1, v/v) to give 
compound 5.4 (3.00 g, 87%) as colorless oil. (Rf=0.30, CH2CI2 : MeOH=9:1, v/v); 
1 H-NMR (400 MHz, CDCb) 0 ppm 3.68 (m, 4H), 3.84 (m, 4H), 5.55 (br, 4H); 13C-NMR 
(100 MHz, CDCI3) 0 ppm 69.69,74.92. 
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6.5.4 tett-butyl 2-{2-{aminooxy}ethoxy}ethoxycarbamate 
5.4 
To the solution of compound 5.4 (4.85 g, 35.6 mmol) in chloroform (20 mL) was 
slowly added di-tert-butyl dicarbonate (1.55 g, 7.12 mmol) in chloroform (50 mL) at 
O°C. The reaction solution was then warmed up to room temperature and stirred for 
-14 hours. The solvent was removed by rotary evaporation and the residual oil was 
purified by silica gel column chromatography (CH2CI2 : MeOH=19: 1, v/v) to afford 
compound 5.5 (1.51 g, 90%, calculate from BOC20) as colorless oil. [Note: the 
unreacted compound 5.4 can be collected as late fraction.] Rf=0.30 
(CH2Cb:MeOH=19:1, v/v); lH-NMR (500 MHz,CDCI3) 0 ppm 1.38 (s, 9H), 3.59 (t, J = 
5.0 Hz, 2H), 3.62 (t, J = 5.0 Hz, 2H), 3.75 (t, J = 5.0 Hz, 2H), 3.93 (t, J = 5.0 Hz, 2H), 
5.52 (br, 2H), 7.91 (s, 1 H) ; 13C-NMR (125 MHz, CDCI3) 0 ppm 28.36, 69.11, 69.57, 
74.67, 75.32, 81.52, 157.00. 
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6.5.5 2,3,4,6-tetra-O-acetyl-~-D-Glucopyranosyl-(1 ~4)-2,3,5,6-tetraacetate 
-~-D-glucose {7 -[(9H-9-tert-butoxycarbonyl)amino]-1 ,4,7 -trioxaheptyimine 
AcO AcO ACO~~ACN 0 ~ 
O /- 'o~ ~o' 'B OAc oc 
AcO OAcAcO 
5.6 
To a solution of linker 5.5 (1.23 g, 5.20 mmol), lactose monohydrate (1.78 g, 4.95 
mmol) in pyridine (20 mL) was added Amberlyst-15 resin (0.20 g). After stirred for 12 h 
at 65°C, the reaction mixture was cooled to O°C and acetic anhydride (20 mL) was 
added dropwise. The reaction mixture was allowed to warm to room temperature and 
then stirred for 12 h. The reaction mixture was diluted with ethyl acetate (200 mL) and 
washed successively with sat'd aq. NaHC03 (3X 200 mL), sat'd aq. CUS04 (3X 200 
mL), Brine (200 mL) and dried (Na2S04)' The solvent was removed by rotary 
evaporation. The residue was purified by column chromatography (Si02) using ethyl 
acetate in hexanes (40% to 70%) to afford compound (2.89 g, 65%) as a white foam; 
TLC (Rf=0.1, ethyl acetate: hexanes=1 :1); 1H-NMR (400 MHz, CDCI3) 0 ppm 1.41 (s, 
9H), 1.91-2.11 (m, 24H), 3.66 (m, 4H), 3.87-4.03 (m, 4H), 4.10-4.18 (m, 5H), 4.45 (dd, 
J = 12, 2.4 Hz, 1H), 4.59 (d, J = 7.6 Hz, 1H), 4.94 (dd, J = 10.4,3.2 Hz, 1H), 5.04 (m, 
1 H), 5.12 (dd, J = 10.0, 8.0 Hz, 1 H), 5.30 (d, J = 3.2 Hz, 1 H), 5.47 (dd, J = 8.4, 2.4 Hz, 
1 H), 5.72 (dd, J = 8.4, 5.2 Hz, 1 H), 7.40 (d, J = 4.4 Hz, 1 H), 7.59 (s, 1 H); 13C-NMR 
(100 MHz, CDCI3) 0 ppm 19.5-19.8 (6 signals), 27.2, 60.5, 60.9, 66.0, 67.9, 68.0 (2 
signals), 68.4, 68.5, 68.6, 70.0 (2 signals) 72.5,74.4,75.2,80.6,100.4,144.7,155.8, 
168.2, 168.6, 168.7, 168.8, 169.0, 169.2, 169.4,169.6. HRMS (ESI) calculated for 
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S.35.S 2,3,4,S-tetra-O-acetyl-J3-D-Glucopyranosyl-(1 ~4)-2, 
3,5,S-tetraacetate-J3-D-glucose(7 -amino-1 ,4,7 -trioxaheptyl)imine 




To a solution of compound 5.S (2.68 g, 2.99 mmol) in CH2CI2 (42 mL) at O°C was 
added water (3 mL) and TFA (15 mL). After the reaction mixture was stirred for -12h, 
CH2CI2 (260 mL) was added. The reaction mixture was washed successively with 
sat'd NaHC03 (2 x 300 mL), Brine (300 mL), and dried (Na2S04). After concentrated 
by rotary evaporation, the residue was purified by column chromatography (Si02) 
using 1.5-4% MeOH in CH2CI2 to afford compound 5.7 (1.98g, 83%) as a foam; [Note: 
the c and Z isomers can be elucidated on TLC]) Rf(E)=0.52, Rf(Z)=0.43, double 
elution in MeOH:CH2CI2= 1 :33; 1H-NMR (400 MHz,CDCI3) 6 ppm 1.98-2.18 (m, 24H), 
3.67-3.73 (m, 4H), 3.83 (t, J = 4.4 Hz, 2H), 3.95 (m, 1 H), 4.06-4.30 (m, 6H), 4.41-4.53 
(m, 1 H), 4.62 (dd, J = 17.2,8.0 Hz, 1 H), 5.00 (m, 1 H), 5.08-5.20 (m, 2H), 5.37 (s, 1 H), 
5.52-5.60 (m, 2H), 5.79 (dd, J = 8.0,5.2 Hz, 0.57H), 6.00 (t, J = 4.4Hz, 0.43H), 6.51 (d, 
J = 4.8 Hz, 0.43H), 7.47 (d, J = 5.2 Hz, 0.57H); 13C-NMR (100 MHz, CDCI3) 6 ppm 
20.5-21.0 (9 signals), 61.2, 61.6, 61.7, 62.0, 66.7, 67.0 (2 signals), 69.0-69.7 (8 
signals), 70.9-71.2 (5 signals), 73.7,74.3, 74.9 (2 signals), 76.4, 101.6 (2 signals), 
145.8, 147.1, 169.3-170.7 (14 signals); HRMS (ESI) calcd. for C32H4SN2Na021 + 
[M+Na+]: 819.2642, found: 819.2641. 
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6.5.7 J3-D-Glucopyranosyl-(1-4)-J3-D-glucose(7 -amino-1 ,4,7 -trioxaheptyl)imine 
A~O AcO 
c (L ____ 0, ~AC 0..J"'0,NH2 
)~o ",N",O/'-....../ ~ 
AcO OAc AcO OAc 
5.7 
To a solution of MeOH (10 mL) was added a piece of Na (-20 mg) under Argon. 
After reaction done (no more gas come out), 2.5 mL of above MeONa/MeOH solution 
was added to the solution of compound 5.7 (1.55 g, 1.95 mmol) in MeOH (5 mL). The 
reaction mixture was stirred -12h and then added DOWEX 50WX8-200 ion-exchange 
resin (0.25 g) which is pre-washed by 30mL MeOH. [ note: do NOT use too much of 
resin, it do absorb the product.] After stirred 1 h in room temperature, the reaction 
mixture was filtered. The solvent was removed by rotary evaporation and finally dried 
by oil pump to afford compound 5.2 (0.863 g, 96%) as white foam. 1H-NMR (400 
MHz,CD30D) 0 ppm 3.53-4.20 (m, 18H), 4.19-4.20 (m, 2H), 4.44-4.52 (m, 2H), 
4.85-4.96 (m, 3H), 6.87 (d, J = 5.2 Hz, 0.27H), 7.55 (d, J = 6.0 Hz, 0.73H); 13C-NMR 
(100 MHz, CD30D) 0 ppm 62.4, 63.5, 63.7, 70.1, 70.5 (2 signals), 70.6, 70.8, 72.4, 
72.8, 72.9, 73.0, 73.3, 74.0, 74.4, 74.7, 75.7, 76.8, 76.9, 81.3, 105.4, 105.9, 152.6, 






















































13C NMR spectrum of compound 5.2 
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LIST OF ABBREVIATIONS 
AcOH: acetic acid 
BOC: N-tert-butoxycarbonyl 
DBN: 1,5-Diazabicyclo[4.3.0]non-5-ene 
DCC: N, N' -Dicyclohexylcarbodiim ide 
DCM: Dichloromethane 
DIAD: Diisopropyl azodicarboxylate 
DMAP: 4-Dimethylaminopyridine 
DMSO: Dimethylsulfonyl oxide 
DOPE: Dioleoylphosphatidylethanolamine 
DOT AP: N-[1-(2,3-dioleoyloxy)propyl]-N, N, N-trimethylammonium chloride 
DOTMA: N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride 
DPA: Dextran polyaldehyde 
eq.: equivalent 
GVs: Giant Vesicles 
h: Hour 
HPLC: High performance liquid chromatography 
HRMS: High resolution mass spectroscopy 
Hz: Hertz 
IR: Infrared 
kbp: Kilo base pair 
kD: kilo dalton 
KHMDS: Potassium bis(trimethylsilyl)amide 
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LBL: Layer by layer 
LOA: Lithium diisopropylamide 
liMOS: Lithium bis(trimethylsilyl)amide 
LUVs: Large unilamellar vesicles 
mg: milligram 
mL: milliliter 
MLVs: Multilamellar vesicles 
mmol: millimole 
MW: Molecular weight 
NMR: Nuclear magnetic resonance spectroscopy 
pONA: Plasmid DNA 
p-TSOH: p-toluenesulfonic acid 
PEG: Poly(ethylene glycol) 
Pht: Phthaloyl 
PG: Protection group 
ppm: Parts per million 
RF: Relative fraction 
RNAi: RNA interference 
rt.: Room temperature 
SUVs: Small unilamellar vesicles 
TBAF: Tetra-n-butylammonium fluoride 




TFA: Trifluoroacetic acid 
THF: Tetrahydrofuran 
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